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SUMMARY
Sensitive radioimmunoassays for glucagon-like peptide-1 (GLP-1) and human 
gastric inhibitory polypeptide (GIF) were developed. The assay for GLP-1 was used 
to demonstrate species-specific differences in the molecular forms of this hormone in 
the pancreas and intestine of rats and pigs. Post-prandial increases in plasma GLP-1 
concentrations were observed in human subjects following carbohydrate, fat, protein 
and mixed meals. The magnitude and timing of the increases were consistent with GLP- 
1 acting as a physiological incretin in man.
Following a mixed meal, short bowel subjects, who exhibited impaired incretin 
effects, were found to have normal or slightly elevated plasma GIF concentrations but 
low plasma GLP-1 concentrations compared control subjects. This provided further 
evidence that GLP-1 may act as an incretin in man.
Plasma GLP-1 concentrations were measured for the first time in species other 
than man. Pigs were found to exhibit substantially greater post-prandial GLP-1 
responses than were observed in man.
The novel GIF assay and an established GIF assay, employing an antiserum 
raised against porcine GIF, detected similar plasma GIF concentrations in human 
subjects. Following a mixed meal, plasma GIF concentrations, measured with either 
assay, were found to be similar in lean and obese subjects. This suggests that GIF 
does not play an important role in the development of hyperinsulinaemia in obesity.
A series of experiments were carried out to investigate various physico-chemical 
factors which may influence the rate and extent of starch digestion and the consequent 
plasma glucose, insulin, GIF and GLP-1 responses to starch in man. The results 
obtained suggested that, for most cooked foods, resistant starch content and degree Of 
starch gelatinization are unlikely to play important roles in determining starch 
digestibility but that the structural integrity of grains may.
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CHAPTER 1
GENERAL INTRODUCTION
1.1 HISTORICAL
The history of research into gastrointestinal (GI) or gut hormones spans ninety 
years. In a comprehensive review on this topic, Mutt (1982a) splits this time into three 
periods. The first of these he terms ’’Prebiochemical.” This started in 1902 when 
Bayliss and Starling showed that intravenous (IV) injection into animals of an acid 
extract from dog upper intestinal mucosa lead to stimulation of pancreatic secretion 
(Bayliss and Starling, 1902). They named the active constituent in their extract 
secretin and coined the term hormone to describe this kind of blood-borne chemical 
messenger.
Soon after that the existence of other hormones was demonstrated. In 1904 
crude secretin preparations were found to be capable of stimulating intestinal motility. 
This was put down to the presence of a contaminating hormone in the preparation 
which the workers named motilin (Hallion, 1904). Similarly, in 1905, the component 
in pyloric and gastric mucosal extracts that was capable of stimulating gastric acid 
secretion in cats was named gastrin (Edkins, 1905). Then came the discovery of 
cholecystokinin (CCK), the hormone responsible for contraction of the gall-bladder 
(Ivy and Oldberg, 1928). Throughout the thirties, forties and fifties the existence of a 
substantial range of GI hormones was proposed. Each of these hypothetical hormones 
was named according to its supposed action. For example, the gut factors supposedly 
responsible for stimulation of pancreatic enzyme and gastric pepsin secretion were 
named pancreozymin (Harper and Raper, 1943) and gastrozymin (Blair et a l , 1953) 
respectively.
It is important to realize that although attempts had been made, none of these 
novel hormones had actually been purified at this time. It was assumed that the 
different biological activities found in a range of gut extracts were each due to distinct 
hormones. However, even now, by no means all of these hypothetical hormones have 
been isolated and in many cases their existence as single chemical entities still lies in
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doubt.
Nevertheless, at the beginning of the nineteen sixties a simple model had been 
formulated which explained the necessary functions of the gut as being controlled by a 
small selection of hormones. In this model secretin and pancreozymin were 
responsible for stimulating secretion of bicarbonate and pancreatic enzymes. CCK 
produced gall-bladder contraction. Gastrin switched on gastric acid secretion and, 
when necessary, enterogastrone switched it off again.
The early sixties also marked the beginning of Mutt’s second period of research 
in GI hormones which he terms the ’’Structural period.” Secretin was finally purified 
(Jorpes and Mutt, 1961) and then its amino add sequence determined (Mutt and Jorpes, 
1966). The same was true for gastrin (Gregory etal, 1964 ). It was realized that CCK 
and pancreozymin were in fact the same polypeptide (Mutt and Jorpes, 1967) which 
was also then sequenced (Mutt and Jorpes, 1971).
The third period of research started in the early seventies. In this period the 
rather neat and simple concepts, described earlier, started to collapse as the true 
complexity of the endocrine system of the GI tract became more apparent. The rate of 
discovery of novel hormones continued to increase (Rehfeld, 1981a). Furthermore, it 
became clear that many of these hormones were to be found in other tissues, in 
particular the pancreas and the brain (Dockray er a/, 1978 ; Rehfeld, 1978). 
Conversely, some polypeptides initially isolated from the brain were subsequently 
found to be present in the gut (Snyder, 1980). In the brain they are presumed to 
function as neurotransmitters rather than as classical endocrine hormones. Some 
peptide hormones, such as vasoactive intestinal polypeptide (VIP), that are present in 
the GI tract appear to be confined to neural rather than endocrine cells (Fuxe et al, 1977; 
lessen etal, 1980). VIP, therefore, probably acts in a neurocrine fashion in the gut. 
Other gut peptides may act in a paracrine fashion. These factors led to some confusion 
over the term gut hormone. A selection of alternative names such as enterins or 
eupeptides have been suggested (Mutt, 1982b) but these have not been widely
adopted.
The use of separation techniques such as gel filtration chromatography 
combined with radioimmunoassay revealed that many of the GI hormones are present 
in tissue and in the circulation in multiple molecular forms (Yalow and Berson, 1970 ; 
Gregory, 1979 ; Dockray, 1977a ; Harvey etal, 1974 ; Mutt, 1976) which can have 
different activities. The relative concentrations of these different molecular forms often 
vary from tissue to tissue (Dockray, 1977a). This heterogeneity is thought to arise 
from post-translational processing of precursor polypeptides.
Many of the hormones appear to have the potential for biological activities other 
than that for which they were originally characterized. In some cases this has proven 
to be due to the presence of other active hormones in the crude preparations. The 
apparent inhibitory action of CCK on gastric acid secretion is a good example of such a 
case (Brown and Magee, 1967) as it later transpired that this activity was due entirely to 
the presence of gastric inhibitory polypeptide (GIP) in the CCK preparation (Brown 
and Dryburgh, 1971). On the other hand, many pure and synthetic hormone 
preparations exhibit more than one biological activity. Back in 1974 Gregory listed as 
many as twelve different activities for both gastrin and secretin (Gregory, 1974). Since 
then still more have been added to the list (Mutt, 1982a).
The problem is to interpret which of these activities are physiologically 
important. Measurement of circulating levels of the hormones in blood, using 
immunoassays, helps to define the range of concentrations in which a hormone should 
be able to exert the effects under examination for them to be taken seriously as 
genuine physiological rather than pharmacological activities (Grossman, 1977).
In summary, considerable advances have been made in this field in the last 
twenty years but these advances, in some respects, demonstrate that the situation is 
more complex than was first imagined.
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1.2 EVOLUTION AND STRUCTURAL 
RELATIONSHIPS OF GI HORMONES
Many GI hormones are found to be widespread throughout the animal kingdom. 
Often there is some heterogeneity between the versions of the same hormone found in 
different species. These differences in amino acid sequence are generally confined to 
specific residues while the other residues show very high conservation reflecting the 
evolutionary constraints placed on them by their importance in determining biological 
activity.
It seems that the ancestors of today’s GI hormones existed at the time of the 
first vertebrates if not before. The evidence for this comes from the examination of the 
entero-endocrine system of cyclostomes (hagfish and lampreys). These are the last 
remaining members of the earliest vertebrate group (Agnatha) which probably diverged 
from the rest of the vertebrates more than 500 million years ago (Marks and Morgan, 
1982). Glucagon-like and CCK-like immunoreactivities have been identified in the 
intestinal mucosa of the creatures (Falkmer etal, 1978 ; Dockray, 1977b).
Analysis of gut hormones reveals that many can be grouped into molecular 
families on the basis of amino acid sequence homology (Mutt, 1982b). The evidence 
suggests that the members of each family arose by duplication of an ancestral gene 
(Barrington, 1971 ; Bell etal, 1983b).
One such family contains gastrin and CCK. The C-terminal pentapeptides of 
both these polypeptides and of caerulein, another related peptide isolated from the skin 
of the frog Hylea caerulea (Anastasi etal, 1968), are identical. In addition, CCK and 
caerulein contain a tyrosine-O-sulphate residue separated from the common 
pentapeptide by one amino acid, whilst gastrin has a tyrosine directly attached to it 
which is sulphated in gastrin II (or s) but not in gastrin I (or ns) (Gregory etal, 1964). 
This sequence conservation may well be due to structural requirements for interaction 
with receptors and for activity. Indeed the biological activity of gastrin is known to
reside in the C-terminus (Tracy and Gregory, 1964 ; Grossman, 1970).
The largest group of GI hormones is the secretin/glucagon family. Included in 
this are secretin, glucagon, glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 
(GLP-2) (Conlon, 1988), VIP (Mutt and Said, 1974), GIP (Brown and Dryburgh, 
1971), peptide histidine isoleucine (PHI) (Tatemoto and Mutt, 1980 ; Szecowka et al, 
1980) and pituitary adenylate cyclase-activating polypeptide (PACAP) (Miyata et al, 
1989). This group is of particular interest in the context of this thesis as it contain both 
the hormones which we have been studying.
As was the case for the gastrin/CCK family, certain amino acid residues in the 
sequences of members of the secretin/glucagon family exhibit very high conservation 
throughout the group. For the gastrin/CCK family the homologies were observed in 
the C-terminal region of the polypeptides. However, for the secretin/glucagon family 
the greatest homology is found near the N-terminus. Most strikingly, the sequence 
Hisi— PhegThr?— at the N-terminus is very highly conserved throughout the group.
The two families described above are the best known but other comparisons can 
be drawn. Neurotensin has some similarities to peptide YY (PYY) (Tatemoto and 
Mutt, 1980). Gastrin-releasing peptide (GRP) (MacDonald etal, 1979) is related to the 
amphibian peptides bombesin and alytesin (Anastasi etal, 1971).
Further analysis reveals that some hormones are not easy to categorize since 
they have structural similarities with members of more than one family. Motilin is one 
such hormone. Sequence homologies between motilin and both secretin (Track, 1976) 
and gastrin (Mutt, 1978) have been noted. There is some evidence of complex inter­
family relationships as well (Jomvall etal, 1982). It is possible that ultimately both the 
gastrin/CCK and secretin/glucagon families originated from an ancient proinsulin-like 
gene since analysis of the proposed mRNAs of gastrin, secretin and glucagon reveals 
similarities with insulin mRNA that has undergone a frameshift mutation (Track, 
1974).
1.3 BIOCHEMICAL APPROACHES AND  
TECHNIQUES
In general, progress in research into GI hormones has not been as rapid as for 
hormones produced elsewhere in the body. There are several clear reasons for this 
which will be discussed in the following sections together with the biochemical 
techniques that have proved useful in overcoming the difficulties.
1.3.1 POLYPEPTIDE PURIFICATION
Purification of GI hormones is more difficult than for hormones produced in 
discrete glands. In the latter the endocrine cells represent a major proportion of the 
tissue and produce at most a few different hormones. However, there are many 
different kinds of endocrine cell in the gut, each producing different peptide hormones 
(Solcia etal, 1978). In addition to this they are spread diffusely along the length of the 
GI tract in distribution patterns peculiar to each cell type. The difficulties associated 
with obtaining a pure preparation of any single GI hormone in the early days of 
research are clearly demonstrated by the gap of forty years between the identification of 
secretin and gastrin and the isolation of these two polypeptides.
The approach used for isolating specific hormones has generally been one based 
on bioassays. That is, a specific biological activity is identified in a crude product 
which is then followed throughout a series of purification techniques such as 
precipitation reactions, gel filtration and ion exchange chromatography. More recently 
another approach has been successfully used where the workers isolated novel 
polypeptides from a crude intestinal extract using a chemical method for identifying 
structures commonly found in GI hormones (Tatemoto and Mutt, 1980).
Although we now have the techniques to allow purification of peptide hormones 
from the gut, the diffuse nature of the endocrine system of the gut makes the isolation
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of large quantities very difficult. In 1971, Mutt and Jorpes used 1000 pieces of hog 
duodenum, each one metre long, to purify Img of porcine secretin (Mutt and Jorpes, 
1971). The necessity for such large quantities of tissue often makes the isolation of 
many hormones, especially human ones, unrealistic. In many cases it has proven better 
to purify small amounts of natural hormones, sequence them and then produce larger 
quantities synthetically rather than to try to purify large amounts directly from tissue.
1.3.2 STUDY OF ENTERO-ENDOCRINE CELLS
The distribution and morphology of entero-endocrine cells has been carried out 
using cytochemical, histochemical and immunocytochemical techniques (Grube and 
Forssman, 1979). Of these, the immunocytochemical approach is the most powerful in 
that it is extremely sensitive and in theory can accurately define the distribution of 
specific hormones. However, great caution must be used when interpreting the results 
since crossreactivity of the antibodies with other hormones is quite possible (Marks and 
Morgan, 1982), particularly given the structural similarities between many of them as 
noted in section 1.2.
1.3.3 RADIOIMMUNOASSAY
The technique of radioimmunoassay (RIA) was first developed by Yalow and 
Berson in 1960 for the quantitative measurement of insulin (Yalow and Berson, 1960). 
It has revolutionized the field of endocrinology since it is generally much more 
sensitive, specific, precise and simple than the bioassays used before. RIA is based on 
the competition between a fixed amount of radiolabelled hormone and a standard or 
unknown quantity of unlabelled hormone for binding sites on a fixed and limiting
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number of antibodies specific for that hormone. The quantity of antibody-bound 
radiolabelled hormone is inversely proportional to the quantity of unlabelled hormone 
present. A standard curve can be constructed using an unlabelled hormone preparation 
at a range of known concentration and from this curve the concentrations in unknown 
samples determined.
There are various problems associated with RIA, particularly for GI hormones. 
These include difficulties in the production of high avidity specific antisera, production 
of stable high specific-activity radiolabelled hormones that retain immunoreactivity, low 
plasma hormone concentrations, proteolytic degradation of GI hormones in samples, 
varying crossreactivity of antisera with heterogenous forms of the hormone being 
assayed and with other GI hormones, and non-specific interference of plasma 
components with the antibody-antigen reaction (Rehfeld, 1981b ; Bryant, 1981). As a 
result of the differing extent to which these various problems affect the assays 
developed by different groups, absolute hormone concentrations reported by different 
workers often vary dramatically.
1.4 THE ENTERO-INSULAR AXIS
1.4.1 INTRODUCTION OF THE CONCEPTS OF THE 
ENTERO-INSULAR AXIS AND INCRETINS
Glucose has long been accepted as the major modulator of insulin secretion. 
Some amino acids are also capable of stimulating secretion of insulin but their role is 
normally only minor in comparison with glucose in man. The mechanism of insulin 
secretion will be discussed in more detail later (section 1.7).
In 1964 McIntyre and co-workers reported an experiment where they had given
healthy human volunteers a glucose load intrajejunally on one occasion and on another 
occasion had given the same volunteers IV glucose in such amounts that circulating 
glucose concentrations were similar to those after the intrajejunal load. A much greater 
insulin response was observed after the intrajejunal load than after the IV load 
(McIntyre etal, 1964). In the same year another group independently reported similar 
results comparing oral and IV glucose loads (Elrick etal, 1964). It was postulated that 
absorption of glucose in the GI tract stimulated the secretion of one or more hormones 
which were responsible for stimulating insulin secretion. A similar phenomenon was 
also noted for oral and IV amino acid loads (Dupre et al, 1968). The term ’’entero- 
insular axis” was introduced by Unger and Eisentraut to encompass the gut factors 
responsible for enhanced insulin stimulation (Unger and Eisentraut, 1969). This has 
been estimated to be responsible for as much as 50% of the insulin secretion observed 
after an oral glucose load (Perley and Kipnis, 1967).
Back in 1929 Zunz and LaBarre had demonstrated that IV injection of a crude 
preparation of secretin was capable of inducing hypoglycaemia and stimulating the 
endocrine pancreas (Zunz and LaBarre, 1929). They proposed that the preparation 
contained another hormone apart from secretin which was responsible for producing 
these effects and they named it incretin.
Since then many of the characterized gut hormones have been demonstrated to 
have the potential to stimulate insulin secretion (Marks and Morgan, 1983). The idea 
that incretin is a single hormone has been replaced so that all the hormones that are 
believed to act as physiological insulin secretagogues are now referred to as incretins.
It should be appreciated that a rise in plasma insulin does not necessarily have to 
occur as a result of increased secretion. Insulin is removed from the blood by hepatic 
extraction. Consequently, a reduction in the rate of insulin extraction would also 
produce higher circulating insulin levels. This has been proposed to play a major part in 
the incretin effect (Creutzfeldt and Ebert, 1985). One way of assessing this effect is to 
measure C-peptide as well as insulin. This peptide is a product of enzymic processing
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of proinsulin and it is co-secreted with insulin in approximately equimolar amounts. 
However, unlike insulin, it is not subject to variable hepatic extraction and may, 
therefore, be used as a more reliable measure for insulin secretion alone.
There appears to be a neural component of the entero-insular axis. The 
importance of this neural control is a matter of some controversy. In particular, in 
pancreatic transplant experiments some groups have reported that the insulin response 
is unaffected despite pancreatic enervation (Linkaer Jensen et al, 1976 ; Clark et al, 
1989) whereas others have found that the entero-insular axis is apparently abolished 
(Humphrey etal, 1975 ; Gibby et al, 1980). A study carried out in rats fed a liquid 
meal suggests that the endocrine and neural components of the entero-insular axis are 
responsible for approximately 30% and 20% respectively of the insulin secretion 
observed post-prandially (Berthoud, 1984).
The pancreas has been demonstrated to contain cholinergic, adrenergic and 
petidergic neurones (Rehfeld etal, 1980 ; Dockray, 1987). The cholinergic neurones 
are apparently involved in enhancing the early insulin response to a meal, increased 
insulin secretion in obesity, regulation of fasting insulin secretion and post-prandial 
insulin secretion (Morgan et al, 1988a ; Flatt and Bailey, 1984 ; Ahren et al, 1986 ; 
Zawalich etal, 1989). Many of the peptidergic neurones contain gut peptides including 
CCK, VIP, neurotensin and GRP. Currently their role is not well understood.
1.4.2 CANDIDATE INCRETINS
It has already been mentioned that many GI hormones are able to stimulate 
insulin secretion. These include secretin, gastrin, VIP, CCK, GIP and GLP-1. 
However, to qualify for the title of incretin they should be capable of stimulating insulin 
secretion at circulating concentrations routinely observed in vivo. They should also be 
released in response to ingestion of nutrients, particularly carbohydrate (Marks and
Morgan, 1983).
Secretin has been reported by some workers to be capable of stimulating insulin 
secretion (Enk, 1976 ; Enk etal, 1976 ; Yjoïoà et al, 1986). Others have found no such 
effect using physiological concentrations of the hormone (Brodows and Chey, 1980). 
Stimulation of endogenous secretin with citric acid has no effect on insulin levels 
(Boyns etal, 1967). It seems that the insulinotropic properties of secretin are, at best, 
weak. Taken in conjunction with the fact that ingestion of glucose does not produce 
marked rises in plasma secretin levels, it is very unlikely that this hormone plays a 
significant role as an incretin.
Very high doses of gastrin can stimulate a small insulin release in glucose- 
primed subjects (Dupre et all, 1969) but the levels required are far higher than those 
observed after a glucose load which produces only a small increase in circulating levels.
VIP is capable of stimulating insulin secretion (Schebalin etal, 1977) but since 
it is restricted to neurones in the gut it is unlikely to act as an endocrine modulator of 
insulin secretion. However, it is present in neuronal synapses at the B cells (Larsson et 
al, 1978) and may act in a neurocrine fashion.
All forms of CCK can stimulate insulin secretion. CCK-8 was reported to be 
the most potent form in experiments with isolated rat pancreatic islets (Versphol et al, 
1986). In the perfused porcine pancreas CCK-4 produced the greatest effect (Rehfeld 
et al, 1980). CCK appears to be released only by the ingestion of protein in rats 
(Liddle et al, 1986). In man, rises in plasma CCK have been observed following 
ingestion of fat, protein, amino acids and glucose but the increase following glucose 
was less than for the other nutrients (Liddle etal, 1985 ; Rushakoff etal, 1987). One 
suggestion is that CCK may act as an incretin for amino acid stimulated insulin 
secretion. However, it does not appear to enhance insulin secretion stimulated by IV 
phenylalanine (Reimers etal, 1988). There is the possibility that CCK released from 
the gut following a meal may act in concert with other hormones to stimulate insulin 
secretion (Zawalich, 1988). It is also possible that CCK largely acts on the endocrine
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pancreas as a result of its release from peptidergic neurones rather than from the gut. 
This will be discussed in a later section in this chapter.
The two remaining hormones from the list, GIF and GLP-1, are the best 
candidates for incretins. In fact, GIF has been widely accepted for some years as an 
important incretin. GLF-1 was discovered much more recently than GIF and has 
consequently been less well researched. However, it may well be just as important or 
even more important than GIF as an incretin. What is known of these two polypeptides 
is discussed in the next two sections.
1.5 GASTRIC INHIBITORY POLYPEPTIDE
It was mentioned briefly earlier that GIF was initially isolated from a crude 
porcine CCK preparation as the contaminant responsible for the preparation’s apparent 
ability to inhibit gastric acid secretion (Brown et al, 1970). When GIF was sequenced 
it was found to be 42 amino acids long and to have 15 and 9 of the 26 N-terminal 
amino acids identical to those of porcine glucagon and porcine secretin respectively 
(Brown and Dryburgh, 1971). More recently human GIF has also been isolated and 
sequenced (Moody etal, 1984). It differs from porcine GIF by only two amino acids.
In 1930 Kosaka and Lim had named the hypothetical hormone responsible for 
inhibition of gastric acid secretion ’’enterogastrone” (Kosaka and Lim, 1930). Now, 
like the incretin concept, it is thought that this phenomenon is not due to the action of a 
single hormone. Instead all hormones that inhibit gastric acid secretion are referred to 
as enterogastrones. GIF may well be an important enterogastrone (Federson and 
Brown, 1972) but of more interest is its apparent ability to act as a potent insulin 
secretagogue.
The potential for GIF to act as an incretin was identified soon after its isolation. 
Dupre and co-workers gave human subjects an IV infusion of porcine GIF together
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with a simultaneous IV infusion of glucose (Dupre etal, 1973). They observed a 
greater insulin response and improved glucose tolerance when GIF was infused 
compared with when glucose was infused on its own. These results were later 
confirmed using synthetic human GIF in a very similar set of experiments (Fiiessl et al, 
1988). The additional aspect of these later experiments was that the subjects were first 
given an oral glucose load and their post-prandial plasma GIF levels determined using a 
specific RIA. The subsequent IV GIF infusion was adjusted to mimic the plasma levels 
observed after the oral glucose load. The integrated incremental insulin response to the 
combined GIF and glucose infusion was only slightly lower than for the oral glucose 
tolerance test and the difference was not statistically significant.
One group reported that endogenous GIF secretion was stimulated in rats in a 
dose-dependent manner by intraduodenal infusion of 0.05 to 0.5 N hydrochloric acid 
(Ebert et al, 1979). When this was carried out at the same time as an IV infusion of 
glucose, an augmented insulin response was observed compared with when the glucose 
infusion was given alone. This was abolished by IV injection of anti-GIF antibodies. 
Holst and co-workers also demonstrated loss of incretin effect in rats given oral glucose 
and rV anti-GIF antibodies (Holst etal, 1980).
Experiments using perfused rat pancreases or isolated rat islets demonstrated 
that GIF could potently stimulate insulin release but in a glucose-dependent manner 
(Federson and Brown, 1978 ; Brown etal, 1980 ; Szecowka etal, 1982). From these 
experiments it is difficult to define an absolute threshold concentration of glucose 
required for GIF to have an effect on insulin secretion since each group used different 
glucose and hormone concentrations and different in vitro systems.
The idea that the action of GIF on insulin secretion requires glucose levels to be 
raised above fasting is further backed up by in vivo studies in humans. Infusions of 
porcine GIF into fasting subjects had no effect on plasma insulin (Dupre etal, 1973). 
In addition, healthy human subjects fed a fat load showed no significant change in post­
prandial plasma insulin even though plasma GIF levels rose markedly. However,
when an IV infusion of glucose was added at the same time as the oral fat load, the 
insulin response observed was significantly greater than for the glucose infusion alone 
(Crockett et a/, 1976). Consequently it has been suggested that this hormone should be 
renamed glucose-dependent (or glucose-mediated) insulinotropic polypeptide so as to 
better describe its function while maintaining the acronym GIF.
In the study by Crockett and co-workers mentioned above, fat-stimulated GIF 
levels were significantly lower when the simultaneous IV infusion of glucose was 
given to the subjects (Crockett et al, 1976). It was proposed that this was due to 
feedback inhibition of GIF secretion by the raised insulin levels. Since then other 
groups have demonstrated similar effects with glucose or insulin infusions (Creutzfeldt 
and Ebert, 1985).
1.5.1 DISTRIBUTION OF GIF IN THE GI TRACT
Immunocytochemical techniques reveal that GIF is localized in the endocrine K 
cells in the gut (Buchan etal, 1978). The highest concentrations are found in the 
duodenum and jejunum (Bloom and Folak, 1980).
1.5.2 STIMULATION OF GIF SECRETION
GIF levels increase in blood following mixed meals (Kuzio etal, 1974). 
Carbohydrates, fats and amino acids are all capable of stimulating GIF secretion. In 
man and dogs fat has been reported as being a more potent stimulator of GIF secretion 
than glucose (Fenman etal, 1981 ; Federson etal, 1975). In rats and pigs it is the other 
way round (Fonter etal, 1990). The GIF response to amino acids is smaller than for 
fat or glucose (Fenman et al, 1981), and some amino acids produce a greater GIF 
response than others (Thomas etal, 1978). Flasma GIF levels have been reported not
to be influenced by ingestion of protein meals in man (Brown etal, 1975).
For carbohydrates to stimulate GIF secretion it appears that they must be 
actively absorbed since non-absorbable or passively absorbed sugars do not elicit GIF 
secretion from perfused gut loops in rats or duodenal infusions in dogs (Sykes et al, 
1980). Furthermore, addition of phloridzin, which inhibits the sodium-dependent 
glucose transporter, to the perfusate in the rat gut loop experiments abolishes the GIF 
response to glucose.
For fatty acids, chain length and degree of saturation determine the extent of the 
GIF response. Only long chain fatty acids appear to be capable of stimulating GIF 
release in obese mice and their potency increases as they become less saturated 
(Kwasowski etal, 1985).
1.5.3 DIETARY MODIFICATION OF GIF SECRETION
Normal human subjects, after 6 weeks on a high sucrose diet, exhibited greater 
GIF and insulin responses to a sucrose load than they did after they had been on a 
similar diet in which the sucrose was replaced with wheat starch (Reiser et al, 1980). A 
similar effect was observed in another study where the subjects had been on a high 
sucrose diet for only one week (Mazzaferri et al, 1984). In rats, too, such a diet 
produces an increased insulin response to IV glucose and improved glucose tolerance 
(Kergoat etal, 1987). These effects may be due to induction of sucrase and 
consequently more rapid absorption of glucose or sensitization of pancreatic B cells to 
the action of glucose (Reiser etal, 1980).
High fat diets can also lead to enhanced post-prandial GIF secretion although 
the effect is not as clear cut as for high sucrose diets. Rats are particularly sensitive and 
exhibit markedly increased insulin and GIF responses to oral glucose and fats after only 
a few days on a high fat diet (Tan etal, 1987 ; Hampton etal, 1983).
A study in which were pigs fed a high fat diet for 11 weeks showed that they 
produced slightly higher GIF levels and had a reduced degree of glucose tolerance 
following a standard meal than pigs fed intermediate fat or high carbohydrate diets 
(Fonter etal, 1991). The same group reported that concentrations of GIF in the small 
intestine were higher following the high fat diet and suggested that this might be 
responsible for the increased post-prandial GIF response.
Man appears to be still less sensitive to the effects of a high dietary fat intake 
than pigs. A high fat diet given to human subjects for 11 days did not alter their GIF 
response to oral fat (Morgan etal, 1983). However, after 35 days on such a diet, 
another group of subjects did have slightly increased plasma GIF levels but not insulin 
levels following oral glucose (Morgan etal, 1988b).
Equivocal results have been obtained in studies on human subjects given low fat 
diets for 35 days. One such study showed an attenuated GIF response following oral 
fat (Morgan etal, 1988c) whilst another showed unaltered GIF and insulin responses to 
a mixed meal (Morgan etal, 1991).
Certain non-starch polysaccharides can attenuate glucose, GIF and insulin 
responses to foods (Jenkins et al, 1978 ; Morgan etal, 1985). They are believed to 
function by slowing gastric emptying and reducing the rate of nutrient absorption 
(Jenkins, 1979 ; Johnson and Gee, 1980).
1.5.4 OTHER ACTIONS OF GIF
GIF may play physiologically important roles other than as an incretin and 
enterogastrone. It has been reported to stimulate somatostatin release from isolated rat 
islet and from perfused rat stomach (Szecowka etal, 1982 ; Brown etal, 1980).
One group have demonstrated that GIF can stimulate glucagon secretion from 
perfused rat pancreas and augment arginine-stimulated glucagon secretion in the
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presence of low plasma glucose levels (Pederson and Brown, 1978). Another group 
found that GIF could stimulate glucagon and pancreatic polypeptide release from the 
isolated mouse pancreatic islet (Bailey et a], 1990). However, supraphysiological 
levels of GIF were required for the effects to be appreciable.
GIF may play an important role in lipogenesis and fat deposition since it can 
activate lipoprotein lipase and stimulate de novo fatty acid synthesis in adipose tissue 
(Eckel etal, 1978 ; Oben etal, 1991a ; Oben etal, 1991b). It can also augment insulin- 
dependent inhibition of hepatic glycogenolysis in rodents (Hartmann etal, 1986).
1.5.5 POSSIBLE ROLE OF GIF IN DISEASE
Since GIF is believed to act as an important incretin it could be associated with 
the abnormal insulin secretion found in obesity and diabetes. Indeed, in animal models 
of these syndromes there is good evidence that this is in fact the case.
The most comprehensively studied animal models of this kind are those of the 
genetically obese-hyperglycaemic ( ob/ob) mouse and the genetically diabetic-obese 
(db/db) mouse. Both of these exhibit obesity, hyperphagia, hyperglycaemia, 
hyperinsulinaemia and hypergipaemia (Flatt et al, 1983a).
It has been demonstrated that IV glucose given to fed ob/ob mice elicits no 
significant change in plasma glucose or insulin levels (Flatt and Bailey, 1981) whereas 
oral glucose produces substantial increase in both these parameters (Flatt and Bailey, 
1982). Consequently, either neural factors or humoral factors or both are implicated in 
the hyperinsulinaemia in these animals.
The small intestine of ob/ob mice exhibits general endocrine cell hyperplasia 
(Folak etal, 1975). The concentration of GIF-secreting K cells has been reported to be 
particularly high (Flatt etal, 1983a). Furthermore, these animals have exaggerated GIF 
responses to glucose, amino acids and fat ingestion and appear to have lost the
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feedback inhibition of GIF secretion by insulin (Flatt et al, 1983b). They are also 
particularly sensitive to dietary manipulation. Flasma and intestinal GIF levels and 
jejunal K cell density in ol/ob mice are increased by a high fat diet (Bailey etal, 1986).
It seems that hyperphagia, increased stimulation of GIF release by nutrients and 
loss of feedback inhibition of GIF secretion by insulin all promote hypergipaemia. And 
this, in turn, makes an important contribution to the observed hyperinsulinaemia in 
ob/ob mice.
The story is probably similar for db/db mice. However, in a third animal 
model, the Zucker fatty {fa f^a ) rat, normal circulating levels are observed together with 
mild hyperinsulinaemia (Morgan, 1979 ; Chan et al, 1984). Here GIF may be 
responsible, in part, for the hyperinsulinaemia due to increased sensitivity of the B cells 
to its insulin-releasing effects (Chan etal, 1984).
In man the role of GIF in diabetes and obesity is confused due to a large array 
of apparently conflicting results. In subjects with insulin dependent (type I) diabetes 
mellitus (IDDM) different workers have found normal (Krarup etal, 1985a), reduced 
(Reynolds etal, 1979) and increased (Creutzfeldt and Ebert, 1977) GIF secretion. 
However, since the B cells retain their sensitivity to GIF, it is likely that their reduced 
mass is the primary cause of impaired insulin secretion (Morgan, 1992).
With non-insulin dependent (type II) diabetes (NIDDM) different research 
groups have demonstrated impaired, normal and enhanced insulin secretion and GIF 
secretion (Morgan, 1992). It has not proved possible to demonstrate a relationship 
between the abnormalities observed for these two parameters (Groop, 1989 ; 
Creutzfeldt etal, 1983).
Again, with obesity in man which is commonly associated with 
hyperinsulinaemia, increased, normal and reduced post-prandial GIF responses have 
been reported (Morgan, 1992). Consequently, it is not yet possible to draw any firm 
conclusions about the role of GIF in NIDDM or obesity.
1.6 GLUCAGON-LIKE PEPTIDE-1
In 1982 the DNA complementary to the mRNA produced in anglerfish 
pancreatic islets which encodes preproglucagon was sequenced (Lund etal, 1982). 
The predicted amino acid sequence of the gene product was determined. It proved to be 
124 amino acids long, containing the complete sequence of anglerfish glucagon flanked 
by N- and C-terminal extensions of 52 and 43 amino acids respectively. In the C- 
terminal extension a glucagon-like sequence of 34 amino acids was identified. This, 
like glucagon itself, was bounded by dibasic amino acid sequences that are 
characteristic of post-translational processing sites (Steiner etal, 1980 ; Docherty and 
Steiner, 1982). It was proposed that post-translational processing of the prohormone 
would release both glucagon and the glucagon-like peptide.
The following year the sequences of hamster, bovine and human 
preproglucagon genes were determined (Bell etal, 1983a ; Lopez etal, 1983 ; Bell etal, 
1983b). Hamster and bovine preproglucagon are both 180 amino acids long whilst 
human preproglucagon lacks the last C-terminal residue and is consequently only 179 
amino acids long. They all contain the sequence of glucagon plus not one, but two, 
glucagon-like peptides (GLP-1 and GLP-2). In the human gene, at least, the three 
polypeptide sequences are encoded by separate exons (Bell etal, 1983b). This lends 
weight to the theory that they arose by gene triplication.
As in the anglerfish proglucagon, the three proposed polypeptides are all 
bounded by dibasic sequences. Amino acid sequence homology between the 
prohormones is very high but is greatest for the sequences corresponding to glucagon, 
GLP-1 and GLP-2. In fact, the predicted sequences of glucagon and GLP-1 are 
identical for all three species. More recently, the preproglucagon gene sequences from 
rat and guinea pig have been determined (Heinrich etal, 1984 ; Seino et al, 1986). 
Both these genes have the same structure as the other mammalian counterparts.
Glucagon has been found to be identical in all mammals where it has been
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sequenced with the exception of the guinea pig. In this species 5 of the 9 C-terminal 
amino acids differ from those of other species. The sequence of GLP-1 is identical in 
all mammals in which it has been described so far including the guinea pig. The unique 
conservation of GLP-1 in mammals and high degree of conservation even with fish 
(Andrews and Ronner, 1985), avians (Hasegawa etal, 1990) and amphibians (Pollock 
et al, 1989) implies strong evolutionary constraints on its sequence and is thought to 
reflect the importance of its biological role.
On the other hand GLP-2 is not as highly conserved as GLP-1 or glucagon and 
is not even present in the anglerfish or chicken proglucagon. At the moment no known 
action of GLP-2 has been identified in the GI tract or pancreas. One group have 
reported that after its release from proglucagon by proteolytic cleavage at the dibasic 
sequences bordering it, GLP-2 undergoes further processing at its C-terminus in pig 
and human small intestine (Orskov etal, 1989a). This may give rise to the biologically 
active form of the polypeptide but this hypothesis is yet to be proved. GLP-2 has been 
shown to stimulate adenylate cyclase in hypothalamic and pituitary cells (Hoosein and 
Gurd, 1984) and it may act as a neurotransmitter in the brain.
The evidence is that there is a single preproglucagon gene in man (Bell et al, 
1983b ; White and Saunders, 1986) which gives rise to a single species of mRNA in 
pancreas and intestine (Mojsov etal, 1986 ; Novak etal, 1987). From this it is 
believed that full length proglucagon is synthesized which subsequently undergoes 
tissue-specific enzymic processing to give rise to a large selection of biologically active 
polypeptides. The details of this processing will be briefly outlined here and discussed 
in greater detail in chapter 4.
Examination of the mammalian gene sequence led to the prediction that GLP-1 
would be 37 amino acids long (GLP-1(1-37)) corresponding to proglucagon (72-108). 
It was noted that the C-terminal amino acid was a glycine residue. Many other GI 
hormones have such a residue at their C-terminus which undergoes decarboxylation to 
leave the amide (Mutt and Jorpes, 1967 ; Gregory et al, 1964 ; Miyata et al, 1989 ;
21
Tatemoto and Mutt, 1980) and in most cases this C-terminal amidation appears 
necessary for the polypeptides to exhibit biological activity (Rehfeld et al, 1980). 
Consequently synthetic versions corresponding to GLP-1(1-37) (proglucagon (72- 
108)) and GLP-l(l-36)amide were produced.
In an early study, GLP-1( 1 -36)amide was found to have no effect on circulating 
glucose or insulin in fasted dogs (Ghiglione etal, 1984). High levels of GLP-1(7- 
36)amide were reported to be capable of weakly stimulating insulin secretion from 
isolated rat pancreatic islets (Schmidt etal, 1985). This stimulation, like that for GIP, 
required the presence of high ambient glucose loads. The workers estimated that GLP- 
l(l-36)amide had approximately 30% of the incretin effect of GIP. Other workers did 
not find that this form of the hormone was effective in stimulating insulin secretion 
from the perfused pig pancreas (Orskov etal, 1986).
It was then realized that GLP-1(1-37) or GLP-1(1 -36)amide underwent further 
specific processing in the intestine to remove the first 6 N-terminal amino acids, giving 
rise to GLP-1(7-37) or GLP-1 (7-36)amide (the latter termed truncated GLP-1 or tGLP- 
1) (Mojsov etal, 1986). GLP-1 was subsequently purified from rat, human and pig 
intestine (Holst etal, 1987 ; Kreymann etal, 1988 ; Orskov et al, 1989b). Mass 
spectrometry revealed that the predominant form was tGLP-1.
Concentrations of natural and synthetic tGLP-1 of 10 lo M and 10-9 M were 
found approximately to double and quadruple insulin release from perfused porcine 
pancreas in the presence of 7 mM glucose. At a glucose concentration of 5 mM the 
effect was far less marked (Holst et a/, 1987).
In the perfused rat pancreas even more dramatic stimulation by tGLP-1 has been 
reported. Mojsov and co-workers found that with 6.6 mM glucose, 5xl0-n M tGLP-1 
stimulated insulin secretion more than 10 fold (Mojsov etal, 1987). They also reported 
that GLP-1(1-37) was without effect for concentrations up to 10-7 M. Another group 
have reported a significant rise in insulin secretion using half as much tGLP-1 again 
(2.5x10-11 M) at glucose concentrations of 11.2 mM (Komatsu etal, 1989).
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Comparison of the effects of tGLP-1 and GIP on insulin secretion suggests that the 
former may be as much as 10 times more potent in molar terms than the latter (Shima et 
al, 1988). In low ambient glucose concentrations, insulinotropic activity is only 
observed for supraphysiological tGLP-1 concentrations (Matsuyama et al, 1988). 
Similar results have also been obtained using rat pancreatic islet cell monolayer 
cultures, demonstrating that tGLP-1 acts directly at the B cells (D’Alessio etal, 1989).
In man plasma concentrations of immunoreactive GLP-1 (IR-GLP-1) rise 
following both oral glucose loads and mixed meals (Kreymann eta/, 1987 ; 0rskov 
and Holst, 1987). Simultaneous IV infusion of glucose and synthetic tGLP-1 into 
normal subjects to match the post-prandial levels observed following an oral glucose 
load produced a greatly enhanced insulin response compared with glucose alone. 
Furthermore, there was a greater insulin response to simultaneous IV glucose and tGLP- 
1 than to simultaneous glucose and GIP (Kreymann etal, 1987). On this evidence it is 
now proposed that tGLP-1 may represent a physiological incretin that rivals the 
importance of GIP.
1.6.1 DISTRIBUTION OF GLP-1 IN THE GI TRACT
In contrast with GIP which is predominantly confined to the upper small 
intestine, by far the most immunoreactive GLP-1 (IR-GLP-1) is found in the ileum and 
colon (Kreymann etal, 1988). It appears to be synthesized in the enteroglucagon cells 
(Vamdell etal, 1985 ; Kauth and Metz, 1987). Secretion of tGLP-1 from these cells is 
accompanied by parallel secretion of GLP-2 and the enteric glucagon-like 
immunoreactant glicentin (0rskov etal, 1986). This suggests that they are co-localized 
in the same secretory granules in the endocrine cells.
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1.6.2 STIMULATION OF tGLP-1 SECRETION FROM THE 
GUT
It has already been mentioned that mixed meals and oral glucose loads produce 
increases in circulating IR-GLP-1 in man (Kreymann et al, 1987). D-glucose also 
stimulates IR-GLP-1 release from the perfused porcine ileum (0rskov et al, 1986). 
There have been no reports published that compare the effects of carbohydrate, fat and 
protein or amino acids on IR-GLP-1 secretion.
One group have investigated the effect of a selection of sugars and sugar 
derivatives on stimulation for IR-GLP-1 secretion from canine ileal loops (Shima etal, 
1990). Based on their results, they proposed that the release is under the influence of a 
glucose sensor on the enteroglucagon cells which has specific steric requirements for 
the binding of sugars. Any sugar that fulfills these requirements can bind to the sensor 
and stimulate IR-GLP-1 release.
1.6.3 OTHER ACTIONS OF tGLP-1
As well as directly stimulating insulin release, tGLP-1 can also stimulate insulin 
gene expression in cultured rat insulinoma cells (Drucker etal, 19SI). tGLP-1 but not 
GLP-1(1-37) stimulates somatostatin and inhibits glucagon release from perfused 
porcine, canine and rat pancreas at concentrations similar to those required for 
stimulation of insulin (0rskov etal, 1988 ; Kawai etal, 1989 ; Komatsu etal, 1989). 
Similarly, in human subjects IV infusions of tGLP-1 significantly suppresses glucagon 
levels (Kreymann etal, 1987).
It is possible that the glucagonostatic effect of tGLP-1 is due to the increased 
levels of insulin and somatostatin acting as paracrine inhibitors of glucagon secretion 
(Klaff and Taborsky, 1987) rather than by direct action of tGLP-1 on the glucagon- 
secreting A cells. If  this is so it could explain the apparently anomalous results
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obtained by D’Allesio and co-workers who reported no effect of tGLP-1 on glucagon 
secretion in their rat pancreatic islet cell monolayer cultures (D’Allesio et al, 1989). In 
such a system the paracrine mechanisms normally found in intact islets may well have 
been disrupted.
Recently claims have been made that tGLP-1 may well act as an enterogastrone. 
In normal human subjects infusion of tGLP-1 to produce plasma concentrations of 
30pM or just under 70pM inhibit pentagastrin-stimulated gastric acid secretion by 36% 
and 50% respectively (Schjoldager etal, 1989 ; O’Halloran et al, 1990). GLP-1(1- 
36)amide was far less potent in this respect.
In experiments with isolated vascularly perfused rat stomachs, tGLP-1, but not 
GLP-1 ( 1 -36)amide, stimulated somatostatin release from the D-cells of the stomach and 
inhibited gastrin release from G-cells (Eisselle et al, 1990). As with glucagon in the 
endocrine pancreas, it is not yet known whether the inhibition of gastrin release is 
caused by direct action of tGLP-1 on the G-cells or indirectly by the increased 
somatostatin levels.
In isolated rat gastric glands and human gastric cancer cells, 60 pM tGLP-1 can 
produce a 50% inhibition of pentagastrin-stimulated gastric acid secretion (Hansen etal, 
1988). A single class of high affinity receptors specific for tGLP-1 has been identified 
on isolated rat fundic glands (Uttenthal and Blazquez, 1990).
In fish hepatocytes tGLP-1 can activate both gluconeogenesis and 
glycogenolysis (Mommsen and Moon, 1990). The magnitude of this effect and 
relative importance of the two mechanisms in the stimulation of glucose production 
varies both seasonally and from species to species (Plisetskaya etal, 1989 ; Mommsen 
and Moon, 1990).
In contrast, Ghiglione and co-workers found no receptors for or effects of GLP- 
l(l-36)amide on rat hepatocytes (Ghiglione et al, 1985). It remains to be shown 
whether or not this lack of effect was due to the fact that they were not using the 
biologically active form.
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There is mounting evidence that tGLP-1 acts as a neurotransmitter. It has been 
isolated from rat brain (Yoshimoto etal, 1989) and high affinity receptors specific for 
the truncated form have been identified (Kanse et al, 1988 ; Shimizu et al, 1987). 
Subcellular distribution experiments indicate that tGLP-1 is present in synaptosomes 
(Jin etal, 1988) and it is released from hypothalamic tissue slices in a calcium- 
dependent manner by potassium stimulation (Kreymann etal, 1989).
1.6.4 POSSIBLE ROLE OF tGLP-1 IN DISEASE
As for GIP, tGLP-1 might be expected to play a part in diseases characterized 
by abnormal insulin levels. There are, however, currently very little experimental data 
relating to this possibility. Two independent group have found raised fasting and post­
prandial plasma IR-GLP-1 in NIDDM subjects (Hirota etal, 1990 ; 0rskov etal, 1991). 
In both cases they demonstrated that the raised fasting concentrations were due to 
increased levels of the IR-GLP-1 form secreted by the pancreas. On the other hand, the 
enhanced response to oral glucose' was due, at least in part, to increased secretion of 
tGLP-1 from the GI tract.
In streptozotocin-induced diabetic rats increased tGLP-1 levels are found in the 
colon (Kreymann et a/, 1988). This may be caused by the characteristic hyperphagia of 
such animals.
Interestingly, the IR-GLP-1 response to oral glucose is dramatically enhanced 
in subjects with post-gastrectomy dumping syndrome (Kreymann etal, 1987 ; Mijolic 
etal, 1990). It is postulated that the rapid gastric emptying observed in these subjects 
is responsible for promoting nutrient absorption in the more distal gut. This then 
stimulates increased tGLP-1 release which is responsible for the hyperinsulinaemia and 
reactive hypoglycaemia associated with this syndrome.
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1.7 MECHANISM OF INSULIN SECRETION
Glucose has traditionally been considered the primary mediator of insulin 
secretion. However, this is not necessarily an accurate description. At normal 
physiological concentrations glucose alone is only a weak stimulator of insulin release 
from the pancreas. Neural and hormonal agents, including the components of the 
entero-insular axis, act in concert to enhance insulin release provided the prevailing 
glucose concentration is sufficiently high.
The proposed mechanism of insulin secretion has recently been 
comprehensively reviewed (Morgan etal, 1988a; Rasmussen etal, 1990). Unusually, 
glucose does not act via surface receptors on the B cells. Instead the products of 
glucose metabolism provide the necessary signal. A high rate of glucose metabolism 
increases the concentration of ATP in the B cells which in turn binds to an ATP- 
sensitive potassium ion channel and reduces potassium ion efflux. The plasma 
membrane potential consequently falls and this produces a small increase in calcium 
(Ca2+) ion influx via a voltage-dependent Ca2+ channel. The resultant Ca2+ signal is 
integral to the action of glucose.
Leucine, the only amino acid capable of stimulating insulin secretion in the 
absence of glucose, probably acts in the same manner as glucose. Arginine and lysine 
enter B cells through specific transporters producing depolarization of the membrane 
and consequently opening the Ca2+ channels (Morgan etal, 1988a).
1.7.1 ACTION OF NEURAL AGENTS
The pancreas has cholinergic, adrenergic and peptidergic innervation. At least 
some of these neurones appear to play a direct role in the stimulation of insulin 
secretion. In this respect, the best characterized neuronal agents are acetylcholine and 
CCK. These appear to function in the pancreas using the same second messenger
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system, namely the activation of hydrolysis of polyphosphoinositides (Malaisse, 1986; 
Zawalich etal, 1987a).
One product of the hydrolysis produces a transient intracellular Ca2+ rise by 
mobilizing intracellular stores. This stimulates phosphorylation of specific cellular 
proteins responsible for the first phase of insulin secretion. Other products cause the 
association of Ca2+-sensitive protein-kinase C with the plasma membrane and enhance 
the glucose-stimulated Ca2+ influx through the voltage-sensitive Ca2+ channels. The 
combination of these results in the phosphorylation of a second set of cellular proteins 
which are responsible for the second phase of insulin secretion.
Prior exposure of islets to CCK and cholinergic agents sensitizes them to the 
effects of glucose (Zawalich etal, 1987b ; Zawalich et al, 1989). This effect is 
probably due to the sustained translocation of protein-kinase C to the plasma membrane 
where it can be immediately activated by glucose-induced Ca2+ influx.
1.7.2 ACTION OF HORMONAL AGENTS
GIP and tGLP-1 also share a common second messenger system. Both bind to 
specific receptors on the B cell (Goke and Conlon, 1988) and activate the enzyme 
adenylate cyclase (Szecowka etal, 1982 ; Drucker etal, 1987 ; Goke etal, 1989). This 
enzyme produces an increase in the intracellular levels of cyclic AMP (cAMP). This 
can increase the influx of Ca2+ and also apparently enhance the effects of the two 
branches of the Ca2+ messenger system activated by acetylcholine and CCK.
Because the hormonal and neural factors employ different second messengers, 
they can act synergistically (Zawalich, 1988).
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1.8 AIMS OF PROJECT
Research into GIP and tGLP-1, as important stimulants of insulin secretion, is 
potentially of interest in the context of diseases associated with abnormal insulin levels, 
since it is possible that one or both of these hormones may play a role in the 
pathogenesis of such diseases. Alternatively, GIP or tGLP-1, or analogues of these 
hormones, might prove useful in the treatment of diseases of disordered insulin 
secretion. However, much still remains unclear about the secretion, molecular 
heterogeneity and biological actions of GIP and, particularly, tGLP-1 in healthy 
subjects, let alone in subjects with diseases such as diabetes, short bowel syndrome or 
obesity.
The initial objective of this project was to develop a sensitive RIA for tGLP-1. 
Secondly, although a sensitive RIA for GIP was already available (Morgan et al, 
1978), the antiserum had been raised against porcine GIP and was known to crossreact 
with other components in human plasma apart from human GIP(l-42) (Krarup, 1988). 
Therefore, antisera were to be raised against a synthetic fragment of human GIP 
containing the 2 amino acid residues that differ from the sequence of porcine GIP, with 
the aim of developing a second RIA exhibiting greater specificity for human GIP(l-42) 
than the first. After validation, the 2 novel assays could be used as tools for the 
investigation of the relevance of GIP and tGLP-1 in the entero-insular axis of man and 
other animals.
To this end, the project was to investigate 3 major areas in assessing the 
contribution of tGLP-1 and GIP in the entero-insular axis. Firstly, characterization of 
the molecular forms of IR-GLP-1 detected by the novel assay. Secondly, examination 
of the acute and chronic effects of different nutrients and whole foods on IR-GLP-1 
and IR-GIP with particular emphasis on the effects of different forms of carbohydrate. 
Thirdly, investigation of the role of tGLP-1 and GIP in the disordered insulin secretion 
associated with obesity and short bowel syndrome.
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CHAPTER 2
MATERIALS AND METHODS
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2.1 MATERIALS
All Standard laboratoiy chemicals were purchased from BDH, Poole
CHEMICALS
Charcoal (Norit OL) 
Dextran T-70 
Sephadex G-50 Fine 
Sephadex-G-25
SUPPLIERS
Hopkin and Williams, Chadwell Heath 
Pharmacia, Uppsala, Sweden 
Sigma Chemical Company Ltd, Poole 
Sigma Chemical Company Ltd, Poole
PEPTIDE HORMONES
GIP (human, synthetic)
GIP (porcine) and
GIP fragment (15-42) (human)
GIP fragments (1-11), (19-25) 
and (19-30) (porcine)
GLP-l(7-36)amide, GLP-1(1-37), 
GLP-1(7-37) and GLP-2 
GLP-1 ( 1 -36)amide 
Glucagon (porcine)
Motilin (porcine)
Secretin (porcine)
VIP (porcine)
SUPPLIERS
Peninsula Laboratories, St Helens
Gift from Professor J.C. Brown, University of 
British Columbia, Vancouver
Gift from Professor JJ . Holst, Panum Institute, 
Copenhagen
Peninsula Laboratories, St Helens 
Sigma Chemical Company Ltd, Poole 
Sigma Chemical Company Ltd, Poole 
Gift from Professor F. Bell, Babraham Royal 
Veterinaiy College, London 
Sigma Chemical Company Ltd, Poole 
Sigma Chemical Company Ltd, Poole
PROTEINS
Albumin, Bovine Serum,
Fraction V (BSA)
Albumin, Human Serum,
Fraction V (HSA)
Aprotinin
Cyanocobalamin
Gel filtration molecular weight markers 
Keyhole limpet haemocyanin (KLH) 
Ovalbumin
SUPPLIERS
Sigma Chemical Company Ltd , Poole
Sigma Chemical Company Ltd , Poole 
Novo Biolabs, Bagsvaerd, Denmark 
Sigma Chemical Company Ltd , Poole 
Sigma Chemical Company Ltd , Poole 
Sigma Chemical Company Ltd , Poole 
Sigma Chemical Company Ltd , Poole
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RADIOCHEMICALS
1251 sodium iodide 
1251-Insulin
SUPPLIERS
ICN Biomedicals Ltd, High Wycombe 
Amersham International PLC, Aylesbury
RIA REAGENTS
Donkey anti-rabbit immunoglobulin G 
Insulin assay kit
SUPPLIERS
Guildhay Antisera Ltd, Guildford 
Guildhay Antisera Ltd, Guildford
MISCELLANEOUS
Accutrol chemistry controls 
(normal and abnormal)
Bacillus Calmette Guerin (BCG)
Calibrator I
Cannulae (Y-Can 19g)
Chromatography Columns 
(polypropylene, 35p filter)
C. Pavum
Fluoride/oxalate tubes 
Glucose Uni-kit III
Lithium heparin tubes
Non-ulcerative Freund’s Adjuvant (NUFA)
Murinyl dipeptide (MDP)
Seitz Filters (Filtrox (W-Steril) filters) 
Silica beads (1000pm diameter, 
porous amino-activated)
Test tubes (plastic, LP3 and LP4)
Test tubes (plastic, Minisorp)
Universal tubes (plastic, 25ml)
SUPPLIERS
Sigma Chemical Company Ltd, Poole 
Evans Medical Limited, Greenford 
Roche Products Ltd, Welwyn Garden 
City
Medical Assist Ltd, Colchester 
Lab m. Bury
Gift from Dr B. Morris, University of 
Surrey
Laboratory Sales Ltd, Cambridge 
Roche Products Ltd, Welwyn Garden 
City
Griffiths and Nielson, Billingshurst 
Guildhay Antisera Ltd, Guildford 
Gift from DrB. Morris, University of 
Surrey
H. Erben Ltd, Ipswich
Gift from Dr P. Kwasowski, Clifmar 
Associates,Guildford 
Luckham Ltd, Burgess Hill 
Life Technologies, Uxbridge 
Philip Harris Scientific, London
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2.2 GLP-1 ASSAY DEVELOPMENT
2.2.1 tGLP-1 lODlNATlON
The technique used was an adaptation of the chloramine-T method described by 
Kwasowski (1986). Synthetic tGLP-1 was weighed out and dissolved in an 
appropriate amount of 0.4M phosphate buffer, pH 7.4, so that it could then be split 
into 3pg aliquots each in a volume of 6pl. These aliquots were stored in autoanalyzer 
cups at -20°C until required.
Sephadex G-25 was allowed to swell overnight in acetate buffer (0. IM sodium 
acetate, pH adjusted to 5.0 with glacial acetic acid). This was then poured into a small, 
disposable plastic column (Lab m. Bury) to give a packed bed height and bed volume 
of approximately 10cm and 5ml, respectively. The column was then equilibrated in 
column buffer (acetate buffer containing, in addition, 0.5% w/v HSA and 50,000 
kallikrein inhibitory units (KIU)/1 aprotinin) by allowing 15ml to drip through under 
gravity.
On the day of the iodination an aliquot of tGLP-1 was defrosted and brought to 
room temperature. To it was added lOjjl (ImCi) of carrier-free 1251 sodium iodide in 
sodium hydroxide solution. Chloramine-T (15pg in lOpl of 0.4M phosphate buffer, 
pH 7.4) was then added. The reactants were mixed for 25 seconds by repeatedly filling 
and emptying the pipette tip used to add the chloramine-T. The reaction was then 
stopped by the addition of sodium metabisulphite (40pg in 20jil of 0.4M phosphate 
buffer, pH 7.4). Approximately 200pl of column buffer was added to the autoanalyzer 
cup and the resultant mixture applied to the top of the sephadex column. Twenty four 
fractions each of 10 drops (approximately 0.5ml) were collected and lOpl of each was 
counted using an LKB 1260 Multigamma counter.
A typical elution profile is shown in figure 2.1. The first peak of radioactivity 
corresponds to the radiolabelled hormone, while the second represents free 1251.
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FIGURE 2.1 TYPICAL GEL FILTRATION ELUTION 
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The fractions containing the greatest amount of radioactivity from the first peak were 
split into 20pl aliquots and stored at -20°C. The recovery of radioactivity eluted from 
the column was calculated by summation of the radioactivity in all the fractions. The 
recovery of tGLP-1 was assumed to be the same as that of the radioactivity. By 
calculating the total radioactivity in the first peak eluted from the column, the specific 
activity of the labelled tGLP-1 was estimated. The value obtained was typically of the 
order of 150 to 200pCi/pg (1.8 to 2 .4x10^6 Bq/mole).
The iodogen technique of iodination was also assessed (Fraker and Speck, 
1978). For this a solution containing 1 mg/ml of iodogen in dichloromethane was made 
up. Aliquots of 40pl of this solution were pipetted into 1.5ml microfuge tubes and the 
solvent evaporated off under a stream of nitrogen. The iodogen-coated tubes were 
stored (desiccated) at 4°C until required.
To carry out the reaction lOpl of 1251 sodium iodide (ImCi) was added to such 
a tube. The tGLP-1 (3jjg in 6pl of 0.4M phosphate buffer, pH 7.4) was then added 
and the tube shaken for 10 minutes at room temperature. The reaction was stopped by 
the addition of 200pg of sodium metabisulphite in 200pl of 0.4M phosphate buffer, pH 
7.4. The radiolabelled tGLP-1 was separated from any free 1251 on a sephadex column 
as described above. A typical elution profile is shown in figure 2.1.
The tracers obtained by both methods were of very similar quality in terms of 
specific activity, stability and binding to antiserum. The chloramine-T method was 
used routinely on the basis of simplicity.
2.2.2 PRODUCTION OF tGLP-1 STANDARDS
tGLP-1 standards of lOOng each were produced exactly as described by 
Kwasowski (1986). Briefly, a small quantity of synthetic tGLP-1 was accurately 
weighed out (typically 20 to 40pg). This was dissolved in a buffer consisting of
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0.14M lactose, 0.04M HSA, llnM  citric acid, 6nM cysteine hydrochloride and 
1600KIU/ml aprotinin in O.IM formic acid (Sarson etal, 1980). Aliquots of lOOpl, 
containing lOOng of tGLP-1, were placed in freeze-drying vials. These were 
lyophilized and stored at -20°C under vacuum ready for use.
2.2.3 PRODUCTION OF CHARCOAL-STRIPPED SERUM
Charcoal-stripped serum (CSS) was produced in the same manner for addition 
to the assay tubes of the standard curves of all plasma RIAs. Several hundred grams of 
charcoal (Norit OL) was suspended in 2 to 3 volumes of distilled water. The slurry 
was swirled briefly and then allowed to settle for 10 minutes. The water above the 
charcoal was decanted off and the volume made up again with a fresh supply of 
distilled water. The procedure of swirling, sedimentation and decanting was carried out 
twice more to ensure removal of fine particles. The charcoal was then dried overnight 
in an oven at 70°C.
Healthy human volunteers donated 500ml of blood after an overnight fast. The 
blood was collected into kilner jars and allowed to clot for at least one hour. The serum 
was separated and centrifuged (1250g, 15 minutes, 4°C) to remove any remaining red 
blood cells. The samples were then pooled and the total volume obtained was 
measured. To this was added 20g of the charcoal per 100ml of serum. The slurry was 
left overnight at 4°C with constant stirring. The following day, the slurry was 
centrifuged at 1850g for 30 minutes at 4°C to sediment as much of the charcoal as 
possible. The supernatant was separated and passed through Seitz filters under vacuum 
using a Buchner flask and Buchner funnel. The filtration process was repeated until no 
visible charcoal was deposited on the filters and the filtrate was a clear, straw-coloured 
liquid. The CSS was then split into aliquots and stored at -20°C.
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2.2.4 PRODUCTION OF ANTISERA
2.2.4.1 PRODUCTION OF tGLP-l-BSA CONJUGATES
Two methods were used to couple chemically tGLP-1 to BSA. In the first, 
200jig (60nmoles) of tGLP-1 and 400pg (6nmoles) of BSA were each dissolved in 
200pl of distilled water and the two solutions combined. A solution containing 60pg 
(SOOnmoles) of l-ethyl-3-(3 dimethylaminopropyl)-carbodiimide hydrochloride made 
up in 1ml of distilled water, was added dropwise with constant stirring. The reaction 
mixture was left stirring at room temperature overnight. It was then dialyzed against 
distilled water (1 litre, 4-5 changes) for a further 24 hours. Finally, the contents of the 
dialysis bag were made up to 2ml and stored at -20°C in 0.5ml aliquots until required.
The second method was an adaptation of that described by Reichlin and 
co-workers (Reichlin etal, 1968) using glutaraldehyde. The conjugation was carried 
out on the morning that the rabbits were to be primed or boosted. The tGLP-1 (lOOjig, 
30nmoles) was dissolved in lOOjil of distilled water and this was mixed with 200pg of 
BSA (3nmoles) that had been made up in 50pl of distilled water. To this was then 
added 150pl of a 2.5% v/v solution of glutaraldehyde (38pmoles). The reactants were 
mixed thoroughly and left to stand at room temperature for between 30 and 60 minutes.
2.2 .4 .2  IMMUNIZATION OF RABBITS AGAINST tGLP-1
Four young (3 month old) female half lop rabbits were obtained (Regal Rabbits, 
Bookham). Two were primed with the equivalent of 50pg of tGLP-1 in the form of the 
conjugate produced with carbodiimide. The other two received an identical dose of the 
conjugate produced with glutaraldehyde. Together with the conjugates, all four rabbits 
were also given lOOpl of BCG to stimulate the immune response.
Both immunogens were thoroughly emulsified with NUFA (2 volumes of oil :
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1 volume of aqueous immunogen). For the prime this emulsion was then injected 
intradermally at 30 to 40 site (approximately 50jul emulsion/site) on the rabbits’ backs.
The animals were bled regularly from a lateral ear vein and the blood allowed to 
clot overnight. The serum was then separated out and stored at 4°C with sodium azide 
added to a final concentration of 0.1% w/v to act as a preservative.
Nine months after the prime and again four months after that the rabbits 
received boosts. In each case, the animals received half the dose of conjugate that they 
had for the prime. BCG was not included in the boosts. The immunogens were 
emulsified in NUFA as before. The emulsions were injected intramuscularly into 4-5 
sites on the animals’ hind legs. They were bled 8,10 and 13 days after each boost and 
then at less frequent intervals after that.
2.2.5 AFFINITY PURIFICATION OF TRACERS
To produce an affinity column for tOLP-1 an early bleed was selected (02- 
14/6/89) on the basis of its moderate titre (see section 2.2.7). Immunoglobulins were 
partially purified from the bleed by ammonium sulphate precipitation. To achieve this, 
2ml of saturated ammonium sulphate solution was added to 2ml of the antiserum. This 
was mixed at room temperature for 30 minutes and then centrifuged at 1850g for a 
further 30 minutes. The supernatant was discarded and the precipitate dissolved in 2ml 
of phosphate buffered saline (PBS) (1.15g/l Na2HP0 4 , 8gd NaCl, 0.2g/l KCl, 0.2g/l 
KH2PO4). This solution was subjected to two more ammonium sulphate precipitations 
in exactly the same manner as the first. The final solution was dialyzed against PBS 
(100 volumes and 4 changes) at 4“C overnight. The protein concentration of the 
contents of the dialysis bag was estimated by measuring its absorbance at 280nm.
The solid phase used was 1000pm diameter, porous, amino-activated silica 
beads. Approximately Ig of this was placed in a stoppered small plastic column
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together with 5ml of a 5% v/v solution of glutaraldehyde. This was left mixing for 30 
minutes at room temperature. The glutaraldehyde solution was then allowed to drip out 
of the column and the solid phase washed thoroughly with distilled water.
The contents of the dialysis bag were made up to 5ml with PBS and added to 
the solid phase in the column which was stoppered and left to mix for 2 hours at room 
temperature. The liquid was then allowed to drip out of the column. It was collected 
and its absorbance at 280nm measured. The value obtained was compared with that for 
the solution that was initially added to ensure that immobilization of the antiserum had 
taken place. The column was then washed by passing 15ml of 0.5% w/v hydrochloric 
acid solution (pH 1.5) then 15ml of distilled water through it. A IM solution of 
ethanolamine (pH adjusted to 7.4 with hydrochloric acid) was then mixed with the solid 
phase for 2 hours at room temperature to block any remaining free aldehyde groups on 
the solid phase.
Finally the column was washed again with 0.5% w/v hydrochloric acid 
followed by distilled water. It was stored at 4'C under bicarbonate buffer (1.59g/l 
NazCO], 2.93 g/1 NaHCOg, pH 9.8).
To affinity purify tracer the column was first washed with 15ml of 0.5% w/v 
hydrochloric acid, then 15ml of distilled water. The column was then equilibrated with 
assay diluent (0.04M phosphate buffer, pH 6.5, containing 0.5% w/v HSA and 
500,000 KIU/1 aprotinin) by dripping 15ml through it. One or more aliquots of 
radiolabelled tGLP-1 were defrosted and loaded onto the column together with 5ml of 
assay diluent. The column was stoppered and the solid phase and tracer mixed for 20 
to 30 minutes at room temperature. The buffer was allowed to drip out and the column 
washed with 15ml of distilled water. The tracer was then eluted by the addition of 5ml 
of 0.5% w/v hydrochloric acid. As before the column was further washed with 
hydrochloric acid then distilled water before being stored at 4°C under bicarbonate 
buffer ready for subsequent uses.
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2.2.6 PHASE SEPARATION TECHNIQUES
Two methods for separating the antibody-bound and free tGLP-1 fractions were 
used during the development of the tGLP- 1 assay. The first was the double antibody 
method used routinely in this laboratory for the long-standing GIP assay (Morgan etal, 
1978). The second method, using dextran-coated charcoal (DCC), was adopted later 
for the tGLP-1 assay as it proved to be affected less by non-specific plasma effects than 
the double antibody method whilst also being faster and as reliable. The practical 
aspects of both techniques are discussed in the following two sections.
2.2.6.1 DOUBLE ANTIBODY METHOD
The second antibody used was donkey anti-rabbit immunoglobulin G (DAR). 
For each new batch of DAR a dilution curve was set in which a fixed amount of first 
antibody was incubated with a fixed amount of tracer for 48 hours at 4°C before 
addition of DAR at a range of different dilutions. The DAR was then used at the 
greatest dilution which still gave maximal binding of the first antibody.
To achieve phase separation, 50pl of DAR, diluted appropriately with assay 
diluent, was added to each assay tube. In addition, 50pl of normal rabbit serum (NRS) 
(diluted 135-fold with assay diluent) and lOOpl of 14% w/v PEG 6000 (in 0.04M 
phosphate buffer, pH 6.5) were added to increase pellet size and accelerate formation of 
double antibody micelles, respectively. The tubes were thoroughly vortexed and left at 
4°C for 4 hours before centrifugation at 1380g for 20 minutes at 4°C. The supernatant, 
containing free tGLP-1, was aspirated and the radioactivity in the pellet counted.
2.2.6.2 DEXTRAN-COATED CHARCOAL METHOD
A stock solution of DCC was produced by dissolving 5g of dextran T-70 in
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llitre of 0.04M phosphate buffer, pH 6.5, followed by addition of 50g of charcoal 
(Norit OL) with constant stirring. This solution was diluted 5-fold with 0.04M 
phosphate buffer on the day of use. The charcoal was kept in suspension by constant 
stirring while 1ml of the solution was added rapidly to all assay tubes. The tubes were 
then vortexed. Superimposable standard curves were obtained for the tGLP-1 assay 
when the tubes were incubated at this stage for 10, 20 or 40 minutes so an incubation 
period of 20 minutes was adopted. The tubes were then centrifuged at 1850g for 30 
minutes at 4'C. The clear supernatant, containing the antibody-bound fraction, was 
decanted into another set of tubes and these were counted for radioactivity.
2.2.7 ASSESSMENT OF ANTISERA
2.2.7.1 ANTISERUM DILUTION CURVES
Titre was assessed for the different bleeds obtained by means of antiserum 
dilution curves. For this, duplicate tubes were set up containing 200pl of assay 
diluent, lOOpl of i25l-labelled tGLP-1 tracer (affinity purified and diluted to 
5000cpm/10pl), and antiserum from the bleed under investigation, at an initial dilution 
of 125, 250, 500, 1000, 2000, 4000 or 8000 times in assay diluent. Identical curves 
were also set up using serum obtained from each animal prior to immunization.
The tubes were vortexed thoroughly and then left for 48 hours at 4'C. 
Antibody-bound tracer was separated from the free fraction by the double antibody 
method essentially as described above (section 2.2.6.1) except that 50pl of assay 
diluent instead of diluted normal rabbit serum was added to tubes in which the first 
antiserum was at an initial dilution of less than 1000-fold, since they would already 
contain sufficient rabbit serum. Furthermore, DAR was used at half the normal dilution 
in these tubes to account for the larger quantities of first antiserum.
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The radioactivity present in the tubes which contained serum from the four 
rabbits prior to immunization was taken to represent non-specific binding. This was, 
therefore, subtracted from the activity in the tubes containing antisera from the 
corresponding animals at the corresponding dilutions. For each bleed the percentage of 
antibody-bound tGLP-1 tracer was plotted against antiserum dilution. The titre was 
taken as the estimated antiserum dilution that would give half maximal binding of the 
label. The titre of the various antisera obtained from the animals are represented 
graphically in figure 2 .2 .
2 .2 .7 .2  CONSTRUCTION OF STANDARD CURVES AND 
OPTIMIZATION OF ASSAY CONDITIONS
A selection of the highest titre bleeds from each rabbit were used to set up 
standard curves. A range of different incubation times and sample volumes were 
investigated so as to obtain reasonable maximum binding of tGLP-1 tracer together 
with the greatest displacement and sensitivity possible.
The best results were obtained for antisera from rabbits G2 and G3. In the 
final protocol, a sample volume of 200pl was adopted and this was incubated for 24 
hours at 4°C in the presence of antiserum (G2-30/6/89 at an initial dilution of 6000-fold 
in assay diluent), before the addition of the tGLP-1 tracer and a further 48 hours at 4'C. 
All samples were mn in duplicate. Tubes containing no antiserum (replaced with lOOpl 
of assay diluent) were included with the standard curve and for each subject whose 
samples were to be assayed, to allow for correction for non-specific binding of the 
radiolabelled tGLP-1. Phase separation was achieved by the dextran-coated charcoal 
method (described in section 2.2.6.2). The tGLP-1 assays were carried out in 
polyethylene Minisorp tubes to minimize peptide adsorption onto the plastic. The 
additions to the different tubes in the assay are outlined in table 2 .1.
42
FIGURE 2.2 ANTI-tGLP-1 ANTISERA TITRES
(A) Titres for the rabbits immunized with the conjugate produced 
using glutaraldehyde. Animal G1 died after 150 days
(B) Titres for the rabbits immunized with the conjugate produced 
using carbodiimide
(A )
TITRE ( T h o u s a n d s )
12 1
RABBITS 
- B -  G1 
G2
10 -
0 50 100 150 200 250 300 350 400 450  500
DAYS AFTER IMMUNIZATION
(B)
TITRE ( T h o u s a n d s )
10  -1
RABBITS
G3
G4
0 50 100 150 200 250 300  350 400 450  500
DAYS AFTER IMMUNIZATION
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TABLE 2.1 ADDITION OF REAGENTS TO tGLP-1 
ASSAY TUBES
NSB = non-specific binding
Total Standard Standard Standard Sample Sample 
NSB Zero NSB
Diluent
CSS
Standard
Sample
Antiserum
200pl
200jil
lOOjil
200jil
lOOpl
lOOpl 200pl 
200pl 
lOOpl
lOOpl
200pl 200pl
lOOpl
INCUBATE FOR 24 HOURS AT 4"C
Tracer lOOjnl lOOpl lOOpl lOOpl lOOjul lOOpl
INCUBATE FOR 48 HOURS AT 4°C
DCC 1ml 1ml 1ml 1ml 1ml
INCUBATE FOR 20 MINUTES AT 4"C 
CENTRIFUGE 1850g FOR 30 MINUTES AND SEPARATE
4 4
2.2.7.3 ASSAY SENSITIVITY
The limit of detection of the assay was assessed by setting up a standard curve 
as normal but with multiple standard zero tubes. The standard deviation of the 
percentage label bound in these replicate zero tubes was calculated. Two times the 
standard deviation was subtracted from the mean percentage label bound at zero. The 
concentration of tGLP-1, read from the standard curve, corresponding to this calculated 
value (as shown in figure 2.3) was defined as the limit of detection of the assay. In this 
way, the value obtained for the limit of detection of this assay was calculated at 6pM.
2.2.7.4 ASSAY REPRODUCIBILITY
The intra-assay coefficients of variation (CV) at 10.3, 19.3 and 24.0pM were 
13.0, 10.1 and 9.3% respectively (n=12 for each). The inter-assay CVs (n=16) for 
quality controls with mean values of 15.4, 29.4 and 33.5pM were 17.4, 14.1 and 
13.4% respectively.
4 5
FIGURE 2.3 PLASMA tGLP-1 ASSAY SENSITIVITY
Error bars denote mean ± standard deviation (S.D.) (n=6), 
except at zero where the error bar denotes mean ± 2 x S.D. 
(n=12)
1 2 5 - I - t G L P - l  BOUND
25 1
20  -
15 -
10 -
6pM
0 20 40 60 80 100 120 140 160
t G L P - 1  CONCENTRATION (pM)
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2.2.7.5 ANTISERUM GROS S REACTIVITY
The crossreactivity of the antisera raised against synthetic tGLP-1 was assessed 
by setting up a normal standard curve and a range of curves constructed using known 
concentrations of other peptide hormones to compete with the tGLP-1 tracer for binding 
to the antisera. Crossreactivity was defined as the concentration of tGLP-1 required to 
inhibit the binding of t25i-labelled tGLP-1 to half that observed at zero divided by the 
concentration of the crossreacting hormone required to have the same effect. This value 
was quoted as a percentage.
The antiserum tested (G2-30/6/89) exhibited no detectable crossreactivity up to 
a concentration of 400,000pg/ml with human GIP, porcine GIP, GLP-2, glucagon, 
VIP, somatostatin, secretin, motilin, and synthetic fragments of porcine GIP 
corresponding to amino acids 1-11, 19-25, and 19-30 (figure 2.4A). It crossreacted 
100% with GLP-l(l-36)amidebut less than 0.2% with GLP-1(7-37) and GLP-l(l-37) 
(figures 2.4B and 2.4C).
2.2.8 ASSAY VALIDATION
2.2.8.1 RECOVERY
Recovery was assessed by assaying a range of samples from one batch of 
plasma that had previously been spiked with synthetic tGLP-1 to increase their total 
tGLP-1 concentrations by 10, 20, or 40pmol/l. The results obtained are displayed 
graphically in figure 2.5. The tGLP-1 concentrations measured with the assay were 
90%, 97% and 111% of the predicted values for the plasma spiked with 10, 20 and 40 
pmol/1 tGLP-1 respectively.
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FIGURE 2.5 RECOVERY FOR tGLP-1 ASSAY
Error bars denote mean ± S.D. (n=4)
Line denotes 100% recovery
ASSAYED t G L P - 1  CONCENTRATION (pM)
70 -|
60 -
50 -
40 -
30 -
20  -
10 20 30 40 50 60 70
PREDICTED t G L P - 1  CONCENTRATION (pM)
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2.2.8.2 PARALLELISM
Two different human plasma samples were obtained that contained moderate 
levels of tGLP-1. Aliquots of both were diluted with human CSS to three quarters, 
half and one quarter of their original concentrations. These were then assayed for tOLP- 
1 together with both the original samples. The results are shown in figure 2.6. For 
both samples the dilution curves obtained were essentially superimposable on the 
standard curve.
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FIGURE 2.6 PARALLELISM OF tGLP-1 ASSAY
Error bars denote mean ± S.D. (n=4)
% 1 2 5 - I - t G L P - l  BOUND
2 5  -I
20  -
1 5  -
10 -
PLASMA SAMPLE
SAMPLE 1
SAMPLE 2
101 100
t G L P - 1  CONCENTRATION (pM)
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2.3 HUMAN GIP ASSAY DEVELOPMENT
The human GIP assay was developed in a manner almost identical to that 
described for the tGLP-1 assay.
2.3.1 GIP lODINATION
Both porcine and human GIP were radiolabelled with 1251 in a similar fashion 
to the chloramine-T technique used for tGLP-1 (section 2.2.1), except that 5jjg of 
either sort of GIP (in lOjil of 0.4M phosphate buffer, pH 7.4) was used and the 
reaction time with the chloramine-T was only fifteen seconds. Typical elution profiles 
for porcine and human GIP are shown in figure 2.7. The specific activities obtained 
were normally in the range of 120 to 150pCi/|ig (2.2 to 2.8xlQi6 Bq/mole) for both 
human and porcine GIP.
Both kinds of tracer were affinity purified as described for tGLP-1 (section 
2.2.5) immediately before being used. The column used for this was a generous gift 
from Dr P. Kwasowski that had been produced in a similar fashion to that described 
above using an antiserum raised in sheep against porcine GIP.
2.3.2 PRODUCTION OF GIP STANDARDS
Standards for porcine and human GIP were produced exactly as described for 
tGLP-1 in section 2.2.2.
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FIGURE 2.7 TYPICAL GEL FILTRATION ELUTION
PROFILES FOR THE lODINATION OF GIP
(A) Human GIF
(B) Porcine GIF
(A )
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2.3 .3  PRODUCTION OF ANTISERA
2.3.3.1 PRODUCTION OF GIP(15-42) CONJUGATES WITH 
OVALBUMIN AND KLH
Synthetic human GIP( 15-42) was conjugated to either ovalbumin or KLH using 
the glutaraldehyde technique (section 2.2.4.1). GIP( 15-42) (lOOjjg, 40nmoles) and 
ovalbumin (470]ig, 8nmoles) were dissolved in 200^1 and lOOjLtl of sterile water, 
respectively. These were combined and conjugated by addition of 150jil of a 2.5% 
solution of glutaraldehyde exactly as described in section 2.2.4.1. The GIP( 15-42)- 
KLH conjugate was produced in the same manner, with the only difference being in the 
quantity of KLH (95pg, ISpmoles) that was used.
2.3.3.2 IMMUNIZATIONS OF RABBITS AGAINST GIP(15-42)
Four male New Zealand White rabbits were obtained (Regal Rabbits, 
Bookham). Two were primed with the ovalbumin conjugate (Rabbits R1 and R2) and 
two with the KLH conjugate (rabbits R3 and R4). The equivalent of lOOpg of GIP( 15- 
42), in the form of the conjugates, was injected into each rabbit for the prime. For one 
animal from each pair, 300jil of immunogen solution was combined with 200pl of 
BCG and 300pl of sterile water. This solution was emulsified with 2 volumes of 
NUFA and injected subcutaneously at approximately 30 sites (50pl at each) on the 
rabbits’ backs. The other two rabbits were treated similarly except that the dose of 
BCG was cut to lOOpl and the 300pl of sterile water was replaced with 300pl of C. 
Pavum and 2mg of MDP in lOOpl of water.
All the animals were boosted 8 and 12 months after the prime,with the 
equivalent of 50pg of GIP( 15-42) in the form of the appropriate conjugate. The 
procedure for the boosts was exactly as described earlier (section 2.2.4.2).
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2 .3 .4  ASSESSM ENT OF ANTISERA
The antisera produced by the rabbits were assessed in the same fashion as 
described for the anti-tGLP-1 antisera (section 2.2.7). The titres obtained are 
represented graphically in figure 2.8. One bleed (R1-20/7/87) was selected from one of 
the rabbits on the basis of its high titre and the displacement observed over a range of 
GIP standards. As for the tGLP-1 assay, different incubation periods were tested to 
optimize the assay sensitivity. The best results were achieved using conditions identical 
to those described for the original, anti-porcine GIP assay (Morgan etal, 1978). The 
additions to the various assay tubes and the incubation periods are outlined in table 2.2.
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FIGURE 2.8 ANTI-HUMAN GIP ANTISERA TITRES
(A) Titres for rabbits immunized with GIP(15-42)-ovalbumin 
conjugates
(B) Titres for rabbits immunized with GIP(15-42)-KLH 
conjugates
(A)
TITRE ( T h o u s a n d s )
10 -,
RABBITS 
- S -  R1
500 700100 200 300 400 600
(B)
DAYS AFTER IMMUNIZATION
TITRE
1500 -1
1000  -
500 J
A N I M A L  D I E D
0
100
RABBITS
200 300 400 500
DAYS AFTER IMMUNIZATION
600 700
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TABLE 2 .2 ADDITIONS OF REAGENTS TO HUMAN GIF 
ASSAY TUBES
NSB = Non-specific binding
NRS = Normal rabbit serum
DAR = Donkey anti-rabbit immunoglobulin G
PEG = Polyethylene glycol 6000
Total Standard Standard Standard Sample Sampli
NSB Zero NSB
Diluent 300pl 200pl lOOpl 300pl 200pl
CSS lOOpl lOOpl lOOpl --- ---
Standard --- lOOpl - - - ---
Sample --- --- lOOpl lOOpl
Antiserum — --- lOOpl lOOpl lOOpl
INCUBATE FOR 24 HOURS AT 4"C
Tracer lOOpl lOOpl lOOpl lOOpl lOOjil lOOpl
INCUBATE FOR 48 HOURS AT 4“C
NRS 50pl 50pl 50pl 50pl 50pl
DAR 50pl 50pl 50pl 50pl 50pl
PEG lOOpl lOOpl lOOpl lOOpl lOOpl
INCUBATE FOR 4 HOURS AT 4"C 
CENTRIFUGE 1380g FOR 30 MINUTES AND ASPIRATE
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Under these conditions, using the antiserum at an initial dilution of4000-fold in 
assay diluent and affinity purified human GIP tracer (diluted to 10,000cpm/100pl) the 
limit of detection (two standard deviations from zero) was 28pM (figure 2.9).
The anti-human GIP antiserum exhibited no detectable crossreactivity with 
tGLP-1, glucagon, VIP, somatostatin, secretin or motilin up to concentrations of 
40,000pg/ml (figure 2.10A). It partially crossreacted (35%) with natural porcine GIP 
but not with synthetic fragments of porcine GIP corresponding to amino acids 1-11, 19- 
25 or 19-30 (figure 2.1GB).
The intra-assay CVs (n=12) at 81, 270 and 394pM were 21.5, 10.8 and 4.7% 
respectively. The inter-assay CVs (n=12) at 49, 299 and 633pM were 18.7%, 9.7% 
and 14.5%, respectively.
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FIGURE 2 .9  PLASMA HUMAN GIF ASSAY SENSITIVITY
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FIGURE 2.10 ANTI-HUMAN GIP ANTISERUM 
CROSSREACTIVITY
(A) Crossreactivity with other GI hormones
(B) Crossreactivity with porcine GIP and porcine GIP (P. GIP) 
fragments
(A)
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2 .3 .5  A SSA Y  VALIDATION
2.3.5.1 RECOVERY
Recovery was assessed by addition of a range of concentrations of synthetic 
human GIP to different fractions of a plasma pool. These fractions together with the 
untreated plasma pool were then assayed for GIP. The recovery in the fractions to 
which synthetic human GIP had been added was calculated as the assayed GIP 
concentrations quoted as a percentage of the expected concentration determined by 
assaying the GIP concentration in the untreated pool. The calculated recoveries were 
102, 103, 108 and 112% for samples treated with synthetic human GIP to increase 
their total GIP concentration by 50, 100, 150 and 200pM respectively (figure 2.11).
2.3 .5 .2  PARALLELISM
This was demonstrated in a similar fashion to that described for the tGLP-1 
assay. However, it proved much easier to obtain human plasma samples containing 
high GIP concentrations than it had to obtain samples high in tGLP-1. Consequently, 
serial dilutions up to 16-fold were made from two such samples. The results obtained 
are shown in figure 2.12. For both samples, the dilution curves closely matched the 
shape of the standard curve.
FIGURE 2.11 RECOVERY FOR HUMAN GIP ASSAY
Error bars denote mean ± S.D. (n=4)
Line denotes 100% recoveiy
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FIGURE 2.12 PARALLELISM OF HUMAN GIF ASSAY
Error bars denote mean ± S.D. (n=4)
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2.4 PORCINE GIF ASSAY
The original plasma GIF assay, with the antiserum raised against porcine GIF 
(Morgan etal, 1978), was for all animal samples. Both the original and new assays 
were used to measure GIF in one set of human samples for comparison.
The protocol was essentially as described originally except that for human 
plasma samples, synthetic human GIF standards and tracer were used. The limit of 
detection of the assay was 16pM. The intra-assay CVs (n=12) at 24, 212 and 327pM 
were 14.5, 2.4 and 4.8% respectively. The inter-assay CVs (n=7) at 37, 163 and 
363pM were 21.2, 8.0 and 3.7%, respectively.
2.5 INSULIN ASSAY
The insulin assay was as described by Hampton (1984). The limit of detection 
was less than 3mU/l. The intra-assay CVs (n=8) at 10.1, 38.6 and 57.8mU/l were 
7.9%, 2.6% and 7.3%, respectively. The inter-assay CVs (n=8) at 10.0, 39.0 and 
54.9mU/l were 14.2, 10.5 and 12.3%, respectively.
2.6 PLASMA GLUCOSE DETERMINATION
Flasma glucose concentrations were determined using an automated hexokinase 
method as outlined below :-
hexokinase
D-glucose + ATF ..............> D-glucose-6-phosphate + ADF
glucose-6-phosphate dehydrogenase 
D-glucose-6-phosphate + NAD+................> D-gluconate-6-phosphate + NADH + H+
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Using this method, the glucose in any plasma sample will be proportional to the 
amount of NADH produced. The concentration of NADH was measured 
photometrically by absorption at 340nm. The reagents required were supplied as a kit 
(Uni-kit II or III and Calibrator I) and the analysis carried out on a Cobas Bio 
Autoanalyzer (Roche Products Ltd, Welwyn Garden City). All samples were assayed 
in duplicate and the mean value calculated. For each individual study, all the samples 
were assayed on one day. Normal and abnormal standards (Sigma Chemical 
Company, Poole) were used as quality controls. These were included in each run. The 
within-day inter-assay CVs were always less than 12% for the normal control (mean 
value 5.1mM) and 7% for the abnormal control (mean value 16.9mM).
2.7 CAPILLARY BLOOD GLUCOSE 
DETERMINATION
Capillary blood was collected by finger-prick using an autolet (Owen Mumford 
Ltd, Woodstock). The glucose concentrations in the drops of blood obtained in this 
manner were measured using BM-Test-Glycemie 1-44 strips and a Refiolux IIM 
glucose meter (BCL, Lewes) used according to the manufacturers instructions.
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2.8 BLOOD SAMPLING
Approval was obtained from the Ethical Committees of the University of Surrey 
and the Royal Surrey County Hospital for all studies involving human subjects except 
for the study described in chapter 8, involving the short bowel subjects, for which 
approval was obtained from the Ethical Committee of the City and Hackney District 
Health Authority. Informed consent was obtained from all the volunteers.
In all such studies, blood was taken from a cannula which had been inserted 
into an antecubital vein in the arm The samples were split between 5ml or 10ml 
lithium heparin tubes for plasma RIAs and 2.5ml fluoride oxalate tubes for plasma 
glucose determination. Where tGLP-1 was to be analyzed, lOOOKIU of aprotinin was 
added to a 5ml lithium heparin tube to inhibit any proteolysis.
The filled, stoppered tubes were inverted to ensure mixing and then immediately 
centrifuged at lOOOg for 15 minutes. The plasma was separated from the red cells and 
stored in aliquots at -20°C for subsequent analysis.
Blood samples from rodents were obtained by cardiac puncture or tail vein 
bleeds. The blood obtained was collected into 1ml or 5ml lithium heparin tubes and 
treated exactly as described for the human samples.
2.9 TISSUE EXTRACTION
Sections of gastrointestinal tract and pancreases were obtained from rodents and 
pigs immediately after slaughter. The pancreases were snap-frozen in a dry 
ice/methanol bath. The sections of GI tract were cleared of any digesta by gentle 
squeezing between gloved fingers and then rinsing with distilled water. These were 
also then snap-frozen as soon after excision as possible. All tissue samples were stored 
frozen at -20°C.
For the extraction procedure (Kenny, 1955), the tissue pieces were weighed
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and placed in plastic universal tubes on ice. Precooled (4°C) acid/ethanol solution 
(150 : 50 : 3 volumes of absolute ethanol : distilled water : 37%w/v hydrochloric acid) 
was added to give either 5 or lOml/g wet weight tissue. The tissue was minced very 
finely using a sharp pair of scissors and then sonicated for 5 minutes in a ultrasonic 
bath (Grant Instruments Ltd, Cambridge). After an overnight incubation at 4°C the 
tubes were centrifuged at 1850g for 30 minutes at 4°C. The supernatant was decanted 
off and stored at -80°C.
The extracts obtained were assayed for GIP and tGLP-1 using the porcine GIP 
assay and tGLP-1 assay as normal except that CSS was replaced with assay diluent in 
the standard curve. A second GLP-1 assay was also used. The protocol for this was 
identical to that used for the first except that a different antiserum (code 2135, used at 
an initial dilution of 10000-fold, a generous gift of Professor J.J. Holst, Copenhagen) 
was used. For each set of extracts a preliminary experiment was carried out to 
determine the optimal dilution, in assay diluent, at which the extracts should be 
assayed.
2.10 GEL FILTRATION CHROMATOGRAPHY
Gel filtration chromatography was carried out to investigate the different GLP-1- 
like and GlP-like immunoreactivities detected by the various assays in plasma and 
tissue extracts.
2.10.1 PACKING OF COLUMN
Sephadex G-50 Fine was allowed to swell overnight at 4°C in 0.04M phosphate 
buffer, pH 6.5. The slurry was degassed under vacuum and then poured into a column 
Im long with an internal diameter of 16mm (C/16/100 column Pharmacia Ltd, Milton
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Keynes) to give a packed bed height of 85-90cm (bed volume 170-180ml). Packing 
was achieved by passing 4-5 bed volumes of 0.4M phosphate buffer, pH 6.5, through 
the column. The flow rate was adjusted to 22ml/hour using a peristaltic pump (Pump 
PI, Pharmacia Ltd, Milton Keynes). After packing the flow rate was reduced to 
20ml/hour. The column was maintained at 4°C for all experiments.
2.10.2 CALIBRATION OF COLUMN
The column was calibrated using a set of standard low molecular weight 
markers consisting of BSA, carbonic anhydrase, cytochrome C, aprotinin and 
cyanocobalamin. For each run 1.5ml of sample was made up in 0.04M phosphate 
buffer, pH 6.5, and loaded onto the column. Fractions, each of 2ml, were collected 
and their absorbance at 280nm measured.
The void volume of the column (Vo) was determined in this way using 3mg of 
dextran blue. BSA (7.5mg) and cytochrome C (3mg) were combined in a second run. 
The third run included carbonic anhydrase (3mg), aprotinin (4.5mg) and 
cyanocobalamin (3mg). The elution volume (Ve) of each of these proteins was taken as 
the volume corresponding to the fraction exhibiting the greatest absorbance at 280nm 
for the appropriate peak. A calibration curve of V^/Wq against log i(/molecular weight) 
was plotted (figure 2.13) for use in determining the apparent molecular weights of 
peptides and proteins from tissue extracts run on the column .
The column was then equilibrated in chromatography buffer (0.04M phosphate 
buffer, pH 6.5, containing 0.1% w/v HSA, 200,000KIU/1 aprotinin and 0.24g/l 
thiomersal). The column calibration was assumed to be still valid with the new buffer 
system since the elution volumes of the coloured markers, cytochrome C and 
cyanocobalamin were unchanged.
68
FIGURE 2.13 CALIBRATION CURVE FOR G-50 
SEPHADEX COLUMN
Ve Denotes volume of elution of each protein
Vo Denotes void volume of column calculated as Ve for dextran
blue
MOLECULAR MASS
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2.10.3 GEL FILTRATION CHROMATOGRAPHY OF 
TISSUE EXTRACTS
Acid ethanol tissue extracts were produced as described above (section 2.9). 
using 10ml of the acid/ethanol solution per gram of tissue. The extracts (3ml 
corresponding to 0.3g of tissue) were placed in glass tubes on ice in a fume cupboard 
and 15ml of diethyl ether (precooled to -20°C) was added. The contents of the tube 
were mixed with a glass pasteur pipette and left on ice to allow the aqueous and organic 
phases to separate. The tubes were then transferred to a dry ice/methanol bath. In this 
the lower, aqueous phase froze allowing the upper, organic to be decanted off 
(Newgard and Holst, 1981). The tubes were removed from the bath and any remaining 
organic solvents were removed under a stream of nitrogen.
A small amount of a mixture of i25l_sodium iodide and i25i-bovine 
thyroglobulin was added to the tubes for determination of total column volume (Vj) and 
Vo respectively. The volume in each tube was then made up to 1.5ml with 
chromatography buffer and this was the form in which the samples were applied to the 
column. The fractions obtained after each sample run were counted for radioactivity. 
Fractions between Vq and V t were assayed for IR-GIP and IR-tGLP-1 in the same 
fashion as for tissue extracts. The elution positions of immunoreactivities were 
designated by their coefficients of distribution (Kd) which was calculated as follows:-
Kd = Ve~ Vq 
Vt - Vq
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2.10.4 GEL FILTRATION CHROMATOGRAPHY OF
UNEXTRACTED, ETHANOL EXTRACTED AND 
IMMUNO-EXTRÀCTED PLASMA SAMPLES
For analysis of GIP-like immunoreactivities in human plasma, 5ml samples of 
fasting or post-prandial samples, obtained by pooling plasma from several subjects, 
were subjected to gel filtration chromatography. These plasma samples were 
centrifuged at lOOOg for 10 minutes at 4oC to remove any fibrin before being applied to 
the column. As for the tissue extracts, small amounts of i^si-sodium iodide and 125I_ 
labelled bovine thyroglobulin were added to the plasma samples, prior to gel filtration, 
for the determination of Vj and V o- The fractions obtained from the gel filtration run 
were assayed for GIP, using both the anti-porcine GIP and anti-human GIP antisera, in 
the same manner as described in section 2.3.4. except that the CSS in the tubes of the 
standard curve was replaced with lOOpl of column buffer.
Pools of human fasting and post-prandial plasma were also subjected to ethanol 
extraction before gel filtration. For this, 90ml of absolute ethanol, precooled to 40C, 
was mixed thoroughly with 30ml of plasma on ice. The mixture was then centrifuged 
at 1850g for 20 minutes at 4oC. The supernatant was decanted into another glass 
vessel and the precipitate discarded. The ethanol was removed from the extract using 5 
volumes of diethyl ether in exactly the same manner as for the tissue extracts (section 
2.10.3). The resultant aqueous, proteinaceous phase was made up to a volume of 1.5 
ml with column buffer and subjected to gel filtration in the same manner as for the 
tissue extracts and whole plasma samples. The fractions obtained were assayed for 
GIP as described for the gel filtration of whole plasma.
Fasting and post-prandial pooled human plasma samples were also subjected to 
immuno-extraction prior to gel filtration. A cocktail of antisera consisting of anti- 
porcine GIP (RICIIID), anti-human GIP (Rl-16/7/89, Rl-25/11/88, R2-20/7/87 and 
R2-25/11/88) and anti-GLP-1 (G2-15/5/89, G2-30/6/89, G3-23/1/90, G3-21/3/90, G4- 
1/5/90 and 2135-4) antisera was produced to encompass all the possible
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cross reactivities of the antisera used in the various GIP and GLP-1 assays. From this 
cocktail affinity columns were produced by the method described in section 2.2.5.
The contents of the affinity columns were mixed at 4°C for 2 hours with 50ml 
of pooled human fasting or post-prandial plasma to which had been added lOOOKIU/ml 
aprotinin. The mixture was then poured back into the columns and the plasma allowed 
to drip out. The solid phase was washed thoroughly with distilled water and antibody- 
bound substances eluted with 5ml of the acid/ethanol mixture used for tissue 
extractions. This eluant was then extracted with 5 volumes of diethyl ether as described 
above, and run on the column. The fractions obtained were assayed for GLP-1 as 
described for the column chromatography of tissue extracts and for GIP as described 
for the gel filtration fractions for whole plasma.
2.11 BREATH HYDROGEN ANALYSIS
Exhaled hydrogen was measured for the wheat starch study described in section 
5.3. For this, duplicate or triplicate exhaled, end-tidal breath samples were collected 
from each subject 10 minutes before each meal, immediately before each meal, every 20 
minutes for 3 hours after commencement of each meal and then every 15 minutes for a 
further period of up to 90 minutes or until a sustained increase in breath hydrogen had 
been observed.
To collect the breath samples, the subjects were told to breath normally. They 
were required to exhale through a plastic T-piece to which a 20ml plastic syringe had 
been attached on one arm while the other arm had been left open. The exhaled breath 
was allowed to escape through the open arm until the subject had reached the point at 
which he or she would normally stop exhaling. Then the open arm of the T-piece was 
blocked by placing a finger firmly over it and the subject would exhale a further 20ml to 
fill the syringe. The full syringes were immediately removed from the T-piece and
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stoppered. As soon as possible (usually within a couple of minutes) the breath samples 
were injected into an 81 HP exhaled hydrogen monitor (Gas Measurement Instruments 
Ltd, Renfrew) which had previously been calibrated with a standard gas mixture 
supplied by the manufacturers.
2.12 STATISTICAL ANALYSES
In acute studies, the total area under the curve over the post-prandial sampling 
period for any parameter was calculated for each individual subject using the trapezium 
rule. The incremental area under the curve was calculated as the total area under the 
curve minus the area corresponding to the mean lasting value for the parameter under 
investigation multiplied by the total post-prandial sampling time. The calculation of 
total area under the curve for the parameters measured in the 24 hour study (chapter 6) 
was calculated in essentially the same fashion as for the acute meal studies but a period 
of 4 hours after each main meal was used for the calculation.
Comparison between experimental groups was made by one-way analysis of 
variance, and differences between groups were identified using Duncan’s ranges test. 
Values ofp<0.05 and p<0.01 were taken to be significant.
Significant changes in post-prandial concentrations of different parameters were 
identified by comparison of the mean fasting concentrations with post-prandial 
concentrations at individual time points using Student’s paired t tests. As before, 
values of p<0.05 and p<0.01 were taken to be significant.
The plasma GIP concentrations measured with the 2 different GIP assays were 
compared by linear regression. The calibration curve for the gel filtration 
chromatography column was also constructed using linear regression.
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CHAPTER 3
COMPARISON OF GIP ASSAYS: 
PLASMA IR-GIP RESPONSES TO 
A MIXED MEAL IN LEAN AND 
OBESE SUBJECTS
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3.1 INTRODUCTION
It has been recognized for some considerable time that hyperinsulinaemia and 
insulin resistance are characteristic in obesity (Karam etal, 1963). The same seems to 
be true for aging and glucose intolerance (DeFronzo, 1979). Insulin resistance is also a 
feature of NIDDM. However, the insulin response to different stimuli can be 
exaggerated, normal or diminished in this condition (DeFronzo etal, 1983).
The entero-insular axis could play a role in the development of abnormal insulin 
secretion. In an early study, Perley and Kipnis gave oral and IV glucose loads to lean 
and obese, diabetic and non-diabetic subjects to assess the relative insulinotropic 
potency of the glycaemic stimulus (insulin secretion following IV load) and, as they 
termed it, the alimentary stimulus (insulin secretion following oral glucose minus that 
following rV glucose) (Perley and Kipnis, 1967). Their results suggested that the 
alimentary stimulus was depressed in both lean and obese diabetic subjects. In 
contrast, it was increased in obese non-diabetics.
As GIP has been recognized for some time as a good candidate incretin, its 
levels in the plasma of obese subjects has been extensively investigated. However, as 
was mentioned briefly in chapter 1 (section 1.5.5), the role of GIP in obesity still 
remains far from clear.
The majority of workers have found, to varying extents, enhanced GIP 
responses to oral glucose and mixed meals (Creutzfeldt etal, 1978 ; Elahi etal, 1984 ; 
Mazzaferri etal, 1985 ; Ebert and Creutzfeldt, 1989 ; Jones etal, 1989). It has been 
suggested that the elevated GIP concentrations observed in these studies were caused, 
at least in part, by loss of feedback inhibition of GIP secretion by insulin (Creutzfeldt et 
al, 1978).
A number of groups have reported experiments that revealed no difference in 
GIP responses between lean and obese subjects (Jorde etal, 1983 ; Sarson etal, 1983 ; 
Amland etal, 1984) and in some cases diminished GIP responses have been observed
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in association with obesity (Groop etal, 1989).
Various factors have been proposed as having played a role in producing these 
contradictory results. These include variation in the energy content and type of test 
meal used, effects of differing dietary regimens prior to study, subject selection and 
methodological differences in the assays used to measure plasma GIP.
Many of the studies mentioned above employed 50, 75 or lOOg oral glucose 
loads. However, in some cases mixed meals were used (Ebert era/, 1976 ; Creutzfeldt 
etal, 1978 ; Jorde etal, 1983 ; Jones etal, 1989). The variation in the relative 
proportions of carbohydrate fat and protein may affect the results since it was shown, 
in one study, that a lOOg oral fat load evoked a greater GIP response in obese subjects 
compared with lean controls, whereas there was no difference in GIP levels between 
lean and obese subjects following lOOg of glucose (Creutzfeldt etal, 1978).
Furthermore, the energy content of the different test loads used varied from 
200kcal (50g glucose) to 1031kcal (Creutzfeldt etal, 1978). This variation could 
potentially play a part in determining whether significant differences in GIP responses 
were observed in any given study. One study was designed to address this factor in 
relation to post-prandial GIP responses in obesity (Ebert and Creutzfeldt, 1989). Sex 
and age matched lean and obese non-diabetic subjects were given mixed liquid meals of 
varying energetic content and volume. Following the lower energy (422kcal meal), 
lower volume (225ml) liquid mixed meal there was no difference in the post-prandial 
GIP concentrations between the 2 groups. A high energy (1031kcal), high volume 
(550ml) liquid mixed meal produced very similar levels in the lean group to those 
observed for the low energy, low volume meal. In contrast, the high energy, high 
volume load elicited a markedly exaggerated GIP response in the obese subjects.
A low energy (422kcal), high volume (550ml) liquid mixed meal produced a 
more rapid post-prandial rise in GIP in both groups than did the low energy, low 
volume meal. Following an intraduodenal liquid mixed meal infusion, GIP levels were 
identical for the 2 groups even though the obese subjects exhibited higher plasma
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glucose and insulin concentrations.
The results of this study strongly implied a significant role of differential liquid 
gastric emptying rates between lean and obese subjects in producing elevated GIP 
responses to large meals. It is possible that obese subjects on high energy diets who 
consume large meals adapt to this regimen so that their maximal rate calorie efflux from 
the stomach is greater than that for lean subjects. This would explain the results 
described above (Ebert and Creutzfeldt, 1989). It would also explain the fact that 
Amland and co-workers found that 5 of 12 lean control subjects suffered from nausea 
and vomiting following a heavy duodenal infusion of fat and glucose, whereas none of 
the 8 morbidly obese subjects investigated complained of any discomfort following 
identical infusions (Amland etal, 1984). Even mild nausea that may have been felt by 
subjects following large test meals in other studies could have slowed gastric emptying 
and consequently altered post-prandial GIP responses.
The composition of the subjects’ diet prior to participation in studies may also 
influence the results obtained. Grey and Kipnis have reported reduced fasting insulin 
concentrations and improved glucose tolerance in obese subjects after 3 or 4 weeks on 
low carbohydrate diets compared with the values observed in the same subjects on 
isocaloric high carbohydrate diets (Grey and Kipnis, 1971). Normal, healthy subjects 
given high carbohydrate diets for as short a period as 1 week have been reported to 
exhibit elevated GIP responses to oral glucose loads (Mazzaferri etal, 1984). The form 
of the carbohydrate may also be important since it has been demonstrated that a diet 
high in sucrose lead to elevated plasma GIP responses compared with a diet containing 
the equivalent amount of carbohydrate in the form of wheat starch (Reiser etal, 1980).
In healthy lean subjects, a high fat diet (fed for 28 days) was found to enhance 
the GIP response to oral glucose (Morgan etal, 1988b). Furthermore, when lean 
subjects who habitually consumed a relatively high fat diet were placed on a low fat diet 
for 35 days, their GIP response to an oral fat load was attenuated (Morgan et al, 
1988c).
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In one study obese subjects were given 3 test loads consisting of a large mixed 
meal, glucose and fat, before and after undergoing 21 days of starvation or a restricted 
energy (SOOkcal/day) diet (Willms etal, 1978). Basal GIP concentrations were found 
to increase while basal insulin concentrations decreased following the starvation period. 
However, the exaggerated GIP and insulin responses to oral glucose observed at the 
start of the study were reduced following both starvation and food restriction. The 
same was true for the GIP response to oral fat. The improvement in GIP levels was 
appreciable after only 5 days of food restriction at which point no change in insulin was 
detectable. The insulin response to IV glucose was unaffected by either regimen. 
These results led the workers to conclude that the exaggerated GIP levels in obesity 
were secondary to increased food intake and that changes in insulin response to food 
were related to changes in GIP response.
A different group who placed obese subjects on strict dietary management for a 
period of 8 weeks to achieve weight loss (8.7±0.95% of body weight) found a similar 
reduction in basal insulin concentrations and insulin response to oral glucose following 
the diet. However, they observed no change in basal or post-prandial GIP levels 
(Jones etal, 1982). It seems, therefore, that whilst the majority of experimental work 
points towards a significant effect of habitual diet on GIP levels, the evidence is not 
conclusive.
Another factor that may play a role in determining whether or not significant 
differences are observed between control and obese subjects is the selection of the 
subjects. Different groups use differing criteria in the selection of lean and obese 
volunteers. Any alterations in GIP secretion that may be associated with obesity are 
likely to be related to the extent of the condition. Differences in age and sex of the 
subjects could also influence the results, although the results of one study did not 
demonstrate any such effect of age on plasma GIP levels (Groop etal, 1989).
Discrepancies in experimental results between groups may also be caused by 
differences in methodologies. A number of different antisera have been raised against
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GIP and used to develop several radioimmunoassays. The GIP assays used in the 
studies discussed above all employed antisera raised against purified porcine GIP as 
this was the only form of GIP available at the time of their development. GIP 
concentrations in human plasma measured with these different antisera vary markedly 
(Alam and Buchanan, 1980b ; Jorde etal, 1983 ; Krarup etal, 1985b).
Human GIP has now been isolated from small intestinal extracts and sequenced 
(Moody et al, 1984). Like porcine GIP, it was found to be 42 amino acids long and 
differs in sequence only at residues 18 and 34. Many of the anti-porcine GIP antisera 
have apparent binding regions that incorporate the sequence differences between the 
porcine and human forms of the hormone (Krarup, 1988).
Gel filtration chromatography carried out on plasma samples has revealed the 
presence of 3 IR-GIP forms (Brown etal, 1975 ; Sarson etal, 1980). One of these 3 
forms (Vo-IR-GIP) elutes in the void volume of sephadex G-50 columns. The other 2 
forms have apparent molecular weights of approximately 8000 and 5000 Da (8000-IR- 
GIP and 5000-IR-GIP). Both porcine and human GIP have actual molecular weights 
close to 5000 Da and purified porcine GIP elutes at the same position as 5000-IR-GIP.
The nature of the 8000-IR-GIP form is not clear. Otte and co-workers found 
that the entire sequence of GIP was not present in 8000-IR-GIP isolated from porcine 
intestine and concluded that it does not represent a proform of the hormone (Otte et al, 
1984). Porcine pancreatic perfusion experiments showed that 8000-IR-GIP is not 
insulinotropic (Krarup etal, 1987a).
Vo-IR-GIP may be produced as a result of an interaction between GIP and large 
plasma proteins. However, concentrations of Vo-IR-GIP did not change following 
stimulation of GIP secretion with oral fat or glucose (Krarup et al, 1985b). So it is 
more likely that the apparent presence of Vo-IR-GIP is caused by non-specific 
interference of plasma proteins in the radioimmunoassays (Kramp etal, 1987b).
Following ingestion of nutrients, the majority of the increase in total IR-GIP in 
plasma is due to an increase in 5000-IR-GIP (Krarup etal, 1985b). Some studies have
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shown post-prandial increases in 8000-IR-GIP and it has been suggested that fat 
produces a more marked elevation in this form than does glucose (Krarup etal, 1985b) 
but a comprehensive study employing a range of different antisera has demonstrated 
only small and inconsistent rises in 8000-IR-GIP following intraduodenal infusions of 
glucose and fat (Krarup, 1988).
The different anti-porcine GIP antisera have markedly different patterns of 
crossreactivity with the 3 forms of IR-GIP present in plasma (Krarup, 1988). Most 
detect all 3 forms, but a few do not crossreact with 8000-IR-GIP (Krarup etal, 1985b ; 
Groop etal, 1989). In other assays plasma extraction is used which removes the Vo-
IR-GIP (Krarup, 1988). Some of the antisera exhibit markedly lower crossreactivity 
with the 5000-IR-GIP form. This is likely to be due to the fact that one or both of the 
amino acid residues in human GIP that differ from those in porcine GIP are in or are 
close to the binding region for these antisera. Such antisera measure artificially low 
plasma GIP concentrations.
The molecular heterogeneity of IR-GIP in plasma and the varying 
crossreactivities of different antisera may be responsible for some of the contradictory 
results obtained by different researchers (Alam and Buchanan, 1980). There is also the 
possibility that the relative proportions of the different IR-GIP forms in plasma are 
altered in obesity or with sex and age. If this were so, different antisera would be 
expected to produce different results.
The anti-porcine GIP antiserum routinely used by our group (Morgan et al, 
1978) for the measurement of human plasma GIP exhibits the greatest crossreactivity 
with Vo-IR-GIP and 8000-IR-GIP of a selection of antisera tested by Krarup and 
coworkers (Krarup, 1988). If the concentrations of these 2 immunoreactive forms 
remain unchanged following consumption of food, the predominant effect of the 
crossreactivity of our antiserum with them is probably to produce artificially high 
apparent fasting GIP concentrations. However, post-prandial variations in the 
concentrations of these 2 immunoreactants, associated with different pathological
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conditions, cannot be ruled out. This crossreactivity, therefore, marks a theoretical 
drawback for the anti-porcine GIP assay.
In an attempt to overcome this, antisera were raised in rabbits against a synthetic 
fragment of human GIP (amino acids 15-42) which contained both the residues that 
differ from the sequence of porcine GIP. In this manner it was hoped to produce a 
radioimmunoassay employing an anti-human GIP antiserum, human GIP standards and 
radiolabelled human GIP. Such an assay would overcome any possible problems 
associated with differing crossreactivity with human and porcine GIP. In addition, it 
was hoped that the antiserum would exhibit reduced or negligible crossreactivity with 
Vo- and 8000-IR-GIP.
Described in this chapter are experiments which were designed to assess the 
relative crossreactivities of the old anti-porcine GIP and the novel anti-human GIP 
antisera with IR-GIP forms in fasting and post-prandial human plasma. In addition, 
plasma GIP concentrations were measured in lean and obese subjects following 
ingestion of a large mixed meal using both the old and new GIP assays. This 
represented part of a larger experiment, the primary aims of which were to determine 
whether GIP concentrations are elevated in obesity and, if so, whether they could be 
responsible for the elevated insulin levels. Furthermore, several factors that have been 
proposed as possible causes of the discrepancies in experimental results obtained by 
different groups concerning GIP levels in obesity were addressed.
The first of these was the possible role of previous diet in determining GIP 
responses to food. Experiments carried out in this laboratory have suggested that 
habitual dietary fat intake can play an important role in determining plasma GIP 
concentrations (Morgan etal, 1988b ; Morgan etal, 1988c). With this in mind, a group 
of lean subjects, matched for dietary fat intake to the obese group of subjects, was 
included in the study as well as a group of lean subjects matched for sex and age to the 
obese group.
The meal to be consumed by the subjects was designed approximately to match
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the energy and nutrient composition of the liquid meal used by Creutzfeldt and 
co-workers (Creutzfeldt et al, 1978) for which marked differences in GIP levels 
between lean and obese subjects had been reported. However, the meal for the study 
described here incorporated both solid and liquid components so as to be more 
representative of a normal meal than the liquid meal used by the other group. The 
possibility that differences in gastric emptying rates could be the cause of abnormal 
GIP responses in obese subjects was investigated. This was carried out by 
incorporating soluble paracetamol into the meal to act as a crude marker of the gastric 
emptying rate.
The final factor under investigation, and the one described in this chapter, was 
the possibility of discrepancies caused by differences in the results obtained by 
measurement of plasma GIP concentrations with different assays. GIP was, therefore, 
measured in the samples from subsets of the lean and obese subjects participating in the 
study using both the old anti-porcine GIP assay and the novel anti-human GIP assay.
3.2 ASSESSMENT OF FORMS OF IR-GIP
DETECTED IN HUMAN PLASMA BY ANTI- 
PORCINE AND ANTI-HUMAN GIP 
ANTISERA
3.2.1 EXPERIMENTAL DESIGN
Two pools of human plasma were generated from spare samples from the 
resistant starch study described later (section 5.3). The first pool consisted of pre- 
prandial samples taken after an overnight fast from 4 of the 6 subjects participating in 
the study. The second pool was made up from samples with high GIP concentrations 
from the same 4 subjects at various times (30, 45, 60 and 90 minutes) after ingestion of 
50g carbohydrate loads (glucose or wheat starch). On separate occasions, 5ml of each 
of these plasma pools were subjected to gel filtration chromatography as described in
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section 2.10.4. The fractions eluted from the column were assayed for IR-GIP with 
both the anti-porcine GIP and anti-human GIP antisera.
3.2.2 RESULTS
With the anti-porcine GIP antiserum Vo-IR-GIP was evident in both the fasting 
and post-prandial plasma pools. However, in the fasting pool, no other IR-GIP forms 
were detected after gel filtration. The anti-porcine GIP antiserum crossreacted with 
small amounts of 2 other molecular forms (apparent molecular weights of 11 and 5kDa) 
in the post-prandial plasma pool (figure 3.1).
The results obtained with the anti-human GIP antiserum were not clear. This 
antiserum crossreacted with the Vq-IR-GIP form but no other well defined IR-GIP 
forms were evident in either the fasting or post-prandial plasma pools. The low 
concentrations of the other IR-GIP forms and the higher limit of detection of the anti­
human assay (28pM) compared with the anti-porcine GIP assay (16pM) were probably 
responsible for this.
To try to overcome these problems, immunopurification of IR-GIP from the 2 
plasma pools was attempted as described in section 2.10.4. However, no IR-GIP was 
detectable after gel filtration in either of the immunoextracts obtained in this manner.
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FIGURE 3.1 IR-GIP DETECTED BY ANTI-PORCINE 
GIP ANTISERUM FOLLOWING GEL 
FILTRATION OF FASTING AND FED 
HUMAN PLASMA POOLS
Pooled human plasma (5ml) was loaded onto the column. The 
IR-GIP concentrations shown in the figures were the 
concentrations determined using the anti-porcine GIP assay for 
the fractions eluted from the column.
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3.3 COMPARISON OF PLASMA IR-GIP 
CONCENTRATIONS IN LEAN AND  
OBESE SUBJECTS FOLLOWING A MIXED 
MEAL DETERMINED WITH ANTI- 
PORCINE AND ANTI-HUMAN GIP 
ANTISERA
3.3.1 STUDY DESIGN
Ten obese subjects and 12 lean subjects were selected from a larger group of 
subjects who had participated in a previous study. The obese subjects (2 males and 8 
females) had body mass indices (BMIs) ranging from 29.2 to 36.1 kg/mz (mean ± S.E. 
= 31.8±1.1 kg/m2) and were aged between 18 and 51 years (mean ± S.E. = 29±3). 
The lean subjects were carefully selected so that they could be divided into 2 
overlapping subgroups each containing 10 people. The first of these subgroups (2 
males and 8 females, BMIs ranging from 19.2 to 21.5 kg/m2 [mean ± S.E. = 20.6±0.2 
kg/m2], aged from 19 to 42 years [mean ± S.E. = 26±3 years]) was matched for sex 
and, as far as possible, also matched for age with the obese subjects. The sexes and 
ages of the obese and matched lean subjects from this group are shown in table 3.1. 
The other subgroup of lean volunteers (2 males and 8 females, BMIs ranging from 
19.2 to 23.1 kg/m2 [mean ± S.E. = 20.9±0.3 kg/m2]^  aged from 19 to 41 years [mean 
± S.E. = 26±3 years]) was matched with the obese subjects in terms of usual dietary 
intake of fat. This was achieved by analysis of 9 day weighed dietary records kept by 
all the subjects participating in the previous study. The average daily fat intakes of the 
matched lean and obese subjects are shown in table 3.2.
The subjects were required to fast overnight before consuming a 1002 kcal test 
breakfast consisting of a bowl of cereal (Kellogg’s Com Flakes, Kellogg Company, 
Manchester) and cheese sandwiches (Tesco White Bread, butter and Mild Cheddar 
Slices, Tesco Stores Ltd, Cheshunt). The complete composition of the meal is shown 
in table 3.3.
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TABLE 3.1 COMPARISON OF SEX/AGE MATCHED 
OBESE AND LEAN SUBJECTS
Subjects 21 and 22 at the bottom of the table were the 2 lean 
subjects excluded from the group matched for sex and age to the 
obese subjects
OBESE GROUP LEAN GROUP
Subject Sex Age Subject Sex Age
Number (Years) Number (Years)
1 M 18 11 M 20
2 M 44 12 M 25
3 F 18 13 F 19
4 F 21 14 F 20
5 F 21 15 F 20
6 F 22 16 F 22
7 F 25 17 F 20
8 F 33 18 F 31
9 F 34 19 F 40
10 F 51 20 F 42
Mean 29 26
S.E . 3 3
[21 F 41]
[22 F 22]
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TABLE 3.2 COMPARISON OF OBESE AND LEAN 
SUBJECTS MATCHED FOR FAT INTAKE
(Subject numbering as in table 3.1)
OBESE GROUP LEAN GROUP
Subject Daily Fat Subject Daily Fat
Number Intake (g) Number Intake (g)
1 132 12 139
2 68 13 77
3 50 21 73
4 103 11 94
5 123 19 114
6 130 18 134
7 53 17 67
8 78 22 79
9 67 14 67
10 109 16 95
MEAN 93 94
S.E . 9 8
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TABLE 3.3 NUTRIENT COMPOSITION OF TEST 
MEAL
CHO = Carbohydrate
ENERGY CHO FAT PROTEIN
(kcal) (g) (g) (g)
W hite bread (105g) 245 52.2 1.8 8.2
Butter (24g) 178 --- 19.7 0.1
Cheese (60g) 244 --- 20.1 15.6
Corn Flakes (22g) 81 18.7 1.9 0.4
Sugar (15g) 59 15.0 --- ---
Whole M ilk (BOOg) 195 14.1 11.4 9.9
Total 1002 100.8 53.4 35.7
Two fasting blood samples were collected 10 minutes before and immediately 
before consumption of the meal. Further samples were taken at 15, 30,45, 60, 90, 
120, 150, 180 and 210 minutes after the subjects commenced eating. The plasma 
samples that were obtained were assayed for GIF using both the anti-porcine GIF assay 
and the novel anti-human GIF assay. For both methods, synthetic human GIF was 
used in the production of standards and radiolabeled GIF.
Statistical analyses were carried out as described in section 2.12.
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3 .3 .2  RESULTS
The plasma GIF concentrations determined for the 3 different subject groups 
using the anti-porcine GIF and anti-human GIF assays are depicted in figures 3.2 and 
3.3 and the values determined are given in tables 3.4 and 3.5 respectively.
The results obtained with the anti-porcine GIF assay suggested that the GIF 
response in obese subjects was somewhat impaired compared with lean subjects. The 
IR-GIF response was greatest for the dietary fat intake matched lean group and plasma 
IR-GIF levels in these subjects were statistically significantly greater than the levels in 
the obese subjects at 90 and 120 minutes post-prandially (p<0.05). The IR-GIF 
response for the sex/age matched lean group was intermediate between the other 2 
groups and plasma IR-GIF was only significantly higher for this group compared with 
the obese group at the 120 minute time point (p<0.05).
With the anti-human GIF assay the post-prandial concentrations also appeared 
to be slightly lower in the obese group compared with the fat intake matched group but 
the disparity was smaller than that determined with the anti-porcine GIF assay and there 
were no statistically significant differences between the 2 groups at any individual time 
point. Flasma GIF concentrations in the sex/age matched lean subjects were very 
similar to those for the obese subjects and again no significant differences were found 
at any individual time point.
There were no significant differences between either lean group and the obese 
group in fasting IR-GIF concentrations or in total or incremental areas under the curve 
over the 31/2hour post-prandial sampling period determined with either antiserum.
Figure 3.4A 3.4B and 3.4C depict the plasma GIF response to the meal 
measured with both assays for the obese group, the fat intake matched lean group and 
the sex/age matched lean group respectively. The assay based on the use of anti-human 
GIF antiserum detected lower fasting GIF concentrations than the anti-porcine GIF 
assay. In contrast, the peak post-prandial concentrations were higher when measured
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with the anti-human GIF assay than with the anti-porcine GIF assay. Linear regression 
analysis of all the results obtained with the 2 antisera yielded a value of r=0.90 
(p<0.001) (figure 3.5).
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FIGURE 3.2 PLASMA IR-GIP CONCENTRATIONS IN 
OBESE AND LEAN VOLUNTEERS 
FOLLOWING A TEST BREAKFAST 
DETERMINED USING ANTI-PORCINE GIP 
RADIOIMMUNOASSAY
Error bars indicate mean ± S.E. (n= 10)
* Denotes significant difference from obese group (p<0.05)
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TABLE 3.4 PLASMA IR-GIP CONCENTRATION IN 
OBESE AND LEAN VOLUNTEERS 
FOLLOWING A TEST BREAKFAST 
DETERMINED USING ANTI-PORCINE GIP 
RADIOIMMUNOASSAY
Values indicate mean ± S.E. (n=10)
* Denotes significant difference from obese group (p<0.05)
IR-GIP CONCENTRATION (pM)
Time Obese Lean Lean
(minutes) matched for matched for
fat intake sex/age
-10 43.1±9.3 66.7±14.8 50.7±13.3
0 43.1±9.7 72.8±12.3 54.3±10.8
15 143.4±32.5 187.3±28.6 166.8±31.3
30 238.7+26.5 296.0±23.7 260.8±28.7
45 260.6±21.0 303.7±28.7 281.7±36.4
60 238.7±31.4 324.5+25.0 296.7±33.1
90 276.4±40.1 396.9+21.9 * 362.2±34.1
120 313.2±34.4 426.6±22.0 * 431.8±23.6 *
150 328.0±33.3 401.0±27.2 370.7±41.0
180 347.1 + 13.8 394.9±29.0 362.0±40.8
210 356.3±30.5 418.0±32.4 355.1+55.0
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FIGURE 3.3 PLASMA IR-GIP CONCENTRATIONS IN 
OBESE AND LEAN VOLUNTEERS 
FOLLOWING A TEST BREAKFAST 
DETERMINED USING ANTI-HUMAN GIP
RADIOIMMUNOASSAY
Error bars indicate mean ± S.E. (n=10)
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TABLE 3.5 PLASMA IR-GIP CONCENTRATION IN 
OBESE AND LEAN VOLUNTEERS 
FOLLOWING A TEST BREAKFAST 
DETERMINED USING ANTI-HUMAN GIP
RADIOIMMUNOASSAY
Values indicate mean ± S.E. (n=10)
IR-GIP CONCENTRATION (pM)
Time Obese Lean Lean
(minutes) matched for matched for
fat intake sex/age
-10 19.0±5.5 40.1115.0 26.619.1
0 29.0±6.1 35.4112.6 26.718.7
15 172.5±61.S 171.5141.6 155.0139.3
30 229.0±38.1 314.1148.8 250.2143.9
45 288.5±4L9 301.7139.1 263.3142.9
60 260.3154.3 342.8138.2 290.3146.4
90 293.8160.1 421.9147.6 371.8148.3
120 426.7163.7 517.0135.1 434.8160.6
150 397.5158.0 460.9141.6 393.0150.3
180 495.2140.1 446.3149.4 377.8156.7
210 458.7157.0 470.1144.5 373.6160.8
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FIGURE 3.5 LINEAR REGRESSION OF PLASMA IR-GIP 
CONCENTRATIONS DETERMINED WITH 2 
DIFFERENT ANTISERA
800 -I
PLASMA I R - G I P  (p M )  (HUMAN ASSAY)
600 -
400
200  -
%
□ /A
A O B E S E
□ LEAN
0 200 400 600 800
PLASMA I R - G I P  ( p M )  ( P O R C IN E  ASSAY)
9 6
3.4 DISCUSSION
Overall, the differences in plasma GIP concentrations between the lean and 
obese subjects observed in this study were very small as determined with either assay. 
The obese subjects, however, did exhibit elevated insulin and C-peptide levels (results 
not shown). This suggests GIP is unlikely to be an important factor in the development 
of hyperinsulinaemia in obesity.
Several possible factors that could be responsible for the discrepant results 
obtained by various workers concerning plasma GIP levels in obesity were addressed 
in this study. The first of these was the possibility that high habitual dietary fat intake 
in obese subjects is responsible for elevated GIP responses. Comparison between 
obese subjects and lean subjects matched for daily fat intake revealed little if any 
difference in fasting or post-prandial GIP concentrations.
A second possible factor was that obese subjects might exhibit more rapid 
gastric emptying than lean subjects. Ebert and Creutzfeldt reported that high energy, 
high volume but not low energy, low volume liquid meals produced exaggerated GIP 
responses in obese subjects (Ebert and Creutzfeldt, 1989). However, the studies 
carried out by these workers employed liquid mixed meals. Such meals are not typical 
of any normal diet and may have produced exaggerated GIP responses in obese 
subjects due to increased liquid gastric emptying. Gastric emptying rates for liquids 
differ from those for solids.
The test breakfast used in the study described here was designed approximately 
to match the energy content and composition of the high energy liquid meal used by 
Ebert and Creutzfeldt so as to test the possibility that high energy meals produce 
exaggerated GIP responses in obesity, but, the meal consisted of both solid and liquid 
foodstuffs. Therefore, it was more representative of a normal meal and less likely to 
produce spurious differences between GIP responses in lean and obese subjects due to 
marked differences in liquid gastric emptying rates in these 2 groups of subjects.
9 7
Measurement of plasma paracetamol was used to estimate liquid gastric 
emptying rates in this study. The results of this analysis showed, contrary to 
expectations, that liquid gastric emptying was faster for the lean subjects than for the 
obese. The difference was, however, small.
The final factor tested that might influence the GIP results obtained was the 
assay system used to determine this parameter. All plasma samples were 
simultaneously assayed for GIP using 2 methods based on different anti-GIP antisera. 
Gel filtration experiments were also carried out to try to define the immunoreactants 
detected in plasma by these 2 antisera.
The results of the meal study showed normal fasting GIP concentrations in the 
obese subjects. The post-prandial GIP response in these subjects was, if anything, 
slightly lower than for both the lean groups of subjects. With the anti-porcine GIP 
assay the differences between the lean and obese groups were greater than those 
determined with the anti-human GIP assay. This lends weight to the suggestion that 
different assay methodologies may play a role in the contradictory results produced by 
different workers.
The absolute IR-GIP concentrations determined with the 2 antisera were of a 
similar order. However, fasting concentrations detected with the anti-human GIP 
antiserum were slightly lower than those detected with the anti-porcine GIP antiserum. 
The most likely explanation for this is that the anti-human GIP antiserum crossreacts to 
a lesser extent with the Vq-IR-GIP and possibly the 8000-IR-GIP than does the anti- 
porcine GIP antiserum. In contrast, the peak post-prandial concentrations determined 
with the anti-human GIP antiserum were slightly higher than those determined with the 
anti-porcine GIP antiserum. This could reflect a higher degree of crossreactivity for the 
anti-human GIP antiserum compared with the anti-porcine GIP antiserum for the 
natural form of GIP in plasma.
Gel filtration of plasma and immunoextracts of plasma did not yield clear results. 
Further attempts should be made to define the degree of crossreactivity of the 2 antisera
9 8
with different immunoreactants in plasma and to investigate the effects of nutrient 
ingestion on the levels of these different immunoreactants.
9 9
CHAPTER 4
TISSUE-SPECIFIC PROCESSING 
AND DISTRIBUTION OF 
IR-GLP-1
0 0
4.1 INTRODUCTION
The complex nature of the mammalian proglucagon gene was briefly mentioned 
in chapter 1 (section 1.6). The gene structure and current knowledge about species- 
specific and tissue-specific post-translational processing of the gene product are 
outlined here together with details of a series of experiments aimed to throw further 
light on this processing and to define the potential crossreactants in the plasma tGLP-1 
assay for different species.
Human preproglucagon is 179 amino acids long. The N-terminal 20 amino 
acids represent the signal peptide responsible for the correct transport of the gene 
product to secretory vesicles. This sequence is proteolytically cleaved during the 
transport process to give proglucagon which is 159 amino acids long.
At intervals along the length of this prohormone are dibasic amino acid 
sequences (Lys-Arg or Arg-Arg) typical of post-translational processing sites (Steiner 
etal, 1980 ; Docherty and Steiner, 1982). It appears that tissue-specific proteolytic 
cleavage at different sites is the mechanism by which the large selection of proglucagon- 
derived peptides are produced.
Proglucagon and the range of proglucagon-derived peptides are depicted 
schematically in figure 4.1. The nomenclature and proposed physiological roles of the 
confusing array of proglucagon-derived peptides produced by different post- 
translational processing of proglucagon in the A cells of the pancreas and the L cells of 
the gut have been reviewed (Conlon, 1988). Apart from referring to GLP-1(7- 
36)amide as tGLP-1, Conlon’s nomenclature shall be used.
In the L cells of the gut the N-terminal portion of the proglucagon gene product 
is cleaved to produce predominantly glicentin (proglucagon (1-69)) and oxyntomodulin 
(proglucagon (33-69)). The C-terminal portion is also processed to give free GLP-1 
and GLP-2. However, the precise nature of the fully processed peptides is not clear.
Gel filtration of extracts from porcine and dog small intestines has revealed a
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major peak of GLP-1-like immunoreactivity (IR-GLP-1) eluting at the same position as 
tGLP-1 plus a small peak of higher molecular weight (0rskov et al, 19S6 ; Suda etal,
1989). Similar experimental procedures suggest that human ileal extracts contain a 
single immunoreactive peak corresponding in size to synthetic GLP-l(l-36)amide 
(George etal, 1985 ; 0rskov etal, 1987). However, the resolution of this technique is 
not great enough reliably to distinguish between tGLP-1,GLP-1(7-37), GLP-1(1- 
36)amide and GLP-l(l-37).
0rskov and co-workers have recently purified IR-GLP-1 from both porcine and 
human small intestine (0rskov etal, 1989b). Amino acid sequencing and mass 
spectrometry showed that the major form was GLP-1(7-36)amide although they also 
found a small amount of GLP-l(7-38) (proglucagon (78-109)).
The majority of IR-GLP-1 in rat gut extracts has an apparent molecular weight 
similar to the form found in porcine and human intestinal extracts (Mojsov etal, 1986). 
Kreymann and co-workers purified this form and subjected it to mass spectrometry 
(Kreymann etal, 1988). They concluded that the predominant form is tGLP-1. 
However, another group have developed a high performance liquid chromatography 
system capable of distinguishing between the differing forms of GLP-1 (Mojsov etal,
1990). Their results suggest that tGLP-1 is the predominant form but that the tissue 
extracts also contain a significant quantity of GLP-l(7-37) and possibly a small 
quantity of GLP-1(1-3 6)amide.
The post-translational processing undergone by proglucagon in the A cells of 
the pancreas differs markedly from that in the L cells of the gut. The N-terminal section 
is predominantly processed into glicentin-related polypeptide (proglucagon (1-30)) and 
glucagon. The processing undergone by the C-terminal section appears to vary 
somewhat from species to species.
Gel filtration of human pancreatic extracts has revealed the presence of 2 IR- 
GLP-1 peaks (George etal, 1985 ; 0rskov etal, 1987). The major peak, which had an 
apparent molecular weight of approximately lOkDa, also contained GLP-2
1 0 3
immunoreactivity and was proposed to be proglucagon (72-158), termed major 
proglucagon fragment (MPGF). The smaller peak eluted at the same position as tGLP- 
1, GLP-1(1 -36)amide and the equivalent non-amidated forms. The pattern of 
processing appears to be similar in dogs (Suda etal, 1989). In pigs MPGF may be the 
only form of IR-GLP-1 produced in the pancreas (0rskov etal, 1986).
For rats, gel filtration profiles of pancreatic extracts also showed 2 peaks 
corresponding to MPGF and one or more of the free forms of GLP-1. However, in 
contrast to the situation in pigs, man and dogs, there appeared to be either as much 
(Mojsov etal, 1986) or more of the smaller immunoreactive form (Shima etal, 1987 ; 
Manaka etal, 1987) than of the MPGF. In common with the results obtained with rat 
intestinal extracts, Mojsov and co-workers have been able to identify GLP-1(1-37), 
GLP-l(l-36)amide and GLP-1(7-36)amide in the lower molecular weight peak 
(Mojsov era/, 1990).
The specificity of our antiserum for amidated forms of GLP-1 provides a useful 
tool for further elucidation of the molecular forms of this hormone produced by 
different tissues. A second anti-GLP-1 antiserum was also obtained (generous gift 
from Professor J.J. Holst, Copenhagen) for use in conjunction with ours. This 
antiserum (code 2135), designated as ’’side-viewing” by the workers who raised and 
characterized it, crossreacts with any polypeptide containing the sequence of GLP-1 (ie 
MPGF as well as tGLP-1, GLP-l(7-37), GLP-l(l-37) and GLP-l(l-36amide) 
(0rskov etal, 1987).
The experiments described in this chapter were designed to compare the 
different immunoreactivities detected by these 2 different antisera in tissue and plasma 
extracts. Pancreatic and ileal extracts from rats and pigs and human plasma extracts 
were investigated. The distribution of IR-GLP-1 along the GI tract of lean and 
genetically obese (ob/ob) mice was also determined. The distribution of IR-GLP-1 
along the GI tract of rats will be discussed in chapter 8 in the context of chronic effects 
of diet.
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4.2 TISSUE AND PLASMA SAMPLES
The rat tissues used in the studies described below were obtained from 4 young 
male ( 100-200g) Wistar rats. Sections of terminal ileum (approximately 2g) and whole 
pancreas were obtained immediately after sacrifice. These were extracted and subjected 
to gel filtration chromatography on a Sephadex G-50 Fine column as described in 
section 2.10.3. Pancreases and sections of terminal ileum (approximately 2g) were 
also obtained from 2 weaned 5 week old Large White/Landrace piglets and these were 
treated in the same fashion. For the gut distribution study, the GI tracts from 4 
genetically obese {ob/oB) mice and 4 of their lean littermates ( 16 to 20 weeks old) on 
the Aston background were excised, divided into sections and extracted.
The pooled fasting and fed human plasma samples used were the same as those 
described in chapter 3 to investigate crossreactivity of the different anti-GIP antisera 
with IR-GIP in human plasma. Samples of each pool were subjected to 
immunoextraction or ethanol extraction as described in section 2.10.3.
4.3 RESULTS
4.3.1 GEL FILTRATION OF RAT ILEAL EXTRACTS
Ileal extracts obtained from 2 rats were applied to the column on different 
occasions. The fractions collected from both runs were assayed for IR-GLP-1 using 
both anti-GLP-1 antisera. The results obtained are shown in figure 4.2.
Both antisera detected a single broad peak of IR-GLP-1 which had a maximum 
at a Kd value of 0.50 to 0.55. From the calibration curve, it was determined that this 
corresponded to a molecular weight of approximately 3.5kDa (see figure 2.13). 
Synthetic i25l-labelled tGLP-1 eluted at a similar position. The profiles obtained with
05
FIGURE 4.2 IR-GLP-1 GEL FILTRATION PROFILES OF 
RAT ILE AL EXTRACTS
Error bars indicate mean and individual values obtained from 
separate chromatography of 2 extracts. The IR-GLP-1 
concentrations shown are those determined in each fraction 
assayed and corrected to give concentration per gram wet weight 
of tissue extracted.
The arrow marks the elution position of synthetic i25i-tGLP-l
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both antisera were very similar as were the peak concentrations of IR-GLP-1 detected. 
This suggests that the majority of the IR-GLP-1 in this peak was C-terminally amidated 
but could have been either tGLP-1 or GLP-1 (l-36)amide.
Apparent IR-GLP-1 concentrations were slightly elevated above basal for all 
fractions when measured with antiserum 2135. This effect was fairly constant for all 
fractions and may have been due to non-specific interference of unrelated proteins 
rather than to the presence of true GLP-1 -like crossreactants.
4.3.2 GEL FILTRATION OF PORCINE ILEAL EXTRACTS
In an identical fashion to that described above for the rat ileal tissue, porcine 
terminal ileal extracts were subjected to gel filtration chromatography. The fractions 
obtained were again assayed for IR-GLP-1 using both antisera. The results obtained 
are shown in figure 4.3.
The ’’side-viewing” antiserum 2135 detected a major peak with a maximum at a 
Kd of 0.50 to 0.55. This corresponded to the elution positions of the IR-GLP-1 peak 
in the rat ileal extracts and synthetic i25l_tGLP-l. There also appeared to be a small 
quantity of IR-GLP-1 at the void volume and another small peak eluting between Kd 
values of 0.1 and 0.2 (corresponding to apparent molecular weights in the range of 
29000 to 22000Da). Low and inconsistent IR-GLP-1 concentrations were observed 
between Kd values of 0.7 and 1.0. The inconsistency of the results obtained over this 
range meant that no distinct IR-GLP-1 peaks could be identified.
With antiserum G2-30/6/89, the major peak eluted at the same position as for 
antiserum 2135. However, the concentrations of IR-GLP-1 in this peak were 
approximately 3- to 4-fold less when assayed using G2-30/6/89 compared with the 
concentrations determined using 2135. This was true for the gel filtration runs of both 
extracts. The antiserum G2-30/6/89 also detected a very small peak of IR-GLP-1 at the
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FIGURE 4.3 IR-GLP-1 GEL FILTRATION PROFILES OF 
PORCINE ILEAL EXTRACTS
Error bars indicate mean and individual values obtained from 
separate chromatography of 2 extracts. The IR-GLP-1 
concentrations shown are those determined in each fraction 
assayed and corrected to give concentration per gram wet weight 
of tissue extracted. The arrow marks the elution position of 
synthetic tzsRtGLP-1
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void volume and there was a suggestion of another extremely small peak of IR-GLP-1 
eluting at a Kd value of approximately 0.2. A fourth small but distinct peak was 
detected with G2-30/6/89 in both gel filtration runs at a Kd of 0.85 (apparent molecular 
weight of less than lOOODa). This low molecular weight immunoreactivity may 
represent a breakdown product.
4.3.3 GEL FILTRATION OF RAT PANCREATIC 
EXTRACTS
The gel filtration profiles for pancreatic extracts from 4 rats are shown in figure 
4.4. A single broad IR-GLP-1 peak was observed with both antisera. The calculated 
Kd for this peak was between 0.50 and 0.55. This corresponded to the Kd for the 
major IR-GLP-1 form in both rat and porcine ileum and for synthetic i25I-tGLP-1.
For antiserum 2135, apparent IR-GLP-1 concentrations were elevated above 
basal in all the gel filtration fractions between the void volume and total volume of the 
column. A similar effect was noted for the gel filtration runs of rat ileal extracts and to 
some extent with porcine ileal extracts. As stated before, since the elevated baseline 
was relatively flat, it is likely to have been caused by non-specific interference of 
protein from the tissue extract rather than by the presence of genuine GLP-1-related 
immunoreactivities. No such effect was observed with G2-30/6/89.
As with the rat ileal extracts, but in contrast to the porcine ileal extracts, the 
quantity of IR-GLP-1 in the peak eluting at Kd 0.5 to 0.55 measured with the 2 
different antisera was very similar. This suggests that the majority of the IR-GLP-1 
present was C-terminally amidated. But, as mentioned before, the resolution of this 
system was not sufficiently good to determine whether the IR-GLP-1 present was in 
the form of tGLP-1 or GLP-1(1-36)amide or both.
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FIGURE 4 .4 IR-GLP-1 GEL FILTRATION PROFILES OF 
RAT PANCREATIC EXTRACTS
Error bars indicate mean ± S.E for 4 extracts 
The IR-GLP-1 concentrations shown are those determined in 
each fraction assayed and corrected to give concentration per 
gram wet weight of tissue extracted.
The arrow marks the elution position of synthetic i25I-tGLF-l
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4.3.4 GEL FILTRATION OF PORCINE PANCREATIC 
EXTRACTS
The IR-GLP-1 detected by the different antisera in extracts from 2 piglet 
pancreases are shown in figure 4.5. The gel filtration profile obtained for antiserum 
2135 was similar to that obtained with the rat pancreases. The majority of the IR-GLP- 
1 detected by this antiserum eluted in a single peak with a Kd of approximately 0.50. 
Again, elevated basal levels were obtained throughout the gel filtration runs with this 
antiserum. Because of this effect and due to the poor resolution of the column used it 
was not possible positively to ascribe any other specific IR-GLP-1 peaks although there 
did appear to be some IR-GLP-1 eluting at the void volume and at several points 
between Kd values of 0.0 and 0.4.
In contrast, very little IR-GLP-1 in the piglet pancreatic extracts crossreacted 
with the antiserum G2-30/6/89. The only detectable increase in IR-GLP-1 occurred at a 
Kd of approximately 0.5, corresponding to the major immunoreactivity identified by 
antiserum 2135. The concentrations of IR-GLP-1 measured with G2-30/6/89 at this Kd 
were approximately 20-fold less than those measured with the other antiserum. These 
results suggest that very little, if any, IR-GLP-1 produced in porcine pancreas 
undergoes C-terminal amidation.
4.3.5 GEL FILTRATION OF HUMAN PLASMA EXTRACTS
Attempts were made to determine the molecular forms of IR-GLP-1 present in 
human plasma that would be detected by the 2 different antisera. Low concentrations 
of IR-GLP-1 prohibited gel filtration of plasma since this technique would dilute the 
samples and, consequently, produce IR-GLP-1 concentrations below the detection 
limits of the assays. Two approaches were used to attempt to concentrate the IR-GLP- 
1 present in plasma. The first of these involved immunopuri fication of IR-GLP-1
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FIGURE 4.5 IR-GLP-1 GEL FILTRATION PROFILES OF 
PORCINE PANCREATIC EXTRACTS
Error bars indicate mean and individual values obtained from 
separate chromatography of 2 extracts. The IR-GLP-1 
concentrations shown are those determined in each fraction 
assayed and corrected to give concentration per gram wet weight 
of tissue extracted.
The arrow marks the elution position of synthetic i25i-tGLP-1
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using a cocktail of antisera covalently linked to a solid phase (described in section 
2.10.4). Gel filtration of the immunoextracts produced in this manner yielded no 
detectable IR-GLP-1 when assayed using either antisera. The low recovery of IR-GLP- 
1 achieved using this technique may have been due to degradation of IR- GLP-1 during 
the incubation with the solid phase even though this step was carried out at 40C in the 
presence of aprotinin. However, it is more likely that the major cause of the low 
recovery was the inability to dissociate IR-GLP-1 bound to the highest avidity 
antibodies on the solid phase.
The second approach to concentrating the IR-GLP-1 was to ethanol extract the 
plasma (section 2.10.4). This process was, therefore, similar to that used for tissue 
extraction. However, once again the recoveries achieved were insufficient for any IR- 
GLP- 1 to be detected after gel filtration.
4.3.6 DISTRIBUTION OF IR-GLP-1 ALONG THE GI 
TRACTS OF LEAN AND GENETICALLY OBESE 
MICE
The GI tracts of genetically obese ( oh/oB) mice and their lean littermates were 
divided into the stomach, duodenum, jejunum, ileum, caecum and colon. For this 
purpose, the duodenum was defined as the length of small intestine between the 
stomach and the ligament of Treitz. The remaining small intestine was divided into 2 
equal lengths. The proximal section was defined as the jejunum and the distal section 
as the ileum. All the individual sections were subjected to acid/ethanol extraction using 
10ml of acid/ethanol per gram wet weight of tissue as described in section 2.9. The 
results obtained after assaying the tissue extracts using both anti-GLP-1 antisera are 
given in table 4.1.
The concentrations along the the length of the GI tracts determined using both
13
antisera were very similar. This suggests that the majority of IR-GLP-1 found in the 
guts of mice is in an amidated form. Based on the results of other workers, discussed 
in the introduction to this chapter, and the results obtained from the gel filtration of rat 
ileal extracts, it appears likely that the predominant form of IR-GLP-1 in mouse gut is 
in fact tGLP-1.
IR-GLP-1 concentrations were found to be highest for all animals in the ileum. 
The second highest concentrations were found in colonic tissue. The concentrations in 
the small intestine progressively decreased from the ileum to the jejunum to the 
duodenum. However, it is interesting that detectable quantities of IR-GLP-1 were 
found even in the most proximal small intestine. In contrast, the stomachs contained no 
detectable IR-GLP-1 determined with either antiserum.
There was no significant difference between lean and obese mice in the 
concentrations of IR-GLP-1 in any section of gut measured with either antiserum. 
However, the obese mice did exhibit the usual hyperphagia with consequent increase in 
gut length and weight (table 4.2). Their GI tracts will, therefore, contain considerably 
more IR-GLP-1, in absolute terms, than the GI tracts of their lean littermates.
4
TABLE 4.1 DISTRIBUTION OF IR-GLP-1 ALONG THE 
GI TRACT OF LEAN AND GENETICALLY 
OBESE (ob/ob) MICE
Values indicate mean ± S.E. (n=4)
ND = Not Detectable. — = Not Measured
IR-GLP-1 CONCENTRATION 
(pmoles/g wet weight of tissue)
ANTISERUM
G2-30/6/89
GUT SECTION
Stomach
Duodenum
Jejunum
Ileum
Caecum
Colon
LEAN MICE
ND
34.5±10.1
66.2±14.5
99.5±24.4
48.114.7
79.3123.3
OBESE MICE
ND
22.214.9
51.918.2
105.5131.9
20.811.6
67.1116.3
2135 Stomach
Duodenum
Jejunum
Ileum
Caecum
Colon
ND
47.219.6
85.8121.6 
107.5117.3
ND
31.214.9
61.019.9 
131.4137.4
TABLE 4.2 WEIGHTS AND LENGTHS OF TISSUE 
SECTIONS FROM LEAN AND OBESE 
( 06/ 06) MICE
Values indicate mean ± S.E. (n=4)
(A) TISSUE WEIGHTS (g)
TISSUE SECTION LEAN MICE OBESE MICE
Stomach
Duodenum
Jejunum
Ileum
Caecum
Colon
0.3710.03
0.3810.03
0.7910.04
0.6310.06
0.3010.04
0.6810.09
0.5910.06
0.5310.06
1.4010.18
1.0510.18 
0.7110.05 
0.8010.19
(B) INTESTINAL LENGTHS (mm)
TISSUE SECTION LEAN MICE OBESE MICE
Duodenum
Jejunum
Ileum
Colon
7014
18114
21315
10815
91110
252110
262115
10615
4.4  DISCUSSION
The results described above for the gel filtration experiments on rat ileal tissue 
extracts are in agreement with results obtained by other workers (Mojsov etal, 1986 ; 
Kreymaim etal, 1988). It seems likely that the predominant form of IR-GLP-1 in the 
guts of these animals is tGLP-1. The similarity in the absolute IR-GLP-1 
concentrations along the GI tracts of lean and genetically obese mice determined using 
the 2 different antisera suggests that the major form of IR-GLP-1 in mouse guts is also 
tGLP-1 and that the type of processing undergone by the proglucagon gene product is 
consistent throughout the length of the GI tract.
Gel filtration of piglet ileal extracts revealed differences from the results 
obtained for rat ileal extracts. The major immunoreactive form eluted at the same 
position as the rat gut IR-GLP-1, but the concentrations detected with antiserum 2135 
were greater than those detected with the C-terminal amide-specific antiserum G2- 
30/6/89. This suggests that not all the GLP-1 produced in piglet intestine had 
undergone C-terminal amidation and that significant quantities of GLP-1(7-37) or other 
non-amidated molecular forms were present in the tissue extracts. These results 
contradict those reported by 0rskov and co-workers (0rskov et al, 1989b) who 
concluded, following peptide purification, amino acid sequencing and mass 
spectrometry, that the predominant molecular form of IR-GLP-1 in pig intestine was 
tGLP-1 although they did find small quantities of GLP-1(7-38). Another group were 
able to demonstrate the presence of significant quantities of GLP-1(7-37) in porcine 
intestinal extracts (Mojsov et al, 1990). However, they also concluded that the 
predominant form was tGLP-1.
It is possible that the discrepancy between the results described here and those 
of other workers is due to a change in intestinal GLP-1 processing with age, since the 
extracts used here were obtained from weaned piglets rather than from adult pigs. 
Another possibility is that the difference in the concentrations of IR-GLP-1 measured
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with the 2 antisera was due to some difference in the nature of the IR-GLP-1 other than 
the presence or absence of C-terminal amidation. One such difference could be 
produced by glycosylation of the tGLP-1. Patzelt and Weber have demonstrated that 
rat MPGF, produced in the pancreas, is glycosylated but they did not determine the 
exact position of the glycosylated residue or residues (Patzelt and Weber, 1986). 
However, the tGLP-1 isolated from porcine intestines could not have been modified in 
this manner as any glycosylation would have been evident in the mass spectrometry 
(0rskov et al, 1989b). Nevertheless, it is still possible that there is a developmental 
change in the glycosylation of intestinal tGLP-1 with age in pigs.
In rat pancreatic tissue extracts the predominant form of IR-GLP-1 appeared to 
be either GLP-1( 1 -36)amide or tGLP-1 as both antisera detected similar quantities. 
There was no clear peak corresponding to MPGF (predicted Kd of approximately 0.40). 
Any MPGF would be expected to be detected only by antiserum 2135. The elevated IR- 
GLP- 1 concentrations observed between Kd values of 0.0 and 0.4 with antiserum 2135 
may have been due, to some extent, to the presence of MPGF or related peptide 
fragments but equally they may have been caused by non-specific interference of 
unrelated peptides and served to mask the presence of any MPGF. Nevertheless, the 
results are in agreement with those reported by other groups who have found either as 
much as or more of the smaller molecular weight IR-GLP-1 than MPGF in rat pancreas 
(Mojsov etal, 1986 ; Shima etal, 1987 ; Manaka etal, 1987).
The porcine pancreatic extracts revealed the most marked difference in IR-GLP- 
1 profiles detected by the different antisera. Antiserum 2135 crossreacted with a major 
IR-GLP-1 form which eluted at a Kd of approximately 0.5. There also appeared to be 
some higher molecular weight immunoreactivities eluting between the void volume and 
a Kd value of 0.4. In contrast, antiserum G2-30/6/89 hardly detected any IR-GLP-1 at 
all. Only a very small peak with a Kd of approximately 0.5 was apparent. The 
evidence, therefore, points towards very little C-terminal amidation of any form of GLP- 
1 in piglet pancreas. Indeed it is possible that the amidating enzyme activity is not
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present in this tissue.
The species- and tissue-specific differences in proglucagon gene product 
processing identified in the experiments described here and by other workers elsewhere 
highlight the possible problems associated with multiple molecular forms of GLP-1 and 
peptides containing the sequence of GLP-1 in plasma samples. The antisera employed 
in different immunoassays will crossreact to varying extents with the different 
molecular forms of GLP-1. Furthermore, the molecular forms present in the plasma of 
different animals will also vary. These factors are likely to lead to significant 
discrepancies in reported plasma IR-GLP-1 concentrations and responses to nutrient 
ingestion.
In rodents, both the antisera tested crossreact with pancreatic and intestinal 
forms of GLP-1. In contrast, antiserum G2-30/6/89, but not antiserum 2135, is 
unlikely to detect any significant quantity of the molecular forms of GLP-1 secreted by 
the pancreas in piglets. Consequently, in pigs G2-30/6/89 can probably be used to 
measure GLP-1 in plasma that has been secreted exclusively from the GI tract. 
However, the specificity of this antiserum for C-terminally amidated forms of GLP-1, 
while providing the advantage of excluding crossreactivity with pancreatic GLP-1, has 
the drawback of also not crossreacting with GLP-1(7-37) which appears to be 
biologically active and may be secreted from the small intestine in significant amounts.
The radioimmunoassay for GLP-1 was developed primarily for the 
measurement of plasma concentrations of the hormone in man. It was not possible to 
obtain any samples of human ileum or pancreas to determine the molecular forms of IR- 
GLP- 1 in them. Attempts were, therefore, made to identify the tnolecular forms of GLP- 
1 that predominate in fasting and post-prandial human plasma. However, the low 
concentrations of IR-GLP-1 in human plasma made this task difficult. Concentration 
of IR-GLP-1 by immunoextraction of plasma proved unsuccessful. Further attempts 
using this approach might be made to work if only low avidity antisera were used for 
the extraction. It should be appreciated that the relative proportions of the different
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molecular forms identified in this manner could not necessarily be taken as 
representative of the situation in whole plasma since the recovery of each form would 
be dependent on the relative avidity of the antiserum for it. A cocktail of different 
antisera with varying specificities might be employed to try to overcome this problem as 
well as ensuring the extraction of all the potentially immunoreactive forms.
The second approach used was ethanol extraction of whole plasma. This 
technique also proved unsuccessful. The recoveries of synthetic tGLP-1 by this method 
could be assessed to determine whether or not this technique could be used 
successfully. However, while being a relatively simple procedure, such an extraction 
is far from ideal since there is a possibility that it will cause the removal of one or more 
genuine immunoreactivities and the recoveries of any remaining IR-GLP-1 forms may 
also vary. Nevertheless, the question of which molecular forms of IR-GLP-1 the 
different assays detect in plasma remains unanswered and needs to be addressed.
The concentrations of IR-GLP-1 in the gut extracts of genetically obese mice 
were normal compared with their lean littermates. This result is somewhat Surprising 
since the gut levels of IR-GIP have been reported to be markedly elevated in these 
animals (Flatt etal, 1983a). Furthermore, elevated IR-GLP-1 concentrations have been 
found in the GI tract of streptozotocin-induced diabetic rats (Kreymann etal, 1988). In 
both cases the increased concentrations have been proposed to be due to the 
hyperphagia associated with the syndromes.
The general pattern of distribution of IR-GLP-1 found along the GI tracts of 
both the lean and obese mice roughly followed that described for rats by other workers 
(Kreymann etal, 1988), with IR-GLP-1 concentrations increasing from proximal to 
distal small intestine and reaching the highest values in the ileum with moderately high 
concentrations also found in the colon. However, the increase of IR-GLP-1 levels 
from proximal to distal small intestine was far more gradual than that reported 
elsewhere and significant quantities were found not only in the jejunum but also in the 
duodenum. A similar distribution of IR-GLP-1 along the small and large intestines of
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rats will be demonstrated in chapter 7 in the context of chronic dietary effects.
This pattern of distribution raises the possibility that following food ingestion, 
IR-GLP-1 may be secreted from the upper small intestine as well as the lower small 
intestine. This may be of importance in explaining the small but rapid post-prandial 
responses observed in man (chapter 5). It would, therefore, be of interest to investigate 
the distribution of IR-GLP-1 along the GI tracts of man and other animals to confirm 
the results obtained here.
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CHAPTER 5
ACUTE EFFECTS OF NUTRIENTS 
ON tGLP-1 AND GIP SECRETION 
IN MAN AND ANIMALS
2 2
5.1 INTRODUCTION
A number of research groups have been able to measure GIP in plasma for 
several years. Consequently, there is considerable available information concerning the 
acute effects of different nutrients on circulating levels of this hormone in man and 
many different animals as described in section 1.5.2.
In comparison with GIP, very little is known about the circulating levels of 
tGLP-1 and the effects of different nutrients on its secretion. There are discrepancies 
between the results obtained by the small number of groups able to assay IR-GLP-1 in 
plasma. These are largely due to varying crossreactivity with pancreatic forms of GLP- 
1 and problems associated with different plasma extraction techniques.
The assay first used by 0rskov and Holst gave fasting plasma levels of IR-GLP- 
1 of 107±7pM (mean ± S.E., n=10) for normal human subjects (0rskov and Holst, 
1987) but subsequently they reported fasting values of 37±3pM (n=8) (0rskov et al, 
1991). They concluded that much of this immunoreactivity was due to the presence of 
pancreatic MPGF in the plasma which crossreacts with their antiserum. Takahashi and 
co-workers have developed two assays for IR-GLP-1 (Takahashi etal, 1990). One of 
these uses an antiserum which recognizes a region including the sequence GLP-1(1-5). 
They claim, therefore, that this assay is specific for the IR-GLP-1 forms secreted by the 
pancreas. The second assay uses an antiserum that recognizes the C-terminal region of 
GLP-1 but is not specific for the amidated forms. This probably has a similar 
specificity to the assay reported by 0rskov and Holst. With this second assay they 
have reported fasting plasma IR-GLP-1 concentrations of 71.5±3.3pM (n=83) in 
healthy human subjects.
When the assays used by 0rskov and Holst and Takahashi and co-workers 
were employed to measure IR-GLP-1 in unextracted plasma both groups found much 
higher levels. They concluded that this was caused by non-specific interference of 
plasma components and both adopted ethanol extractions to overcome the problem.
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This may explain, at least in part, the high IR-GLP-1 concentrations observed by 
Hirota and co-workers who reported fasting IR-GLP-1 concentrations in normal 
subjects of 236.5±19.1pM (n=43) using an assay with unextracted plasma and an 
antiserum of similar crossreactivity to that described by the other two groups (Hirota et 
al, 1990).
In contrast, Kreymann and co-workers found fasting levels in normal human 
subjects of only 15±6pM (n=5) (Kreymann etal, 1987). The lower levels observed by 
this group are probably due to the retention of MPGF on the Sep-Pak cartridges used to 
extract their plasma samples (0rskov etal, 1991), although they could also result from 
a lack of crossreactivity of the anti serum with MPGF. Consequently, the assay used 
by this group probably gives the best representation of circulating tGLP-1 
concentrations.
It was this group that first reported a rise in IR-GLP-1 in man following 
ingestion of a glucose load or a mixed meal. Most other groups mentioned above have 
also found a small rise in circulating plasma IR-GLP-1 following oral glucose 
(Takahashi etal, 1990 ; 0rskov etal, 1991) or a mixed meal (0rskov and Holst, 1987). 
In contrast, Hirota and co-workers observed a reduction in total IR-GLP-1 in normal 
subjects following an oral glucose load (Hirota etal, 1990). However, gel filtration of 
the fasting and fed plasma samples revealed that the glucose had, in fact, led to 
increased tGLP-1 levels but this had been masked by a reduction in the concentration of 
pancreatic MPGF.
The first experiment described in this chapter was designed to investigate the 
effects of ingestion of different macronutrients on plasma tGLP-1 and GIP 
concentrations in man. Following on from that, a series of experiments, funded by the 
Ministiy of Agriculture, Fisheries and Food were carried out in conjunction with the 
Flour Milling and Baking Research Association (FMBRA), Chorleywood. The aim of 
these experiments was to investigate the role of various factors in determining the rate 
of digestion and absorption of complex carbohydrate in man. This was to be assessed
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by measurement of acute glycaemic and insulinaemic responses to starches and cereals. 
These studies also provided an ideal opportunity to examine the relative effects of 
rapidly absorbable and slowly absorbable carbohydrates on tGLP-1 and GIP secretion.
In addition to the measurement of IR-GLP-1 in man, measurement of plasma IR- 
GLP- 1 has been extended to animal models. The effects of feeding on circulating IR- 
GLP- 1 levels in lean and genetically obese ( oh/ob ) mice, piglets and adult pigs are 
described.
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5.2 EFFECTS OF CARBOHYDRATE, FAT 
AND PROTEIN ON IR-GLP-LAND IR-GIP 
SECRETION IN HEALTHY HUMAN 
SUBJECTS
This experiment was designed to investigate the effects of ingestion of single
component meals containing different macronutrients on circulating levels of IR-GLP-1 
and IR-GIP in man.
5.2.1 STUDY DESIGN
Eight healthy non-obese (defined as having a BMI less than 25kg/m2) 
volunteers, 5 males and 3 females, aged between 21 and 24 years, participated in the 
study. At 8a.m. on three separate occasions after an overnight fast, they each 
consumed, in random order, equicaloric (375kcal) meals consisting of carbohydrate, fat 
or protein. The carbohydrate was served as 155ml of lemon flavoured, Hycal 
(Beecham Products, Brentford) which is a solution of short chain dextrose polymers. 
The fat meal consisted of 84ml of double cream flavoured with blackcurrant (Scientific 
Hospital Supplies Ltd, Liverpool). The protein meal was in the form of 352g of extra- 
lean turkey previously grilled for 8 minutes and reheated immediately prior to 
consumption. The carbohydrate, fat and protein meals were served together with 
145ml, 216ml and 300ml of water, respectively, so that the total liquid volume ingested 
was constant for all three meal types.
Venous blood samples were collected over a three hour period following each 
meal as described in section 2.8 and the plasma obtained was assayed for glucose, 
immunoreactive insulin (IRI), IR-GIP and IR-GLP-1.
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5.2 .2  RESULTS
All but one of the subjects managed to consume the 3 meals in less than 15 
minutes. The remaining subject consumed the carbohydrate and fat meals in less than 
15 minutes but required 20 minutes to consume the protein meal.
5.2.2.1 PLASMA GLUCOSE RESPONSES
The glucose responses to the three different meals were as expected. The 
results are represented graphically in figure 5.1 and the values given in table 5.1. 
Following the carbohydrate load, a marked rise in plasma glucose concentrations was 
observed, peaking at 30 minutes and then slowly declining until reaching basal values 
again at 150 minutes after the meal. In contrast, no significant change from fasting 
plasma glucose levels was observed at any point in the three hour period following the 
fat or protein meals.
5 .2.2.2 PLASMA IRI RESPONSES
Plasma IRI levels exhibited a similar pattern of change to that observed for 
glucose (depicted in figure 5.2 and values given in table 5.2). There was a marked, 
rapid rise in IRI following the carbohydrate meal. The levels peaked at 30 minutes and 
then slowly declined, reaching basal values 180 minutes after the meal. There was no 
change in IRI following the fat meal. Although there was a slight increase in mean IRI 
levels following the protein meal, the rise was very small and was not significantly 
different from fasting values at any point.
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FIGURE 5.1 PLASMA GLUCOSE LEVELS IN HEALTHY 
HUMAN SUBJECTS FOLLOWING 
ISOENERGETIC (375kcal) 
CARBOHYDRATE, FAT AND PROTEIN 
MEALS
Error bars indicate mean ± S.E. (n=8)
** Denotes values significantly higher than for fat or protein 
loads (p<0.01)
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FIGURE 5.2 PLASMA IRI LEVELS IN HEALTHY 
HUMAN SUBJECTS FOLLOWING 
ISOENERGETIC (375kcal) 
CARBOHYDRATE, FAT AND PROTEIN 
MEALS
Error bars indicate mean ± S.E. (n=8)
** Denotes values significantly higher than for fat or protein 
loads (p<0.01)
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TABLE 5.1 PLASMA GLUCOSE LEVELS IN HEALTHY 
HUMAN SUBJECTS FOLLOWING 
ISOENERGETIC (375kcal) 
CARBOHYDRATE, FAT AND PROTEIN 
MEALS
Values indicate mean ± S.E. (n=8)
** Denotes values significantly higher than for fat or protein 
loads (p<0.01)
PLASMA GLUCOSE (mM)
Time Carbohydrate Fat Protein
(minutes) Meal Meal Meal
-10 4.45±0.18 4.8810.18 4.6610.13
0 4.74±0.17 4.8710.15 4.8210.15
15 6.17+0.38 ** 4.4310.12 4.3010.24
30 7.53+0.47 ** 4.4910.17 4.3810.16
45 7.14+0.57 ** 4.3610.13 4.2710.10
60 6.67±0.60 ** 4.4310.17 4.3510.11
90 5.9910.62 4.2710.07 4.1310.19
120 5.3210.41 4.4010.13 4.5110.29
150 4.3110.30 4.4610.20 4.2510.16
180 3.7610.27 4.5110.12 4.3210.15
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TABLE 5.2 PLASMA IRI LEVELS IN HEALTHY 
HUMAN SUBJECTS FOLLOWING 
ISOENERGETIC (375kcal) 
CARBOHYDRATE, FAT AND PROTEIN 
MEALS
Values indicate mean ± S.E. (n=8)
** Denotes values significantly higher than for fat or protein 
loads (p<0.01)
Time Carbohydrate
PLASMA IRI (mU/1) 
Fat Protein
(minutes) Meal Meal Meal
-10 7.211.0 10.211.6 7.911.5
0 10.111.2 12.511.6 9.711.7
15 41.314.6 12.212.2 14.512.2
30 84.317.9 ** 13.612.4 15.011.8
45 79.317.4 ** 14.512.7 14.511.9
60 58.716.4 ** 12.512.2 16.512.3
90 53.419.6 ** 11.312.4 18.312.2
120 58.6116.1 ** 9.611.5 19.013.1
150 30.1110.4 10.211.8 18.712.4
180 14.214.4 9.411.5 16.712.3
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5.2.2.S PLASMA IR-GIP RESPONSES
Plasma IR-GIP concentrations increased after both the carbohydrate and fat 
meals but not after the protein meal (figure 5.3 and table 5.3). IR-GIP concentrations 
were significantly elevated (p<0.01) at all time points from 15 to 120 minutes after the 
carbohydrate meal. The concentrations reached their maximum 45 minutes after the 
meal and had not returned to basal values by 180 minutes.
For the fat meal, the IR-GIP response appeared to be delayed compared with 
the carbohydrate meal. The initial rise in IR-GIP was slower than for the carbohydrate 
but continued to rise, peaking 90 minutes post-prandially. The IR-GIP levels were 
significantly elevated above fasting values from 15 to 180 minutes (p<0.01 from 15 to 
150 minutes, p<0.05 at 180 minutes). The calculated integral IR-GIP responses over 
the 3 hour period to the carbohydrate and fat meals were not significantly different.
5 .2 .2 .4  PLASMA IR -G L P-1 RESPONSES
The IR-GLP-1 responses to the different meals were much smaller than for the 
other parameters measured. The results obtained are shown in figure 5.4 and the 
values given in table 5.4. Mean fasting levels were in the range 14 to 17pM. 
Significant rises in these levels were observed following all 3 meals, but these rises 
were small and transient.
After the carbohydrate meal IR-GLP-1 peaked at 30 minutes (23.2±1.7pM) and 
remained elevated for 2 hours post-prandially. However, this rise above fasting 
concentrations was only statistically significant (p<0.01) at the 30 minute time point.
IR-GLP-1 concentrations appeared to rise slowly after the fat meal, reaching a 
peak value of 23.0±1.3pM at 150 minutes. This was the only time point at which IR- 
GLP-1 was statistically significantly greater than fasting levels (p<0.05).
For the protein meal, a transient peak of IR-GLP-1 was observed at 30 minutes
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FIGURE 5.3 PLASMA IR-GIP LEVELS IN HEALTHY 
HUMAN SUBJECTS FOLLOWING 
ISOENERGETIC (375kcal) 
CARBOHYDRATE, FAT AND PROTEIN 
MEALS
Error bars indicate mean ± S.E. (n=8)
** Denotes values significantly higher than for protein load
(p<0.01)
++ Denotes value significantly higher than for both fat and 
protein loads (d<0.0 1 )
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FIGURE 5.4 PLASMA IR-GLP-1 LEVELS IN HEALTHY 
HUMAN SUBJECTS FOLLOWING 
ISOENERGETIC (375kcal) 
CARBOHYDRATE, FAT AND PROTEIN 
MEALS
Error bars indicate mean ± S.E. (n=8)
** Denotes values significantly higher than for fat load
(p<0.01)
+ Denotes value significantly higher than for carbohydrate load 
(p<0.05)
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TABLE 5.3 PLASMA IR-GIP LEVELS IN HEALTHY 
HUMAN SUBJECTS FOLLOWING 
ISOENERGETIC (375kcal) 
CARBOHYDRATE, FAT AND PROTEIN 
MEALS
Values indicate mean ± S.E. (n=8)
** Denotes values significantly higher than for protein load
(p<0.01)
++ Denotes value significantly higher than for both fat and 
protein loads (p<0.01)
Time Carbohydrate
PLASMA IR-GIP (pM) 
Fat Protein
(minutes) Meal Meal Meal
-10 305±49 311±53 346±53
0 233+52 222±51 254±40
15 674±85 ++ 316±46 288±37
30 896±78 ** 606±95 ** 271±36
45 923177 ** 859±126 ** 276±42
60 915±193 ** 925^124 ** 
1043±157 **
290±35
90 863±97 ** 308±41
120 819+97 ** /^ 7 ± 7 3  ** 346±41
150 647±132 X  959±81 ** 343±39
180 563±129 /  743±58 412144
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TABLE 5.4 PLASMA IR-GLP-1 LEVELS IN HEALTHY 
HUMAN SUBJECTS FOLLOWING 
ISOENERGETIC (375kcal) 
CARBOHYDRATE, FAT AND PROTEIN 
MEALS
Values indicate mean ± S.E. (n=8)
** Denotes values significantly higher than for fat load
(p<0.01)
+ Denotes value significantly higher than for carbohydrate load 
(p<0.05)
PLASMA IR-GLP-1 (pM)
Time Carbohydrate Fat Protein
(minutes) Meal Meal Meal
-10 15.112.0 16.911.4 14.412.3
0 12.212.3 11.712.3 11.512.8
15 20.112.1 14.612.1 14.211.6
30 23.211.7 ** 14.411.1 21.611.9 **
45 21.213.5 13.110.9 17.312.1
60 17.112.9 18.811.8 17.212.3
90 18.813.6 18.812.0 18.112.1
120 20.012.9 18.211.0 19.712.7
150 13.512.4 23.011.3 + 19.713.1
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(21.6±1.9pM) followed by a steady rise throughout the rest of the 3 hours (22.813.6 
pM at 180 minutes). However, as for the carbohydrate meal, only the levels at 30 
minutes were significantly elevated above fasting (p<0.01).
Plasma IR-GLP-1 concentrations were significantly higher at 30 minutes 
following both the carbohydrate and protein loads compared with the fat load (p<0.01), 
and at 150 minutes after the fat load compared with the carbohydrate load (p<0.05). 
There were no significant differences between the total integrated IR-GLP-1 responses 
to the different meals over the 3 hours.
5.2.3 DISCUSSION
The results for plasma glucose levels for this study were exactly as would be 
expected and serve only to demonstrate that the fat and protein loads did not contain 
significant amounts of carbohydrate. Much the same is true of the results for IRI. The 
only point of controversy for these is the lack of response to the protein meal. In a 
study of similar design to the one described here, a rise in post-prandial IRI 
concentrations was observed following a protein load (Penman etal, 1981). However, 
the protein source used in that study was Maxipro. This consists of soya bean protein 
supplemented with free amino acids. Several amino acids, particularly arginine and 
leucine, given orally have been shown to be capable of eliciting an insulin response 
(Dupre etal, 1969).
In the present study, the protein source did not contain free amino acids. 
Ingested protein is absorbed largely in the form of short peptides rather than as free 
amino acids (Matthews and Adibi, 1976). Furthermore, the mechanisms and rate of 
absorption of these short peptides differ from those of free amino acids. These factors 
may explain the discrepancy.
The results obtained for IR-GIP were as might be expected based on the
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documented stimulation of GIP secretion (discussed in section 1.5.2). As was the case 
for IRI, no change in IR-GIP levels were observed following the protein meal. This is 
in agreement with the results of Brown and co-workers (Brown etal, 1975) but not 
with those of Penman and co-workers (Penman etal, 1981). Again this could be due 
to the presence of free amino acids in the protein load used by the latter group.
Carbohydrate and fat loads were found to be approximately equipotent in the 
stimulation of IR-GIP release although the response to the fat was delayed compared 
with that to the carbohydrate. The results obtained by Penman and co-workers also 
showed a delayed IR-GIP response to an oral fat load compared with a carbohydrate 
load although they found that overall, integrated IR-GIP response to an oral fat load 
was greater than to an oral glucose load. The delayed IR-GIP response to fat in the 
study described in this chapter and in the study described by Penman may have been 
due to a slower gastric emptying rate following the fat meal.
The marked rise in IR-GIP concentrations observed in the present study 
following the fat meal together with the lack of IRI response demonstrates that GIP can 
only act as an incretin in the presence of raised circulating glucose concentrations. This 
protects against inappropriate hypoglycemia following ingestion of fat alone.
The specificity of our antiserum for amidated forms of GLP-1 means that it 
does not crossreact with any MPGF or GLP-1(1-37) in plasma. These are the 
predominant forms secreted from the porcine and probably also the human pancreas. 
Consequently, our assay is effectively specific for tGLP-1 produced in the gut.
The fasting plasma IR-GLP-1 levels of 14 to 17pM described above in this 
chapter are in good agreement with those reported by Kreymann (Kreymann et al, 
1987). The small rise in IR-GLP-1 (less than lOpM above fasting) observed in the 
present study following the carbohydrate meal was, however, somewhat smaller than 
the rise reported by the other group following an oral glucose load or mixed meal where 
peak concentrations of 48±4pM and 37±3pM were observed, respectively. In both 
studies, peak IR-GLP-1 levels occurred 30 minutes post-prandially following the
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carbohydrate loads.
Increases in plasma IR-GLP-1 levels following the fat and protein meals were 
also demonstrated. The protein produced a transient peak at 30 minutes whereas the IR- 
GLP-1 levels reached their maximum values 150 minutes post-prandially for the fat 
meal. As with the IR-GIP this delayed response may be due to slower gastric 
emptying.
5.3 EFFECT OF RESISTANT STARCH ON THE 
METABOLIC RESPONSE TO A 
CARBOHYDRATE LOAD IN HEALTHY 
HUMAN SUBJECTS
The plasma glucose and insulin responses following ingestion of foods 
containing complex carbohydrates are dependent on a range of factors that affect rate 
and extent of starch digestion (Thome etal, 1983). Some sources of starch give rise to 
flattened post-prandial blood glucose and insulin levels compared with simple sugars 
and other starchy foods. The concept of a glycaemic index has been introduced in an 
attempt to quantify this effect (Jenkins et a/,1981). Glycaemic index is calculated as 
the integrated incremental capillary blood glucose response over 2 hours after ingestion 
of a known quantity of a particular food (normally the equivalent of 50 or 25g of 
carbohydrate) divided by the same parameter calculated for an equivalent carbohydrate 
load of glucose or white bread. The value obtained is quoted as a percentage.
Factors that affect glycaemic index include the composition of the starch 
(amylose to amylopectin ratio), its interaction with other food components such as fat, 
protein and fibre, reduced accessibility to enzymes due to cell structure, the presence of 
anti-nutrients (phytates and tannins), processing and cooking (Thome etal, 1983).
For example, cooking in the presence of water causes the starch granules to 
swell and ultimately become disrupted. This process, termed gelatinization, enhances
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the digestibility of the starch (Wootton and Chaudry, 1980 ; Holm etal, 1988).
On the other hand, if the food is then allowed to cool the starch can undergo 
rétrogradation. In this process semicrystalline starch structures form that are resistant 
to enzymic degradation in vitro (Berry, 1986). In addition to the formation of this 
resistant starch (RS), rétrogradation can also lead to the formation of partially resistant 
starch (PRS) which is only slowly digested in vitro. RS and PRS are thought to play a 
role in determining the rate and extent of starch digestion in vivo. Hence, they 
probably influence the post-prandial glucose tolerance and insulin response to foods.
So far, the work on in vivo digestion of starches has been based almost 
exclusively on the measurement of post-prandial plasma insulin and glucose levels 
together with assessment of malabsorption and mouth to caecum transit time using 
breath hydrogen analysis. In this study, measurement of plasma GIP and tOLP-1, 
which are likely to be influenced by the rate, extent and site of absorption of the 
carbohydrate, have also been included as they will, in turn, affect insulin levels.
Different digestion rates of complex carbohydrates might not affect GIP and 
tGLP-1 secretion in the same manner. If tGLP-1, like GIP, is secreted from the gut by 
active absorption of nutrients it might be expected that, due to the distribution of tGLP- 
1 in the gut, nutrients absorbed further down the small intestine would provide a greater 
stimulus to tGLP-1 levels than other nutrients absorbed more proximally. In contrast 
the reverse would be predicted for GIP which is secreted predominantly from the upper 
small intestine. More slowly digested carbohydrates might, therefore, give rise to 
different GIP and tGLP-1 responses than more readily digested forms.
A previous study in this laboratory comparing the metabolic responses in man 
to maize starch preparations of markedly differing RS content revealed flattened plasma 
glucose, IRI and IR-GIP response curve to starches of very high RS content compared 
with a low RS starch preparation (unpublished data).
In the study described here the metabolic responses to a glucose load and two 
purified wheat starch preparations of identical source, with RS contents typical of most
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starchy foodstuffs, have been determined.
One batch of wheat starch had been autoclaved to promote RS formation. The 
second batch had been subjected to extrusion. In this extreme form of processing the 
starch, together with a small quantity of water, is forced under high pressures through a 
small aperture. Under the pressure the starch and water become heated to very high 
temperatures. Consequently, on emerging on the other side of the aperture the sudden 
drop in pressure causes the water to boil instantly. The granular structure of the starch 
is totally destroyed in the process. The sudden cooling and the absence of water inhibit 
the formation of RS and PRS leaving the starch in the most readily digestible form 
possible.
5.3.1 STUDY DESIGN
The study design was essentially the same as described in section 5.2.1 except 
that only six subjects (2 male and 4 female) participated. The 3 meals that they 
consumed consisted of 50g of glucose or the equivalent quantity as autoclaved or 
extruded wheat starch. In calculating the appropriate quantity of each starch 
preparation, the loss of water on the polymerization of glucose to form starch was taken 
into consideration (50g glucose = 45g starch). A further adjustment was made to 
account for the moisture content of the different starch preparations.
The glucose or starches were dissolved or suspended in 135ml of water, 15ml 
of lactulose solution for assessment of mouth to caecum transit time by exhaled 
hydrogen analysis and 10ml ofPLJ (Beecham Products Ltd, Brentford) for palatability. 
Each meal was served with a further 350ml of water.
In addition to venous blood samples, capillary blood samples were assessed for 
glucose as described in section 2.7 and exhaled hydrogen was measured as described in 
section 2.11 for up to 270 minutes post-prandially.
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The starch preparations were supplied by the FMBRA, Chorleywood, who also 
analyzed their RS content, degree of gelatinization and moisture content. They found, 
using an in wïrodigestion technique (Berry, 1986), that the autoclaved and extruded 
starch preparations contained 7.5% and 0.3% RS, respectively. Differential scanning 
calorimetry (Biliaderis etal, 1980) revealed that the degree of gelatinization for the two 
starches was similar (83% for the autoclaved starch and 88% for the extmded starch).
5.3.2 RESULTS
All subjects found the starch meals unpalatable, but nevertheless managed to 
consume them and the glucose load in less than 15 minutes.
5.3.2.1 EXHALED HYDROGEN RESPONSES
The exhaled hydrogen responses to the meals were extremely variable both 
within and between subjects. One subject had low basal exhaled hydrogen and no rise 
was observed at any point after all 3 meals. This subject was, therefore, excluded from 
the analysis. The mean incremental exhaled hydrogen values for the other five subjects 
obtained following the two starch meals are shown in figure 5.5. Mouth to caecum 
transit time was arbitrarily taken as the time at which the exhaled hydrogen rose to 
greater than 20ppm above fasting values and remained at least as high for two 
subsequent readings. The results obtained are summarized in table 5.5.
Unfortunately, due to failure of the exhaled hydrogen monitor, it was not 
possible to follow breath hydrogen after the glucose load for subjects 1 to 3. Subjects 
2 and 5 produced very marked increases in exhaled hydrogen (up to 80ppm above 
basal) following all meals where measurements were made. Subject 1 also showed a 
large increase following the extmded wheat starch but no sustained rise after the
40
FIGURE 5.5 INCREMENTAL EXHALED HYDROGEN 
FOLLOWING WHEAT STARCH MEALS IN 
HEALTHY HUMAN SUBJECTS
Error bars indicate mean ± S.E, (n=5)
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TABLE 5.5 MOUTH TO CAECUM TRANSIT TIMES 
FOR WHEAT STARCH STUDY
Numbers indicate the transit time in minutes.
*** indicates no data
— indicates that no sustained rise was observed
MEAL
SUBJECT 
3 4
Glucose ***
Autoclaved Wheat 180 
Extruded Wheat
***
195
195
* * *
270
60
100
180
100
160
140
autoclaved wheat starch. It is of interest that this subject had suffered a stomach upset a 
few days before taking the autoclaved wheat starch load which, although this had not 
been treated with antibiotics, may have affected colonic bacterial populations.
The exhaled hydrogen values obtained from subject 3 were very erratic and only 
after the autoclaved wheat starch load was a sustained rise observed that was large 
enough to define transit time by our criteria.
Subject 4 produced consistent rises in exhaled hydrogen for all the meals. For 
this subject, the mouth to caecum transit times following the glucose and autoclaved 
wheat starch loads were shorter than those observed for the other subjects. However, 
the same person apparently had a more typical transit time for the extruded wheat 
starch.
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5.3.2.2 CAPILLARY BLOOD GLUCOSE RESPONSES
The capillary blood glucose levels rose after all 3 different carbohydrate loads 
(figure 5.6 and table 5.6). Over the first two hours post-prandially the responses to the 
two starches were very similar and the levels observed were only slightly lower than 
those for the glucose load. However, this apparent difference was only statistically 
significant (p<0.05) at the 15 minute time point. The total and incremental integrated 
response over the 3 hours did not differ significantly between any of the different 
meals.
The glycaemic indices were calculated to be 67 and 63 for the autoclaved and 
extruded wheat starches, respectively, when individual incremental values below basal 
were taken as zero. There were, however, no statistically significant difference 
between any of the meals in the total or incremental integrated responses over the 3 
hours.
5.3.2.3 VENOUS PLASMA GLUCOSE RESPONSES
The venous plasma levels of glucose measured following the different 
carbohydrate loads are shown in figure 5.7 and the values given in table 5.7. The 
curves obtained are very similar indeed and there were no significant differences 
between the meals at any individual time point or for the integrated responses over the 3 
hours.
5.3 .2 .4  PLASMA IRI RESPONSES
The plasma IRI concentrations following the different meals closely matched 
each other for the first 45 minutes post-prandially (figure 5.8 and table 5.8). After that 
the levels observed for the two starch meals appeared to return back to basal more 
rapidly than for the glucose load but the differences were not statistically significant at
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FIGURE 5.6 CAPILLARY BLOOD GLUCOSE 
RESPONSES TO GLUCOSE AND WHEAT 
STARCH MEALS IN HEALTHY HUMAN 
SUBJECTS
Error bars indicate mean ± S.E. (n=6)
* Denotes value significantly greater than for both 
starch loads (p<0.05)
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TABLE 5.6 CAPILLARY BLOOD GLUCOSE 
RESPONSES TO GLUCOSE AND WHEAT 
STARCH MEALS IN HEALTHY HUMAN 
SUBJECTS
Error bars indicate mean ± S.E. (n=6)
* Denotes value significantly greater than for both 
starch loads (p<0.05)
Time
(minutes)
CAPILLARY BLOOD GLUCOSE (mM) 
Glucose Autoclaved Extruded
Wheat Starch Wheat Starch
-10 4.2±0.5 5.010.5 4.710.3
0 4.1+0.6 4.210.3 4.410.1
15 7.510.6 * 4.910.6 5.310.4
30 9.010.7 7.810.1 7.510.8
45 10.210.7 8.210.3 9.310.7
60 8.910.7 8.610.6 8.310.5
90 6.610.5 5.210.8 5.510.6
120 3.410.6 4.410.1 4.110.4
150 3.410.2 3.910.3 3.410.3
180 3.410.1 3.810.1 3.610.4
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FIGURE 5.7 VENOUS PLASMA GLUCOSE RESPONSES 
TO GLUCOSE AND WHEAT STARCH 
MEALS IN HEALTHY HUMAN SUBJECTS
Error bars indicate mean ± S.E. (n=6)
PLASMA GLUCOSE ( m M )
8
- B -  GLUCOSE
-0 -  AUTOCLAVED WHEAT7
EXTRUDED WHEAT
6
5
4
3
100 120 140 160 180 2000 20 40 60 80-2 0
TIME ( m i n u t e s )
FIGURE 5.8 PLASMA IRI RESPONSES TO GLUCOSE 
AND WHEAT STARCH MEALS IN 
HEALTHY HUMAN SUBJECTS
Error bars indicate mean ± S.E. (n=6)
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TABLE 5.7 VENOUS PLASMA GLUCOSE RESPONSES 
TO GLUCOSE AND WHEAT STARCH 
MEALS IN HEALTHY HUMAN SUBJECTS
Error bars indicate mean ± S.E. (n=6)
Time
(minutes)
VENOUS PLASMA GLUCOSE (mM) 
Glucose Autoclaved Extruded
Wheat Starch Wheat Starch
-10 4.5610.13 4.4910.11 3.9810.27
0 3.9510.11 4.2610.13 4.0510.24
15 5.2810.28 4.9510.18 5.1010.17
30 6.5510.61 5.9410.17 6.4510.29
45 7.1110.55 6.6410.61 7.0010.63
60 6.5010.65 6.7010.57 6.5210.50
90 5.5810.26 4.9110.71 4.9210.65
120 3.6210.33 4.3110.26 4.0010.28
150 3.4510.33 4.1310.31 3.9410.25
180 3.6110.11 3.5610.40 3.9610.15
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TABLE 5.8 PLASMA IRI RESPONSES TO GLUCOSE 
AND WHEAT STARCH MEALS IN 
HEALTHY HUMAN SUBJECTS
Error bars indicate mean ± S.E. (n=6)
Time
(minutes)
PLASMA IRI (mU/1) 
Glucose Autoclaved
Wheat Starch
Extruded 
Wheat Starch
-10 5.310.8 8.413.5 11.813.5
0 6.011.2 8.411.5 11.314.0
15 48.6123.8 30.3110.8 28.515.6
30 64.018.8 58.7115.6 71.1117.2
45 65.818.2 77.0112.0 69.2111.7
60 84.7114.4 52.415.2 68.6111.2
90 42.2110.2 18.315.2 23.015.6
120 12.814.0 10.312.2 12.313.5
150 5.311.8 11.513.7 6.211.7
180 5.811.3 6.011.7 5.910.8
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any time point or for the integrated response over the 3 hour period.
5 .3 .2 .5  PLASMA IR-GIP RESPONSES
The mean IR-GIP response patterns to the 3 meals appeared to differ from each 
other (figure 5.9 and table 5.9). Peak concentrations were obtained at different time 
points for each (at 45, 60 and 90 minutes post-prandially for the autoclaved starch, 
glucose and extruded starch, respectively). However, as for the IRI, there were no 
significant differences between any of the meals at any individual time point or for the 
integrated IR-GIP responses over the 3 hours.
5 .3 .2 .6  PLASMA IR-GLP-1 RESPONSES
The IR-GLP-1 responses to the different meals are represented graphically in 
figure 5.10 and the values given in table 5.10. For all 3 meals a clear rise in IR-GLP-1 
was evident from 15 to 45 minutes post-prandially. The increases from fasting values 
were statistically significant for the glucose and extruded wheat starch meals at 30 and 
45 minutes post-prandially and for the autoclaved wheat starch meal at 30 minutes post- 
prandially (p<0.05 in all cases). Peak values occurred at 30 minutes after all meals, 
with the extruded wheat starch giving the greatest peak and overall response and the 
autoclaved wheat starch giving the lowest. However, there were no statistically 
significant differences between the responses to the different meals at any individual 
time points or for the integrated response over the 3 hour period.
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FIGURE 5.9 PL A SM A  IR -G IP R E SPO N SE S TO  
G LUCO SE A N D  W H EAT ST A R C H  M E A L S
IN H EALTH Y H U M A N  SU BJEC TS
Error bars indicate mean ± S.E. (n=6)
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TABLE 5.9 PLASMA IR-GIP RESPONSES TO 
GLUCOSE AND WHEAT STARCH MEALS 
IN HEALTHY HUMAN SUBJECTS
Error bars indicate mean ± S.E. (n=6)
Time
(minutes)
PLASMA IR-GIP (pM)
Glucose Autoclaved Extruded
Wheat Starch Wheat Starch
-10 34±9 88±37 80±43
0 23±8 57±22 80±32
15 220±78 203±108 170±43
30 223±53 256±86 200+39
45 286±59 260±82 161±41
60 317±52 245±82 208±81
90 231±72 127±40 249±91
120 117±31 93±33 209±91
150 65±40 54±17 136±79
180 43±13 42±12 54±21
TABLE 5.10 PLASMA IR-GLP-1 RESPONSES TO 
GLUCOSE AND WHEAT STARCH MEALS 
IN HEALTHY HUMAN SUBJECTS
Error bars indicate mean ± S.E. (n=6)
Time
(minutes)
Glucose
PLASMA IR-GLP-1 (pM)
Autoclaved 
Wheat Starch
Extruded 
Wheat Starch
-10
0
15
30
45
60
90
120
150
180
16.4±2.7
13.3±2.6
20.3+4.9
27.4±12.9
25.114.4
20.014.0
13.513.3 
9.512.9 
12.213.6
13.113.3
14.313.1
16.513.2
20.513.7 
26.613.4 
20.212.9
17.512.8
12.012.2 
12.012.2
14.511.9
12.712.9
14.512.8 
16.512.2
28.116.5 
33.616.7
24.513.6
19.814.0
15.012.9
14.413.1
13.913.1 
15.312.4
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5.3.3 DISCUSSION
The inconsistent results obtained for exhaled hydrogen measurements highlight 
the problems associated with this technique. The sampling technique requires some 
practice on behalf of the subjects to obtain reproducible results at each time point.
Some people produce methane instead of hydrogen. This is dependent on their 
gut micro flora. Ideally, in studies where exhaled hydrogen is to be measured the 
potential subjects should be screened by giving them a lactulose load to ensure that they 
are hydrogen producers.
In more recent studies, some workers have gone to the lengths of giving their 
subjects a standard meal on the evening before a trial, designed to give low basal breath 
hydrogen, as well as requiring them to carry out a mouth-wash immediately before the 
trial, to stop any buccal fermentation, and insisting on the subjects remaining supine 
throughout the study to avoid any possible mixing effects caused by movement 
(Cloarec era/, 1990).
The results described here, while not being conclusive, suggest that there was 
no difference between the mouth to caecum transit times for the 2 starch meals but that 
the transit time for the liquid glucose load was faster.
The small differences observed in capillary blood glucose levels after ingestion 
of the oral glucose load compared with those following the purified starch preparations 
suggest that the starches, regardless of their vaiying RS content, were almost as readily 
digested and absorbed as the glucose load. This was corroborated by the marked 
similarities in the responses to the different carbohydrates for the other parameters.
This study served to confirm that carbohydrate does stimulates tGLP-1 
secretion. The increases in plasma IR-GLP-1 were more marked but of shorter 
duration than for the larger carbohydrate load described in the previous study. As in 
that study, the maximum concentrations were observed 30 minutes post-prandially. 
This is surprising, since mouth to caecum transit times were in the range of 60 to 100
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minutes for the liquid glucose load and 100 to 195 minutes for the starch meals. If 
tGLP-1 were indeed released in response to nutrient absorption in the lower small 
intestine, peak plasma concentrations would be expected to occur considerably later 
than 30 minutes after the meals. It may be that secretion of tGLP-1 is stimulated by 
another mechanism.
5.4 COMPARISON OF THE METABOLIC 
RESPONSES TO GLUCOSE, RICE AND  
BARLEY MEALS IN HEALTHY 
HUMAN SUBJECTS
The starch test meals described in the previous section were extremely 
unpalatable and not representative of any normal foodstuff. For the subsequent 
studies, therefore, high carbohydrate whole foods were investigated.
Several factors other than RS have been proposed to influence the rate of 
digestion of starch. In plant cells, starch is packaged, in a partially crystalline form, in 
dense granules. The starch in these native granules is poorly digested but cooking 
leads to greater digestibility in vitroand in vivo(Bomet etal, 1989 ; Snow and O’Dea, 
1981). Cooking in the presence of water leads to gelatinization of the starch. This 
involves the loss of the partial crystallinity of the starch, swelling of the granules as 
water is absorbed, and ultimately their total disruption. Gelatinization has been 
proposed to play an important role in determining the in vitroand in wVodigestibility of 
starch (Holm etal, 1988 ; Wootton and Chaudrey, 1980). Cooking may also influence 
the rate of starch digestion by disrupting the cell wall integrity and consequently 
increasing the accessibility of the starch to degradative enzymes.
The study described here addressed the role of different types of cereal in 
determining rate and extent of starch digestion and the consequent post-prandial plasma 
glucose, IRI, IR-GIP and IR-GLP-1 responses. Brown rice and pearl barley were
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selected as the 2 types of cereal to be investigated. The rice and barley were cooked in 
such a manner that the difference in their in vitro starch digestibilities would be 
minimized. Any differences in the metabolic responses to the 2 cereals in vivo, 
therefore, would be likely to result from differences in the structural integrity of the 
grains or differences in non-starch polysaccharide contents.
A third meal consisting of glucose was included to act as a control showing the 
metabolic responses to rapidly absorbed carbohydrate.
5.4.1 STUDY DESIGN
Preliminary experiments were carried out at the FMBRA, Chorleywood. In 
these, brown rice (Sainsbury’s American Whole Grain Brown Rice, Sainsbury, 
London) and pearl barley (Sainsbury’s Pearl Barley, Sainsbury, London) were cooked 
for a range of different times.
To cook the cereals, 650ml of water was brought to a rolling boil in a pan. Rice 
or barley (equivalent to 75g of carbohydrate) was then added to the boiling water and 
carefully simmered for the appropriate length of time.
The cooked cereals were milled. The in v/7/o digestibility and RS contents of 
the starch from the 2 cereals were then determined for each of the different cooking 
times. The cooked cereals were given starch digestibility factors which were calculated 
as follows :-
Digestibility factor = 0.5x[200 - (% starch undigestedlo + % starch undigested^o) 
Where starch undigestedx = starch undigested after X minutes of enzymic
degradation in vitro
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From the results obtained it was possible to identify cooking times for the 2 
cereals at which the in vitro digestibilities were matched. Cooking times of 15 minutes 
for the rice and 20 minutes for the barley were selected for the trial on the basis that 
they made both cereals edible and produced similar in vitro digestibility factors (84.6 
for the rice and 86.0 for the barley). The RS contents of the cooked cereals were 3.5% 
for the rice and 5.3% for the barley.
The equivalent of 75g of carbohydrate was served in each meal. For this, 97g 
of rice and 107g of barley were required. Portions of each cooked cereal were placed 
in 250ml measuring cylinders and water added until the cereals were totally covered and 
the volume made up to 250ml. By subtraction of the volume of water required to do 
this, the solid volume of the portions of each cereal were determined.
Both the rice and barley meals were served together with 100ml of pureed 
canned tomatoes (containing less than 2g of carbohydrate) to improve palatability. The 
total volume of each meal was made up to 450ml with a glass of water. Thus, the rice, 
which had a cooked volume of 190ml, was served with the 100ml of pureed tomato 
plus a 160ml glass of water. The barley, which had a cooked volume of 200ml, was 
served the 100ml of pureed tomato and a 150ml glass of water.
The glucose meal (containing 75g of carbohydrate) was given in the form of 
116ml of lemon flavoured Hycal, short chain dextrose polymer syrup (Beecham 
Products, Brentford) diluted to a total volume of 300ml with water and served with a 
further 150ml glass of water (450ml total meal volume). The subjects were asked to 
drink the Hycal syrup and water over a period of approximately 10 minutes. The 
precise nutritional composition of the different meals is shown in table 5.11.
The study design was the same as that described in section 5.2.1 except that the 
8 healthy volunteers (2 females and 6 males, aged 19 to 23 [mean ± S.E. = 20.0±0.5] 
with BMIs ranging from 21.5 to 29.0 [mean ± S.E. = 23.3±0.9]) were required to 
consume the glucose, rice and barley meals. The rice and barley meals were always 
served immediately after cooking to avoid changes in RS content.
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TABLE 5.11 NUTRITIONAL COMPOSITION OF 
GLUCOSE, RICE AND BARLEY TEST 
MEALS
NSP = Non-starch polysaccharide
Carbohydrate
Fat
Protein
NSP
Energy (kcal)
Hycal
75
282
Rice
77
3.1
8.4
5.5
345
Barley
77
1.6
8.4
10.0
338
5.4.2 RESULTS
All the subjects managed to consume the Hycal and rice meals within 15 
minutes but 3 of the subjects took 20 to 25 minutes to consume all of the barley meal.
5.4.2.1 PLASMA GLUCOSE RESPONSES
There were no significant differences in the fasting plasma glucose 
concentrations but there were marked differences in the post-prandial responses for the 
different meals (figure 5.11 and table 5.12). For the Hycal meal, plasma glucose 
concentrations increased considerably, peaking 45 minutes post-prandially before 
declining steadily to and below fasting concentrations by 120 minutes.
The plasma glucose response to the rice meal was much flatter than for the 
Hycal. Peak concentrations occurred 30 minutes post-prandially but the levels had not 
completely returned to fasting concentrations after 3 hours. A similar pattern was
57
obtained for the barley meal, but the post-prandial increases were even lower than those 
for the rice meal.
The post-prandial plasma glucose concentrations were significantly higher for 
the Hycal meal compared with the rice meal at the 45 minute time point (p<0.05) and 
compared with the barley meal from 15 to 60 minutes (p<0.01). They were 
significantly lower for the Hycal meal compared with the rice meal from 120 to 180 
minutes (p<0.01) and compared with the barley meal from 120 to 180 minutes (p<0.05 
at 120 minutes ; p<0.01 at 150 and 180 minutes).
The plasma glucose concentrations following the barley meal were significantly 
lower than for the rice meal at 30,45, 60, 90 and 150 minutes post-prandially (p<0.05). 
The total area under the curve for the barley meal was significantly less than for the rice 
meal (p<0.05).
The total area under the curve for the Hycal meal did not differ significantly 
from those for either of the other meals. This reflects the fact that, although the 
increases were substantially greater over the first hour for the Hycal meal than for the 
rice and barley meals, in the second and third hour plasma glucose concentrations 
rebounded to below fasting concentrations for the Hycal meal but remained elevated for 
the other 2 meals.
5 .4 .2 .2  PLASMA IRI RESPONSES
The differences between the plasma IRI responses to the Hycal meal and the 2 
cereal meals (figure 5.12 and table 5.13) were even more marked than were evident for 
the plasma glucose responses. Fasting concentrations did not differ significantly 
between the 3 meals. Following the Hycal meal, the plasma IRI increased rapidly and 
substantially to a maximum 45 minutes post-prandially and remained significantly 
elevated above fasting levels for 2 hours (p<0.01 from 30 to 60 minutes ; p<0.05 at 15, 
90 and 120 minutes).
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FIGURE 5.11 PLASMA GLUCOSE RESPONSES TO 
GLUCOSE, RICE AND BARLEY MEALS IN 
HEALTHY HUMAN SUBJECTS
Error bars indicate mean ± S.E. (n=8)
* Denotes values significantly different to those for the Hycal 
meal (p<0.05)
** Denotes values significantly different to those for the Hycal 
meal (p<0.01)
+ Denotes values significantly different to those for the rice meal 
(p<0.05)
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Error bars indicate mean ± S.E. (n=8)
* Denotes values significantly different to those for the Hycal 
meal (p<0.05)
** Denotes values significantly different to those for the Hycal 
meal (p<0.01)
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TABLE 5.12 PLASMA GLUCOSE RESPONSES TO 
GLUCOSE, RICE AND BARLEY MEALS IN 
IN HEALTHY HUMAN SUBJECTS
Values bars indicate mean ± S.E. (n=8)
* Denotes values significantly different to those for the Hycal 
meal (p<0.05)
** Denotes values significantly different to those for the Hycal 
meal (p<0.01)
t  Denotes values significantly different to those for the rice meal 
(p<0.05)
PLASMA GLUCOSE (mM)
Time Hycal Meal Rice meal Barley Meal
(minutes)
-10 5.09+0.13 4.9110.16 4.7810.12
0 5.09+0.13 4.8110.17 4.8910.10
15 6.95±0.54 5.8410.23 5.2610.18 **
30 8.79±0.75 7.2010.30 5.8710.21 ** t
45 8.89±0.69 6.9810.52 * 5.6710.19 ** t
60 8.29±0.70 6.9810.52 5.6710.19 t
90 6.08±0.48 6.7910.35 5.6910.22 t
120 4.45+0.36 6.2410.42 ** 5.5310.27 **
150 4.05±0.22 5.9810.15 ** 5.3810.19 ** t
180 3.9410.22 5.3110.16 ** 5.4610.10 **
6 0
TABLE 5.13 PLASMA IRI RESPONSES TO GLUCOSE, 
RICE AND BARLEY MEALS IN HEALTHY 
HUMAN SUBJECTS
Values bars indicate mean ± S.E. (n=8)
* Denotes values significantly different to those for the Hycal 
meal (p<0.05)
** Denotes values significantly different to those for the Hycal 
meal (p<0.01)
PLASMA IRI (mU/1)
Time Hycal Meal Rice meal Barley Meal
(minutes)
-10 6.010.5 7.411.7 6.911.1
0 8.812.2 6.611.0 8.011.1
15 38.819.6 19.915.5 11.112.0 *
30 78.7119.1 33.5113.3 21.413.9 *
45 101.7116.7 31.618.7 ** 23.917.1 **
60 85.9111.7 28.215.3 ** 20.113.5 **
90 63.8111.6 28.216.3 * 20.113.5 **
120 27.916.7 24.614.8 16.313.2
150 18.119.1 25.517.1 12.812.2
180 18.6111.0 18.614.3 5.410.1
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The post-prandial increases in plasma IRI concentrations were considerably less 
for both the rice and barley meals. Nevertheless, plasma IRI concentrations were 
significantly elevated above fasting for the rice meal from 45 to 180 minutes (p<0.05 at 
45 minutes ; p<0.01 from 60 to 180 minutes) and for the barley meal from 30 to 180 
minutes (p<0.01 at all time points from 30 to 180 minutes) post-prandially. Although 
the mean post-prandial plasma IRI concentrations were lower for the barley meal than 
for the rice meal, the differences were small and did not reach statistical significance at 
any time point or for the total areas under the curve. In contrast, plasma IRI levels 
were significantly higher following the Hycal meal from 45 to 90 minutes (p<0.01 at 
45 and 60 minutes ; p<0.05 at 90 minutes) compared with the rice meal and from 15 to 
90 minutes (p<0.05 at 15 and 30 minutes ; p<0.01 from 45 to 90 minutes) compared 
with the barley meal. Furthermore, the total area under the curve over the 3 hour 
sampling period was significantly greater for the Hycal meal compared with both the 
rice (p<0.05) and barley (p<0.01) meals.
5 .4.2.3 PLASMA IR-GIP RESPONSES
The plasma IR-GIP responses to the different meals are depicted in figure 5.13 
and the values given in table 5.14. There were no differences between the meals in the 
fasting IR-GIP concentrations. The Hycal meal again produced the largest response. 
Plasma IR-GIP concentrations increased over 30 minutes to a plateau which was 
maintained for a further 60 minutes. After this the concentrations started to decline. 
The concentrations were significantly elevated (p<0.05) above fasting from 30 to 120 
minutes post-prandially.
The IR-GIP responses to the 2 cereal meals were similar and substantially lower 
than that for the Hycal. For the rice meal, the IR-GIP concentrations were significantly 
elevated above fasting from 30 to 180 minutes (p<0.05 at 30 and 120 minutes ; p<0.01 
at 45, 60, 90, 150 and 180 minutes). For the barley meal, the post-prandial increases
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never quite reached statistical significance (p=0.07 at 30 minutes).
Plasma IR-GIP concentrations were significantly higher for the Hycal meal 
from 15 to 90 minutes (p<0.05 from 15 to 60 minutes ; p<0.01 at 90 minutes) 
compared with the rice meal and from 15 to 120 minutes (p<0.05 in all cases) 
compared with the barley meal. The total area under the curve for IR-GIP following 
the Hycal meal was significantly larger than for both the rice and barley meals 
(p<0.05).
5 .4 .2 .4  PLASMA IR-GLP-1 RESPONSES
The plasma IR-GLP-1 responses to the different meals are shown in figure 5.14 
and the values given in table 5.15. The fasting levels did not differ significantly 
between the 3 meals. There was an increase in plasma IR-GLP-1 concentrations over 
the first 45 minutes following ingestion of the Hycal before the concentrations fell 
again. Concentrations were significantly elevated above fasting at the 30 (p<0.05) and 
45 (p<0.01) minute time points.
For the rice meal, the mean plasma IR-GLP-1 concentration appeared to 
increase transiently 15 minutes after the rice meal. However, this apparent increase did 
not achieve statistical significance. Plasma IR-GLP-1 concentrations did not increase 
at all at any time point following the barley meal.
At 30 and 45 minutes post-prandially, the plasma IR-GLP-1 concentrations in 
response to the Hycal meal were greater than those in response to the rice or barley 
meals (p<0.01 in all cases). There were no significant differences between the meals in 
total or incremental areas under the curve.
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FIGURE 5.13 PLASMA IR-GIP RESPONSES TO 
GLUCOSE, RICE AND BARLEY MEALS IN 
HEALTHY HUMAN SUBJECTS
Error bars indicate mean ± S.E. (n=8)
* Denotes values significantly different from those for the Hycal 
meal (p<0.05)
** Denotes values significantly different from those for the 
Hycal meal (p<0.01)
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FIGURE 5.14 PLASMA IR-GLP-1 RESPONSES TO
GLUCOSE, RICE AND BARLEY MEALS IN 
HEALTHY HUMAN SUBJECTS
Error bars indicate mean ± S.E. (n=8)
** Denotes values significantly different from those for the rice 
and barley meals (p<0.01 )
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TABLE 5.14 PLASMA IR-GIP RESPONSES TO 
GLUCOSE, RICE AND BARLEY MEALS IN 
HEALTHY HUMAN SUBJECTS
Values bars indicate mean ± S.E. (n=8)
* Denotes values significantly different from those for the Hycal 
meal (p<0.05)
** Denotes values significantly different from those for the 
Hycal meal (p<0.01)
Time
(minutes)
PLASMA IR-GIP (pM)
Hycal Meal Rice meal Barley Meal
-10 53+20 52111 72117
0 42+14 4219 65116
15 162±30 83113 * 77115 *
30 192±38 101114 * 92117 *
45 196+33 101110 * 91114 *
60 191±33 95112 * 98116 *
90 188±29 93112** 89116 *
120 131120 96112 81113 *
150 99+11 9619 73111
180 68+11 94110 74113
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TABLE 5.15 PLASMA IR-GLP-1 RESPONSES TO 
GLUCOSE, RICE AND BARLEY MEALS IN 
HEALTHY HUMAN SUBJECTS
Values bars indicate mean ± S.E. (n=8)
** Denotes values significantly different from those for the rice 
and barley meals (p<0.01 )
Time
(minutes)
PLASMA IR-GLP-1 (pM)
Hycal Meal Rice meal Barley Meal
-10
0
15
30
45
60
90
120
150
180
10.012.3 
7.812.4
19.815.5
26.414.5 **
27.515.3 **
13.713.1 
12.312.7
12.913.5 
8.512.9
11.213.1
13.113.3
7.412.1
16.913.0
10.312.0
6 . 112.2
6.912.0
8.512.3 
9.512.2 
9.912.9 
10.012.8
11.813.3
11.413.3
12.813.2
12.813.2 
9.113.9
7.113.2 
6.912.1 
11.213.3 
8.212.6 
13.214.8
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5.4.3 DISCUSSION
The plasma glucose responses to the rice and barley meals clearly demonstrated 
slower absorption than for the Hycal meal. This was likely to have been due to slow 
enzymic degradation of the starch in these 2 cereals as a result of interaction with other 
food components. The effect was more marked for the barley than for the rice.
The plasma IR-GIP response, which can be considered as a marker of nutrient 
absorption, was also greater for the Hycal meal than for either of the cereals. This 
probably played an important role in producing the substantially enhanced plasma IRI 
levels observed following the Hycal meal.
No significant increase in IR-GLP-1 was observed following either the rice or 
barley meals. In contrast, there was a distinct increase in IR-GLP-1 concentrations 
after ingestion of the Hycal. This reached a peak 45 minutes post-prandially. The 
timing and magnitude of the increase lend further weight to the concept that tGLP-1 can 
act as a physiological incretin in man following carbohydrate ingestion. These results 
also strongly suggest that tGLP-1 secretion from the gut is stimulated by glucose 
absorption and that a minimum rate of glucose absorption is necessary for an 
appreciable increase in plasma IR-GLP-1 concentrations to be observed.
Contrary to the prediction made in the introduction to this chapter, the results of 
this study suggest that rapidly absorbable, simple carbohydrate can provide a greater 
stimulus to tGLP-1 secretion from the gut than can more slowly absorbed complex 
carbohydrates even though these are likely to cause absorption of glucose further down 
the small intestine.
Overall, the barley starch appeared to be digested more slowly than the rice 
starch. The differences between the 2 cereals were likely to have been caused by the 
greater degree of granular structural integrity of the barley, since other factors, such as 
the varying composition of the starches from different cereals, including barley, do not 
appear to have a significant effect on the rate of starch digestion in more highly
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processed foods such as breads (Elliott etal, 1991).
After 20 minutes cooking the pearl barley grains were still firm and all the 
subjects found the barley very chewy. The barley contained a higher proportion of non­
starch polysaccharide than the rice. Most of this is located on the exterior of the grains. 
The higher non-starch polysaccharide content of the barley, may have acted as a more 
effective physical barrier to the degradative enzymes.
This hypothesis is supported further by the fact that, following milling, the 
starch in the rice and barley exhibited similar in vitro digestibilities. This demonstrates 
the fact that great care must be taken if in vitro digestibility data are to be used to attempt 
to predict 7/2 vjVo responses.
5.5 EFFECT OF COOKING TIME ON THE 
METABOLIC RESPONSES TO A RICE 
MEAL IN HEALTHY HUMAN SUBJECTS
Following on from the barley and rice meal study, another meal study was 
carried out which was designed to investigate the effects of different cooking times on 
the metabolic responses to brown rice. Wolever and co-workers reported that rice 
cooked for 5 minutes produced a lower glycaemic response than rice cooked for 15 
minutes (Wolever et al, 1986). They showed that after 5 minutes cooking the 
individual rice grains were intact and had swelled less than the grains cooked for 15 
minutes which had split. The difference in glycaemic response was believed to be due 
to increased accessibility of the rice starch to enzymic degradation in the rice cooked for 
the longer time.
The study described here extended the previous work by including assessment 
of the physical properties of the starch in the rice. The degree of gelatinization and in 
v/7ro digestibilities of the rice starch cooked for different times were determined so that 
any differences in the in v/vometabolic responses to the rice meals might be related to
168
differences in these 2 factors.
5.5.1 STUDY DESIGN
Preliminary experiments were carried out at the FMBRA to determine the degree 
of gelatinization of starch, determined by differential scanning calorimetry (Biliaderis et 
al, 1980), and the in v/Vro starch digestibilities for brown rice ( Sainsbury’s American 
Wholegrain Brown Rice) cooked for a range of different times. The starch was found 
to undergo rapid gelatinization (figure 5.15). The in vitrostarch digestibility also 
increased rapidly with cooking but, whereas gelatinization was complete within 30 
minutes, starch digestibility continued to increase up to the maximum cooking time of 
45 minutes (figure 1.16).
From these experiments, 3 cooking times were selected. A cooking time of 15 
minutes produced rice that was undercooked but edible. Under these conditions the 
starch was found to be 85% gelatinized.
After 30 minutes of boiling, the rice was completely (100%) gelatinized but the 
grains still intact and firm (al dente). However, after 45 minutes of boiling (100% 
gelatinized) the grains were overcooked and had lost some structural integrity.
Rice (97g containing 75g of carbohydrate) which had been cooked either for 
15, 30 or 45 minutes was consumed by the 8 volunteers (aged 18-25 with BMIs 
ranging from 20.0 to 24.7 kg/mZ [mean ± S.E. = 21.6±0.6 kg/m2]) on 3 separate 
occasions using an experimental design otherwise identical to that described in section 
5.2.1.
The rice was cooked in the same manner as described in section 5.4.1. Once 
cooked the rice was drained and served together with a glass (150ml) of water. In order
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FIGURE 5.15 EFFECTS OF COOKING TIME ON DEGREE 
OF RICE STARCH GELATINIZATION
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FIGURE 5.16 EFFECTS OF COOKING TIME ON IN VITRO 
RICE STARCH DIGESTIBILITY
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to minimize any possible effects of RS formation the meals were served immediately 
after cooking before the rice could cool.
5.5.2 RESULTS
The subjects all managed to consume the meals in less than 15 minutes, except 
for 2 who took 20 to 25 times to consume the rice which had been cooked for 45 
minutes.
5.5.2.1 PLASMA GLUCOSE RESPONSES
The plasma glucose responses to the different rice meals are depicted in figure 
5.17 and the values given in table 5.16. The post-prandial concentrations were very 
similar. There were no significant differences between the 3 different meals at any time 
point or in total or incremental areas under the curve for the 3 hour sampling period.
5.5 .2 .2  PLASMA IRI RESPONSES
The plasma IRI concentration observed following the different rice meals are 
shown in figure 5.18 and the values given in table 5.17. As with the plasma glucose 
the post-prandial responses were very similar for the 3 meals. Again there were no 
significant differences between the 3 different meals at any time point or in total or 
incremental areas under the curve.
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FIGURE 5.17 EFFECT OF COOKING TIME ON PLASMA 
GLUCOSE RESPONSE TO A RICE MEAL 
IN HEALTHY HUMAN SUBJECTS
Error bars indicate mean ± S.E. (n=8)
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FIGURE 5.18 EFFECT OF COOKING TIME ON PLASMA 
IRI RESPONSE TO A RICE MEAL IN 
HEALTHY HUMAN SUBJECTS
Error bars indicate mean ± S.E. (n=8)
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TABLE 5.16 EFFECT OF COOKING TIME ON PLASMA 
GLUCOSE RESPONSE TO A RICE MEAL 
IN HEALTHY HUMAN SUBJECTS
Values indicate mean ± S.E. (n=8)
Time
(Minutes)
PLASMA GLUCOSE (mM)
15 Minutes 
Cooking Time
30 Minutes 
Cooking Time
45 Minutes 
Cooking Time
-10
0
15
30
45
60
90
120
150
180
5.0310.16
5.2710.21
5.8310.20 
7.3310.46 
7.5710.39 
6.2110.26 
5.6810.34
5.6710.28
5.7810.29
5.2510.20
5.1610.21
5.3710.14
6.8310.49
8.0110.49 
7.2810.59
6.7410.49 
5.5510.32
5.3510.25
5.3810.23
5.0910.28
5.2910.16
5.4010.16
6.3410.23 
7.7510.56 
7.7410.58 
6.6310.53 
5.9210.61
5.4210.25 
5.4510.18 
5.2710.10
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TABLE 5.17 EFFECT OF COOKING TIME ON PLASMA 
IRI RESPONSE TO A RICE MEAL IN 
HEALTHY HUMAN SUBJECTS
Values indicate mean ± S.E. (n=8)
Time 15 Minutes
PLASMA IRI (mU/1) 
30 Minutes 45 Minutes
(Minutes) Cooking Time Cooking Time Cooking Time
-10 5.210.6 6.211.5 5.310.7
0 5.210.9 6.411.2 5.210.7
15 19.513.1 34.317.9 39.2111.4
30 52.5111.7 60.2112.1 60.519.6
45 44.118.6 41.518.6 54.2112.7
60 29.116.1 30.317.5 28.815.5
90 19.416.5 17.512.9 16.914.0
120 15.814.8 14.212.5 13.213.3
150 15.313.2 13.012.7 13.212.4
180 12.912.2 14.213.1 10.011.9
7 4
5.5.2.3 PLASMA IR-GIP RESPONSES
The plasma IR-GIP responses to the different rice meals are depicted in figure 
5.19 and the values given in table 5.18. As with the other 2 parameters measured, the 
IR-GIP responses to the rices cooked for different times were effectively 
superimposable. There were no significant differences between the 3 rice meals at any 
time point or in total or incremental areas under the curve.
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FIGURE 5.19 EFFECT OF COOKING TIME ON PLASMA 
IR-GIP RESPONSE TO A RICE MEAL IN 
HEALTHY HUMAN SUBJECTS
Error bars indicate mean ± S.E. (n=8)
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TABLE 5.18 EFFECT OF COOKING TIME ON PLASMA 
IR-GIP RESPONSE TO A RICE MEAL IN 
HEALTHY HUMAN SUBJECTS
Values indicate mean ± S.E. (n=8)
Time 15 Minutes
PLASMA IR-GIP (pM) 
30 Minutes 45 M inutes
(Minutes) Cooking Time Cooking Time Cooking Time
-10 193±27 187133 209145
0 184±24 178136 188133
15 395±46 505184 468144
30 677±51 691156 684124
45 578151 590151 606136
60 529+43 547150 526131
90 523+52 486135 469135
120 474152 466141 437131
150 488166 454138 439138
180 460171 479157 427142
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5.5.3 DISCUSSION
The results obtained from this study suggest that starch digestion and 
absorption are unaffected by different cooking times. The differences in the degree of 
gelatinization between the rice meals cooked for 15, 30 and 45 minutes were small 
since there was a high degree of gelatinization (85%) even in the rice cooked for the 
least time. A larger range of degree of gelatinization could not have been obtained since 
rice cooked for less than 15 minutes would have been inedible.
It is not possible to conclude from this study that the degree of gelatinization of 
starch is not important in determining the metabolic responses to foods. However, in 
most cooked foods the starch gelatinization will be complete or almost complete. 
Consequently, other factors probably play a more important role in determining the rate 
of digestion of the starch.
Interaction of starch with other dietaiy components (non-starch polysaccharide, 
protein and lipids) could be such a factor. The granular structure of brown rice may 
slow starch digestion by reducing the accessibility of the starch stored in the centre of 
the grains to the degradative enzymes. The possibility that different cooking times 
influenced the rate of starch digestion by disrupting, to different extents, the structural 
integrity of the grains was also investigated. After 30 minutes of boiling the individual 
grains were still firm whereas after 45 minutes of boiling they were soft and partially 
degenerated. Even though the grains that had been boiled for 45 minutes had obviously 
been more extensively disrupted than those cooked for 15 or 30 minutes, the metabolic 
responses for these 3 groups were almost identical. This suggests that the starch in 
cooked brown rice grains is readily accessible to enzymic degradation after 15 or more 
minutes of boiling. If there is any change in starch digestibility caused by alteration in 
rice grain structure it must occur after less than 15 minutes of boiling.
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5.6 PLASMA IR-GLP-1 LEVELS IN LEAN AND  
GENETICALLY OBESE MICE
It was mentioned earlier (section 1.5.5) that genetically obese (ob/ob) mice 
exhibit raised plasma GXP levels as well as the characteristic hyperglycaemia and 
hyperinsulinaemia. Like GIP, it has been proposed that tGLP-1 may play a role in 
obesity since it has been demonstrated to be able to stimulate fatty acid synthesis in 
vitro (Oben et al, 1991). However, plasma tGLP-1 concentrations have not been 
previously investigated.
Normal concentrations of IR-GLP-1 along the GI tract of genetically obese mice 
have already been demonstrated (section 4.3.6) but it was speculated that the greater gut 
tissue weights and lengths found in these obese animals might contribute to elevated 
plasma concentrations of tGLP-1. In this study we have investigated the fasting and 
fed IR-GLP-1 concentrations in the plasma of obese mice and their lean littermates.
5.6.1 STUDY DESIGN
Twelve obese {ob/ob) mice and 12 lean littermates on the Aston background 
aged 16-20 weeks were used for the study. Six animals of each type were fasted 
overnight whilst the remaining animals were allowed to feed ad libitum. The following 
morning, blood samples were taken from all the animals by cardiac puncture. These 
were treated as described in section 2.8 and the resultant plasma assayed for IR-GLP-1.
5.6.2 RESULTS
The plasma IR-GLP-1 values determined for the 4 groups of animals are shown 
in table 5.19. There was no significant difference between the fed and fasting IR-GLP- 
1 concentrations within either the lean or obese groups. However, the plasma
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TABLE 5.19 PLASMA IR-GLP-1 CONCENTRATIONS IN 
LEAN AND OBESE MICE
Values indicate mean ± S.E. (n=6)
IR-GLP-1 (pM)
FASTED FED
LEAN 47.5±8.2 42.2±6.5
OBESE 70.5+3.4 54.2+10.2
concentrations in the obese animals (fed and fasting combined) were significantly 
greater than in their lean littermates (62.3±5.7pM for obese compared with 
44.8±5.0pM for the lean, p<0.05).
5.6.3 DISCUSSION
Obese (ob/ob) mice on the Aston background exhibit circulating GIP 
concentrations greater than 10-fold those found in their lean counterparts (Bailey et al, 
1986). However, in this study, we have found only marginally raised IR-GLP-1 levels 
in the obese compared with the lean animals.
It is interesting to compare these results with those obtained for the IR-GLP-1 
found in gut tissue extracts of lean and obese mice (section 4.3.6). The concentrations 
of IR-GLP-1 along the length of the GI tract were not found to differ between the lean 
and obese animals. In contrast, GIP concentrations are reported to be markedly 
elevated in the GI tract of obese compared with lean mice (Bailey etal, 1986).
The slightly raised plasma concentrations IR-GLP-1 in the obese group could 
be due to the hyperphagia exhibited by these animals. However, a confounding factor
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in the measurement of circulating tGLP-1 levels in mice is that the pancreatic processing 
of the proglucagon gene differs from that observed in humans and pigs. Like rats 
(section 4.3.3), gel filtration of extracts of mouse pancreas reveals a single, large peak 
of material crossreactive with our antiserum (G2-30/6/89) which probably corresponds 
to GLP-l(l-36)amide (Knapper, 1992). The concentrations of this biologically 
inactive form are likely to fluctuate in proportion with the secretion of pancreatic 
glucagon.
The presence of this crossreacting form of GLP-1 in plasma may explain the 
higher IR-GLP-1 concentrations found in both the lean and obese mice compared with 
those in humans. It may also be that a change in pancreatic GLP-l(l-36)amide 
concentration is responsible for masking increased tGLP-1 levels in the fed animals 
compared with those in the fasting groups as was the case with MPGF in man for the 
study by Hirota and co-workers (Hirota etal, 1990) discussed in section 5.1.
5.7 PLASMA IR-GIP AND IR-GLP-1 LEVELS 
IN SUCKLING PIGLETS
The processing of the proglucagon gene in the gut and pancreas appears to be 
similar in both pigs and humans (chapter 4). Pigs could, therefore, represent a good 
model for comparative studies with man on the secretion and roles of GIP and tGLP-1. 
In the study described here, circulating GIP and tGLP-1 levels were measured in 
fasting and fed piglets.
8
5.7.1 STUDY DESIGN
This study was carried out in conjunction with Unilever Research, Shambrook. 
Sixteen piglets (18 days old, 8 per litter) were fasted for 12 hours by removing them 
from the sows. Fasting blood samples were taken from the animals and they were then 
returned to the sows to milk continuously. Blood samples were taken 1 and 3 hours 
after the start of suckling. The plasma samples obtained were assayed for IRI, IR-GIP 
and IR-GLP-1.
5.7.2 RESULTS
The results are shown in figure 5.20 and the values given in table 5.20. 
Marked rises were observed for all 3 parameters at the 1 and 3 hour time points 
compared with the fasting values. Whilst the peak IRI concentrations were somewhat 
lower than normally found post-prandially in man, there was a sustained rise in plasma 
IR-GIP levels to values 2 to 4-fold that observed for human subjects.
The fasting concentrations of IR-GLP-1 were very low (2. l±0.5pM, below the 
detection limit of the assay). However, after 1 hour of suckling the levels had risen to 
54.1±5.2pM (approximately twice the peak concentrations observed in the human 
studies). At 3 hours, the concentration was still significantly raised above fasting but 
had dropped to 23.0±2.8pM.
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TABLE 5.20 PLASMA IR-GIP, IR-GLP-1 and IRI 
CONCENTRATIONS IN SUCKLING 
PIGLETS
Values indicate mean ± S.E. (n= 16)
** denotes values significantly greater than fasting 
concentrations (p<0.01)
IR-GIP IR-GLP-1 IRI
(pM) (pM) (mU/1)
Fasting 112±2 2.1±0.5 5.4±1.0
1 Hour o f  Feeding 865±10 ** 54.1±5.2 ** 35.0111.6 **
3 Hours o f Feeding 829±8 ** 23.0±2.8 ** 21.412.3 **
5.7.3 DISCUSSION
High circulating GIP concentrations have been reported in other studies 
involving pigs (Ponter et al, 1991). The concentrations observed here were similar to 
those reported by other groups. IR-GLP-1 has not previously been measured in 
plasma from pigs. The increase in concentration that we found in this study is more 
marked than in any of the human studies. However, since GIP was also raised and 
insulin somewhat lower than found in healthy humans, it is not possible to conclude 
from these results that tGLP-1 necessarily plays a more important role as an incretin in 
the piglet than it does in man.
Sow milk contains fat, carbohydrate and protein. It was not possible to 
determine from this study which of these nutrients were responsible for the increased 
tGLP-1 secretion.
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5.8 PLASMA IR-GLP-1 CONCENTRATIONS IN 
THE PIG FOLLOWING INTRADUODENAL 
INFUSION OF FAT AND  
CARBOHYDRATE
In effect, the piglets in the study described above consumed a mixed meal. The 
study described below attempted to address the question of whether carbohydrate or fat 
is the major stimulus for tGLP-1 secretion from the gut in pigs. The results obtained so 
far are from a pilot study using only one animal to assess the practical difficulties 
associated with the project and the appropriate doses to give the animals. Further work 
is currently underway.
5.8.1 STUDY DESIGN
As for the suckling piglet trial, this work was carried out in conjunction with 
Unilever Research, Shambrook. One young female pig (10 weeks old) was surgically 
cannulated at the duodenum and catheterized at the jugular vein. After a recovery 
period, this animal was given a series of 8 intraduodenal infusions after 24 hour fasts. 
A gap of at least 4 days was left between each trial. The infusions were each carried 
out at a uniform rate over a 30 minute period. Blood samples were taken at intervals 
over a period of 4 hours after the start of each infusion.
On 3 different occasions, control infusions of 100ml of 0.85% w/v saline were 
carried out. One carbohydrate load, consisting of 20g of glucose in a volume of 100ml 
of water, was infused on a fourth occasion. On 4 further occasions, fat was infused in 
the form of 2 different emulsions. One was a mixture of the soya bean oil (48% wAv), 
dextran (9%wAv), casein (13% w/w) and water (40% w/w) (emulsion A). The second 
(emulsion B) contained soya bean oil (48% w/w) in water emulsified with Bolek K 
(5% w/w) (Unilever, Shambrook). Doses of either 30g and 60g of each emulsion
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(containing 14.4g or 28.8g of soya bean oil, respectively) were infused on different 
occasions.
5.8.2 RESULTS
Since the results are only from one animal it is not possible to carry out any 
statistical analysis. Consequently, the following discussion is essentially anecdotal.
The post-infusion plasma IR-GLP-1 concentrations observed are shown in 
figure 5.21. Only small fluctuations in IR-GLP-1 concentrations were observed 
following the saline infusions. There was no discernable rise in IR-GLP-1 following 
the glucose load although assessment of plasma glucose showed a marked rise from 
fasting values in the order of 4 mM to a maximum concentration of 9.2mM at the 30 
minute time point (data not shown). In contrast, both doses of both fat emulsions 
produced marked rises peaking at 30 minutes. However, the IR-GLP-1 responses to 
the larger doses of the emulsion were not appreciably greater than for the smaller doses, 
in fact, for emulsion A the reverse appeared to be the case.
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5.6.3 DISCUSSION
Whilst the results of this study are only preliminary, they suggest that fat is a 
more potent stimulator of tGLP-1 release than glucose in the pig. This is in marked 
contrast to GIF for which glucose provides a greater stimulus to secretion than does fat 
(Ponter etal, 1991). The fact that the IR-GLP-1 response to the fat emulsion infusions 
did not appear to increase with increasing load may mean that even the smaller dose 
represented an excess load for this system.
The flat responses to saline demonstrated that tGLP-1 secretion was not induced 
by distension of the small bowel in response to the infusion .
Unlike the piglets described in the study above, the fasting concentrations and 
concentrations observed throughout the saline infusions in this set of experiments were 
similar to those measured in humans. On the other hand, the peak plasma 
concentrations attained after the fat infusions (45-50pM) were higher than those found 
in humans but similar to the peak values attained in the suckling piglet study.
5.9 SUMMARY AND CONCLUSIONS
The GIF results described in this chapter are generally in good agreement with 
other published work. In man, plasma IR-GIP concentrations were found to increase 4- 
to 5-fold over fasting levels following oral carbohydrate and fat loads but there was no 
change following an oral protein load. Both the fasting and fed IR-GIP concentrations 
in pigs were higher than those normally found in humans.
Based on the knowledge of the species-specific and tissue-specific processing 
of the proglucagon gene, the crossreactivity of our antiserum and the plasma 
concentrations determined in the experiments described here, it seems likely that our 
radioimmunoassay for IR-GLP-1 represents a good means of assessing tGLP-1 levels 
in plasma from man and pigs, although it could underestimate the true concentration of
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biologically active forms of GLP-1 since any GLP-1(7-37) that might be present would 
not be detected. In the case of rodents, the same assay probably suffers from unwanted 
crossreactivity with biologically inactive GLP-l(l-36)amide secreted from the 
pancreas.
The values for IR-GLP-1 in fasting human plasma determined with our assay 
were in good agreement with the values reported by Kreymann and co-workers 
(Kreymann etal, 1987). However, the post-prandial increases following the various 
meals in our studies were somewhat lower than those observed by this other group.
Preliminary results in pigs suggest that, as for GIP, they produce more marked 
rises in IR-GLP-1 post-prandially than do humans. Furthermore, in these animals it 
may be that fat is a more potent stimulator of tGLP-1 secretion from the gut than is 
carbohydrate. In comparison, we found that in man oral carbohydrate, fat and protein 
all produced small increases in circulating IR-GLP-1. For equicaloric loads of these 
different macronutrients the post-prandial increases were approximately equal in 
magnitude although the carbohydrate perhaps produced a marginally greater response. 
In the studies using wheat starch preparations and glucose, rice and barley, rapidly 
absorbable carbohydrate sources elicited distinct increases in plasma IR-GLP-1, 
whereas slowly absorbable sources had little or no effect.
A somewhat curious aspect of the results described here and those from other 
groups is that peak IR-GLP-1 concentrations were consistently observed approximately 
30 minutes after ingestion of meals. The timing of the increase in plasma IR-GLP-1 
was, therefore, similar to that observed for IR-GIP although the distributions of these 2 
hormones along the GI tract are very different. The cells that secrete tGLP-1 are found 
predominantly in the lower small intestine and nutrients would not be expected to have 
passed so far down the GI tract in such a short period. The results obtained from the 
comparison of metabolic responses to glucose, rice and barley loads in man suggested 
that tGLP-1 was released as a result of nutrient absorption. Consequently, it seems 
likely that the acute increases in circulating tGLP-1 concentrations observed in man post­
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prandially are produced as a result of release of this hormone from the small number of 
tGLP-1-secreting cells in the proximal small intestine in response to nutrient 
absorption, or as a result of tGLP-1 release from the distal small intestine via some 
other mechanism.
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CHAPTER 6
TWENTY FOUR HOUR GI 
HORMONE PROFILES IN 
HEALTHY SUBJECTS ON A 
NORMAL WESTERN DIET
6.1 INTRODUCTION
Acute meal studies of the type described in chapters 3, 5 and 8 are useful for 
comparison of the metabolic responses to specific nutrients and foods in different 
subjects. However, they are not necessarily representative of normal meals. The acute 
studies described so far have been arranged to take place first thing in the morning after 
an overnight fast. On a day to day basis this kind of situation only arises at breakfast. 
Other meals are consumed after much shorter fasts and the metabolic response to these 
may be influenced by the previous meal.
Carroll and Nestel have reported that in a trial in which normal healthy 
volunteers were given oral glucose loads at 7a.m and 7p.m after 10 hour fasts, glucose 
tolerance was diminished and the insulin response was delayed after the evening meal 
compared with the morning meal (Carroll and Nestel, 1973). Constant glucose 
infusion experiments have also been employed to investigate diurnal variations in 
glucose tolerance. Such experiments have revealed nocturnal decreases in glucose 
tolerance (Shapiro etal, 1988 ; Van Cauter etal, 1989). These same experiments did 
not reveal any consistent diurnal variation in insulin levels. However, other 
researchers have reported a diurnal variation in insulin sensitivity (Gibson and Jarrett, 
1972 ; Gagliardino etal, 1976).
In another study, normal volunteers were given one mixed meal and then 
required to fast for 24 hours (Arendt etal, 1982). The results showed that plasma IR- 
GIP concentrations did not return to lasting levels until approximately 7 hours after the 
meal. In comparison plasma IRI concentrations returned to lasting concentrations 3 to 
4 hours after the meal. Once concentrations of both these parameters had returned to 
lasting values no subsequent diurnal variations were observed.
This sustained post-prandial rise in plasma IR-GIP is reflected in the results 
reported by Jones and co-workers (Jones et al, 1985). They gave a group of normal 
volunteers 4 isocaloric, non-identical meals at 9:00, 13:00, 16:00 and 19:00 hours.
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Plasma IR-GIP did not return to fasting concentration at any time between the various 
meals. In fact, a steady rise in the pre-prandial IR-GIP concentrations was observed 
with each meal. In another similar study, IR-GIP levels were also found to remain 
elevated throughout the day (Jorde et al, 1980). After the last meal of the day, it took 9 
hours for the plasma IR-GIP concentrations to fall to true fasting values.
Taking into account variations in glucose tolerance, insulin sensitivity and 
sustained elevation of GIP, and possibly of other GI hormones, it seems likely that the 
metabolic responses to any particular meal are likely to vary according to the time of 
day of consumption as well as the timing and composition of previous meals.
Previous studies investigating diurnal variations in glucose, insulin and GIP 
have been designed in such a fashion that the food consumption of the volunteers was 
not representative of their normal diet. The aim of the study described in this chapter, 
was to investigate the plasma concentrations of glucose, IRI, IR-GIP and IR-GLP-1 in 
normal healthy subjects over a 24 hour period fed a diet designed to approximate the 
normal quantity, composition and pattern food of consumption in Western society.
6.2 STUDY DESIGN
Six healthy volunteers (3 male and 3 female, aged between 24 and 26 with 
BMIs ranging from 20.1 to 31.0 kg/m2 [mean ± S.E. = 23.6±1.7kg/m2]) participated 
in the study. The subjects were put on a fixed diet for 4 hours before and throughout 
the 24 hour blood sampling period. This diet was designed to provide a total energy 
intake intermediate between the average energy requirement intakes for males and 
females between 19 and 49 years (Department of Health, 1991). The proportion of 
carbohydrate, fat and protein was arranged to reflect a typical Western diet.
The subjects started on the fixed diet with lunch at 13:00 hours on the first day 
of the trial followed by a mid-aftemoon snack at 15:30. Blood sampling commenced at
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17:00 hours. Over the subsequent 24 hours the subjects were served 3 main meals and 
3 snacks. The meals and snacks are described below and their nutrient and energy 
content is given in table 6.1.
Supper was served at 19:00 and the mid-evening snack at 21:30. The subjects 
went to bed at 23:00 hours. All the subjects were able to sleep during the night 
between blood samples and some did not even wake during the sampling.
They were woken for breakfast at 8:00. At 10:30 they were given their mid- 
morning snack. Lunch and the mid-aftemoon snack were identical to those served on 
the previous day and were given to the subjects at the same times as before. All the 
meals and snacks were consumed by the subjects in less than 15 minutes. Throughout 
the trial the subjects were allowed to consume water ad libitum. During waking hours 
over the blood sampling period the subjects took part in only light physical activity 
(e.g. reading, writing and laboratory work). Blood samples were taken hourly for 24 
hours. Additional blood samples were taken 20 and 40 minutes after each main meal. 
The plasma obtained was assayed for glucose, IRI, IR-GIP and IR-GLP-1.
All meals and snacks were served with a glass of orange squash. This 
consisted of 20ml of the concentrate (Whole orange drink, Tesco Stores Ltd, Cheshunt) 
diluted to taste with water.
The test breakfast consisted of a bowl of cereal (2 Weetabix, Weetabix Ltd, 
Kettering) served with 200ml of semi-skimmed milk, 2 slices of wholemeal toast 
(Tesco Medium Sliced Wholemeal Bread, Tesco Stores Ltd, Cheshunt) with 20g of 
butter and 20g of marmalade.
Lunch was served as 3 cheese sandwiches, a packet of ready salted crisps (25g 
packet, Tesco Stores Ltd, Cheshunt) and a satsuma. The sandwiches were made from 
3 slices of wholemeal bread, lOg of margarine (Flora, The Flora Food Company, 
Burgess Hill), 3 slices (each of 20g) of cheese (Mild Cheddar Slices, Tesco Stores Ltd, 
Cheshunt) and several slices of tomato.
For supper, the subjects were given half a deep pan cheese and tomato pizza
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(Tesco Stores Ltd, Cheshunt) cooked in a microwave oven. This was served with a 
bowl of salad containing lettuce and tomato plus 10ml of salad dressing (Tesco French 
Dressing, Tesco Stores Ltd, Cheshunt).
The mid-morning, mid-aftemoon and mid-evening snacks consisted of one 
Chewy Crisp Bar (Tesco Stores Ltd, Cheshunt) , one Ostler (Lyons Biscuits Ltd, 
Barnsley) and a pot of yogurt (Greek Style Yogurt, Tesco Stores Ltd, Cheshunt) 
respectively.
6.3 RESULTS
6.3.1 PLASMA GLUCOSE LEVELS
The mean plasma glucose levels for the 6 subjects over the 24 hour period are 
depicted in figure 6.1 and the values given in table 6.2. Plasma glucose increased 
following each of the 3 main meals.
The glucose levels following breakfast and lunch were very similar. Peak 
concentrations occurred 40 minutes after each meal and then dropped at 60 minutes. 
There was then a second, smaller increase at the 2 hour time point followed by a steady 
decline reaching basal values 4 to 5 hours post-prandially.
The glucose levels following supper appeared to be rather different. Maximal 
values occurred 2 hours after the meal. The mean concentration implies that there was 
an initial, smaller peak 40 minutes post-prandially followed by a small drop at 60 
minutes. However, inspection of the levels for the individual subjects revealed the 
transient decrease in glucose at 60 minutes only occurred in 2 of the 6 subjects. As for 
the other 2 meals, plasma concentrations returned to basal values 4 to 5 hours post- 
prandially. The integrated total glucose response over a 4 hour post-prandial sampling 
period was not significantly different for supper compared with the other 2 meals.
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TABLE 6.1 COMPOSITION OF MEALS AND SNACKS
AMOUNT ENERGY CHO FAT PROTEIN
(kcal) (g) (g) (g)
BREAKFAST
WEETABIX 2 128 24.7 0.2 4.2
SEMI-SKIMMED
MILK 200ml 96 3.4 9.8 6.8
WHOLEMEAL
TOAST 2 SLICES 128 23.7 1.5 6.0
BUTTER 20g 128 — 16.2 —
MARMALADE 40g 104 28.0 — ------
ORANGE SQUASH 20ml 19 5.2 — —
(603) (85.0) (27.7) (17.0)
MID-MORNING SNACK
CHEWY CRISP I 112 11.8 6.3 2.6
ORANGE SQUASH 20ml 19 5.2 ------ —
(131) (17.0) (6.3) (2.6)
LUNCH
WHOLEMEAL
BREAD 3 SLICES 192 35.6 2.3 9.0
MARGARINE lOg 74 — 8.1 —
CHEESE 60g 246 — 20.7 15.0
CRISPS 25g PACKET 130 10.6 9.3 1.0
SATSUMA 1 20 5.0 — —
ORANGE SQUASH 20ml 19 5.2 — —
(681) (56.4) (40.4) (25.0)
MID-AFTERNOON SNACK
OSTLER 1 122 16.2 6.0 1.7
ORANGE SQUASH 20ml 19 5.2 — —
(141) (21.4) (6.0) (1.7)
SUPPER
PIZZA 492 53.8 20.0 26.8
SALAD — — — — —
SALAD DRESSING 10ml 46 ——— 5.0 —
ORANGE SQUASH 20ml 19 5.2 — —
(557) (59.0) (25.0) c%j)
MID-EVENING SNACK
GREEK YOGURT 1 POT 238 20.0 14.0 9.3
ORANGE SQUASH 20ml 19 5.2 ------ —
(257) (25.2) (14.0) (9.3)
TOTAL 2370 264.0 119.4 82.4
% ENERGY (42) (45) (13)
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TABLE 6.2 PLASMA GLUCOSE CONCENTRATIONS IN 
HEALTHY HUMAN SUBJECTS 
CONSUMING A NORMAL DIET OVER A 24 
HOUR PERIOD
(n=6)
TIME
GLUCOSE (mM) 
MEAN S.E . TIME
GLUCOSE (mM) 
MEAN S.E .
17:00 4.79 0.12 06:00 4.54 0.13
18:00 4.32 0.14 07:00 4.47 0.11
19:00 4.46 0.07 08:00 4.31 0.04
19:20 4.63 0.16 08:20 5.31 0.35
19:40 5.69 0.30 08:40 5.85 0.45
20:00 5.40 0.34 09:00 4.88 0.33
21:00 6.59 0.61 10:00 5.26 0.41
22:00 5.28 0.25 11:00 4.83 0.27
23:00 4.47 0.03 12:00 4.50 0.28
00:00 4.48 0.20 13:00 4.45 0.10
01:00 4.94 0.09 13:20 4.90 0.16
02:00 4.78 0.08 13:40 6.07 0.23
03:00 4.48 0.13 14:00 4.66 0.40
04:00 4.55 0.06 15:00 5.37 0.28
05:00 4.59 0.08 16:00 4.95 0.11
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Neither the plasma glucose concentrations immediately before lunch nor those 
immediately before supper were significantly higher than those before breakfast.
The snacks were each consumed 21/2 hours after the 3 main meals. At this time 
point plasma glucose concentrations were falling. The mid-moming and mid-aftemoon 
snacks appeared to have no effect on glucose levels. The mid-evening snack also had 
no immediate effect on the declining plasma glucose concentrations following supper. 
However, a small rise did occur at 01:00, 31/2 hours after this snack. This increase did 
not achieve statistical significance
6.3.2 PLASMA IRI LEVELS
The mean plasma IRI levels observed for the group are depicted in figure 6.2 
and the values given in table 6.3. The peak post-prandial IRI concentrations occurred 
at identical times to those for plasma glucose. In particular, the post-prandial IRI levels 
following supper mimicked the glucose levels. For the other 2 main meals, however, a 
single peak in plasma IRI occurred 40 minutes post-prandially at the same time as the 
main glucose peak but no second peak of IRI was observed 2 hours post-prandially as 
had been for glucose.
Plasma IRI levels took approximately 5 hours to return to fasting concentrations 
after each main meal. Consequently, pre-prandial plasma IRI concentrations for both 
lunch and supper were only slightly, but nevertheless significantly (p<0.05) elevated 
above the true fasting levels observed before breakfast (4.6±0.9 mU/1 for breakfast, 
11.3±4.9 mU/1 for lunch and 7.2±2.0 mU/1 for supper).
None of the snacks appeared to influence plasma IRI levels. Even though there 
had been a small increase in plasma glucose concentrations between 01:00 and 03:00, 
no corresponding increase in plasma IRI concentrations was evident.
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TABLE 6.3 PLASMA IRI CONCENTRATIONS IN 
HEALTHY HUMAN SUBJECTS 
CONSUMING A NORMAL DIET OVER A 24 
HOUR PERIOD
(n=6)
IRI (mU/1) IRI (mU/1)
TIME MEAN S.E . TIME MEAN S.E .
17:00 14.3 1.1 06:00 5.3 0.7
18:00 9.4 2.3 07:00 5.3 0.8
19:00 7.2 2.0 08:00 4.6 0.9
19:20 13.1 2.8 08:20 47.4 10.0
19:40 31.6 8.1 08:40 71.4 13.4
20:00 28.0 4.9 09:00 46.9 4.7
21:00 57.0 20.6 10:00 39.7 14.0
22:00 42.5 10.6 11:00 32.0 11.6
23:00 23.4 4.4 12:00 9.7 2.6
00:00 8.0 2.0 13:00 11.3 4.9
01:00 8.1 3.7 13:20 23.6 6.1
02:00 6.3 1.6 13:40 54.7 5.4
03:00 6.1 1.1 14:00 33.4 10.9
04:00 5.5 1.4 15:00 32.1 4.9
05:00 4.3 1.1 16:00 26.1 4.8
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6.3 .3  PLASMA IR-GIP LEVELS
The plasma IR-GIP concentrations observed in the volunteers over the 24 hour 
period are depicted in figure 6.3 and the values given in table 6.4. There was a 
substantial increase in the IR-GIP concentrations following each of the main meals with 
peak concentrations arising 2 to 3 hours post-prandially. The peak values observed 
following supper and breakfast were very similar, whilst those following lunch were 
slightly higher. Lunch produced the greatest overall GIP response (total area under the 
curve for 4 hours post-prandially) of the 3 main meals. This parameter was 
significantly greater for lunch compared with breakfast (p<0.01) but not compared with 
supper. The overall GIP response to supper was also greater than that for breakfast 
(p<0.05).
The snacks were given to the volunteers at times that coincided with peak IR- 
GIP concentrations following the main meals. No supplementary increase in IR-GIP 
concentrations in response to any of the snacks was evident. There was a small, 
transient rise in IR-GIP concentrations at 03:00, but the values were not statistically 
significantly greater than at 02:00.
The pre-prandial IR-GIP concentrations were substantially greater for lunch and 
supper compared with those for breakfast (l±lpM for breakfast, 210±36pM for lunch 
[p<0.001] and 219±52pM for supper [p<0.05]). In agreement with the results of 
others (Arendt etal, 1982), IR-GIP levels did not reach fasting values for more than 9 
hours after supper. This sustained post-prandial increase in IR-GIP explains the 
elevated pre-prandial levels observed prior to lunch and supper.
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TABLE 6.3 P L A SM A  IR -G IP  C O N C E N T R A T IO N S IN  
H EA LTH Y  H U M A N  SU BJEC TS  
C O N S U M IN G  A  N O R M A L  D IE T  O V E R  A  24  
H O U R  PERIO D
(n=6)
TIME
IR -G IP  (p M )  
MEAN S.E . TIME
IR -G IP  (p M )  
MEAN S .E .
17:00 441 70 06:00 10 9
18:00 297 37 07:00 27 14
19:00 219 52 08:00 1 1
19:20 206 40 08:20 164 44
19:40 360 39 08:40 229 47
20:00 364 27 09:00 327 26
21:00 380 29 10:00 374 44
22:00 395 25 11:00 339 27
23:00 362 23 12:00 253 42
00:00 240 18 13:00 210 36
01:00 171 25 13:20 267 42
02:00 87 29 13:40 367 46
03:00 121 56 14:00 445 40
04:00 42 19 15:00 460 27
05:00 32 13 16:00 344 41
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6 .3 .4  PLASMA IR-GLP-1 LEVELS
The mean plasma IR-GLP-1 concentrations for the 6 subjects over the 24 hour 
sampling period are depicted in figure 6.4 and the numerical values given in table 6.5. 
As for IR-GIP, pre-prandial IR-GLP-1 concentrations were higher for lunch 
(16.2±2.4pM) and supper (15.0±2.3pM) than those observed at breakfast 
(10.7±2.3pM) after an overnight fast (p<0.05).
Increases in plasma concentrations of IR-GLP-1 occurred after each of the 3 
main meals. For breakfast and lunch the post-prandial rise appeared to be biphasic with 
an initial peak after 40 minutes for breakfast and 20 minutes for lunch followed by a 
second peak 2 hours post-prandially. The snacks consumed 21/2 hours after each of
these meals did not produce any discernable increase in circulating IR-GLP-1 levels.
The post-prandial IR-GLP-1 response to supper was somewhat different to that 
observed for the other 2 main meals. Again the pattern appeared to be biphasic but 
spread over a longer timescale. IR-GLP-1 concentrations initially peaked 60 minutes 
post-prandially. The second peak was slightly larger and occurred after 4 hours. Due 
to the timing of this increase it is not possible to be sure whether it was a delayed 
response to the supper or a response to the snack taken 21/2 hours after supper.
The total areas under the curve for 4 hours after each meal did not differ 
significantly.
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TABLE 6.5 PLASMA IR-GLP-1 CONCENTRATIONS IN 
HEALTHY HUMAN SUBJECTS 
CONSUMING A NORMAL DIET OVER A 24 
HOUR PERIOD
(n=6)
IR-GLP-1 (pM) IR-GLP-1 (pM)
TIME MEAN S.E . TIME MEAN S.E .
17:00 17.1 1.2 06:00 7.7 1.7
18:00 16.6 3.4 07:00 8.7 1.2
19:00 15.0 2.3 08:00 10.7 2.3
19:20 17.0 2.1 08:20 21.0 2.3
19:40 21.7 3.3 08:40 22.9 2.4
20:00 21.5 4.1 09:00 19.5 3.6
21:00 18.0 3.5 10:00 22.7 2.1
22:00 19.6 2.5 11:00 20.5 2.4
23:00 23.5 4.3 12:00 16.2 2.1
00:00 18.7 3.4 13:00 16.2 2.4
01:00 10.1 1.3 13:20 21.8 3.3
02:00 12.8 2.1 13:40 19.2 2.8
03:00 11.2 0.9 14:00 17.1 2.5
04:00 9.8 11.2 15:00 21.8 2.0
05:00 8.4 1.6 16:00 16.9 2.0
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6.4 DISCUSSION
The total integrated plasma glucose response to supper was slightly but not 
significantly greater than for the other 2 main meals even though the carbohydrate 
contents of supper and lunch were very similar and the energy content of breakfast was 
considerably greater. The increased glucose response to supper may have been due to 
reduced glucose tolerance later in the day as reported by Carroll and Nestel (Carroll and 
Nestel, 1973). These workers also reported a delayed insulin response to oral glucose 
in the evening compared with the morning. In the study described here, both the peak 
glucose and IRI levels observed after supper were delayed compared with those 
observed after breakfast and lunch. However, the total integrated IRI response to 
supper was not significantly greater than for the other 2 meals. This delay in IRI 
response could have been caused by delayed gastric emptying.
Peak IR-GIP concentrations occurred 2 hours after both breakfast and lunch. 
In comparison, the peak levels occurred 3 hours after supper. As GIP secretion is 
known to be induced by active absorption of nutrients, plasma IR-GIP concentrations 
provide a rough guide to rate of nutrient absorption. The delayed peak in IR-GIP levels 
observed following supper, therefore, lends further weight to the idea of slower gastric 
emptying following this meal.
None of the snacks produced any obvious change in plasma glucose 
concentrations. Each snack was given to the volunteers 21/2 hours after a much larger 
meal. At these times the plasma glucose levels were still falling and plasma IRI 
concentrations were still markedly elevated above basal values. Furthermore, the 
volunteers’ stomachs would not have completely emptied all the nutrients from the 
previous meal. Taking these factors into consideration together with the relatively low 
carbohydrate content of the snacks compared with the preceding meals, the absence of 
an immediate glucose response is, perhaps, not surprising. It is more likely that the 
snacks acted by topping up the remaining contents of the stomach and effectively
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prolonging the insulin GIP and GLP-1 responses to the main meals.
The apparent late increase in plasma glucose concentrations (peaking at 01:00) 
was a little surprising. Small increases in plasma IR-GIP and IR-GLP-1 levels at about 
the same time (peaking at 03:00 and 02:00 respectively) suggest that the observed rise 
in glucose levels may have been due to nutrient absorption. However, there was no 
corresponding increase in plasma IRI levels. One possible method of explanation for 
this is to invoke the diurnal variation in plasma glucose levels observed in healthy 
human subjects given a constant IV glucose infusion (Shapiro etal, 1988 ; Van Cauter 
et al, 1989). The workers who performed these experiments reported a nocturnal 
increase in plasma glucose of about 15%, peaking mid-sleep. In contrast, and in 
agreement with the results presented here, IRI levels showed no consistent diurnal 
variation. Plasma GIP concentrations were not measured. However, since GIP shows 
no diurnal variation in fasting subjects (Arendt etal, 1982), it might also be predicted 
not to exhibit diurnal variation in response to IV glucose. This remains to be 
demonstrated. Furthermore, diurnal variation of tGLP-1 levels has not been 
investigated either in fasting subjects or in subjects given constant IV glucose 
infusions.
In the experiment described here, the glucose infusion was effectively produced 
by gastrointestinal absorption. The late rise in plasma glucose could have been due to a 
nocturnal decrease in glucose tolerance. This would not, however, explain the small 
increases observed in plasma IR-GIP and IR-GLP-1 levels. Thus, whilst it is possible 
that the brief increase in plasma concentrations of these 2 hormones was due to natural 
diurnal variation, it seems more likely that the increases in glucose, IR-GIP and IR- 
GLP-1 levels were actually produced by a transient increase in intestinal absorption of 
nutrients from supper or the evening snack. This could have been caused by a postural 
effect on gastric emptying. The subjects went to bed at 23:00, therefore changing from 
a predominantly seated to a supine posture. This change may have produced a transient 
increase in gastric emptying rate. However, if this were so, a transient increase in
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plasma IRI levels, concomitant with the rises in the other parameters, might have been 
expected.
In contrast to both plasma glucose and IRI concentrations, the peak IR-GIP 
concentrations observed following lunch were slightly greater than those observed 
following the other 2 meals. This was due, presumably, to the higher fat content of the 
lunch compared with breakfast and supper.
Plasma IR-GLP-1 concentrations were observed to increase following all the
\
main meals, but as with the acute studies the changes were small. The most 
pronounced increase was observed following breakfast. However, this was only the 
case because the pre-prandial concentrations were lower for this meal than for the other 
2. Peak concentrations were similar following all the main meals.
The IR-GLP-1 response to the meals appeared to be biphasic in nature. There 
is a suggestion that the IR-GLP-1 response to supper, like those for the other 
parameters, was delayed compared with the responses to breakfast and lunch.
Whilst both glucose and IRI fell to basal or near-basal concentrations between 
each meal, IR-GIP concentrations remained elevated throughout the day, only returning 
to fasting values approximately 9 hours after supper. IR-GLP-1 concentrations also 
remained elevated throughout the day and appeared to take a similar length of time to 
return to fasting levels. The rapid post-prandial increases in both IR-GIP and IR-GLP- 
1 concentrations are consistent with the proposed role of these hormones as 
physiological incretins during the immediate post-prandial period. However, they must 
cease to act as incretins in the subsequent period when both glucose and insulin levels 
are falling or have returned to basal. At these times, the sustained elevated levels of 
GIP and tGLP-1 may play a role in lipid metabolism as both these hormones have been 
implicated in augmenting fatty acid synthesis (Oben etal, 1991a) and GIP is known to 
be capable of activating lipoprotein lipase and hastening systemic triglyceride clearance 
(Oben etal, 1991b).
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CHAPTER 7
CHRONIC EFFECTS OF 
DIFFERENT CARBOHYDRATES 
ON TISSUE AND PLASMA 
LEVELS OF IR-GLP-1 AND 
IR-GIP IN RATS
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7.1 INTRODUCTION
In chapter 5 the acute metabolic responses to different nutrients, in particular 
different forms of carbohydrate, were investigated. It was demonstrated that purified 
starch preparations and whole cereals could elicit varying post-prandial plasma glucose, 
IRI, IR-GIP and IR-GLP-1 responses depending on the digestibility of the starch. 
However, little is known about the chronic effects of different carbohydrates on GIP, 
tGLP-1 and insulin levels.
In human subjects fed a diet high in sucrose (30% of total energy) for 6 weeks, 
enhanced GIP and insulin responses to a sucrose test load were observed compared 
with those in subjects fed an equivalent diet in which the sucrose had been replaced 
with wheat starch (Reiser et al, 1980). This may have been due to increased sucrase 
activity in the GI tract of the subjects fed the high sucrose diet (Rosenweig and 
Herman, 1970).
Rats fed a high sucrose diet for 1 month exhibited an elevated insulin response 
to IV glucose (Kergoat etal, 1987). This appeared to be caused by hyper-reactivity of 
the pancreatic B cells to glucose.
Therefore, it seems that chronic ingestion of rapidly absorbable carbohydrate 
can produce adaptation which influences glucose tolerance and insulin secretion. One 
possible mechanism of adaptation is that changes in activities of the enzymes 
responsible for digesting carbohydrate alter the rate of glucose absorption. Tissue and 
plasma levels of GI hormones may be altered. The response of B cells to the actions of 
glucose and GI hormones may also be affected.
The experiments described in this chapter were designed to investigate the 
chronic effects of different dietary carbohydrates, in the form of various starch 
preparations and cereals which had undergone different processing, on plasma and gut 
concentrations of IR-GIP and IR-GLP-1 as well as on blood glucose and plasma IRI in 
rats.
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7.2 CHRONIC EFFECTS OF HIGH
CARBOHYDRATE DIETS BASED ON RAW 
OR PROCESSED MAIZE AND CORN 
STARCHES IN RATS
In the chronic study described here, the possible influences on metabolic 
parameters of 2 factors which may determine the rate and extent of starch digestion 
were investigated. The first of these was the source of the starch. Different cereals 
contain varying ratios of amylose and amylopectin. Amylose is a straight chain glucose 
polymer, whereas amylopectin is a glucose polymer with an extensively branched 
structure. There is good experimental evidence that amylose is less readily digestible in 
VIVO than amylopectin (Behall etal, 1988). Most cereals contain 10 to 35% of their 
starch in the form of amylose (Williams, 1968), however, mutant strains of maize are 
available which contain unusually high amount of amylose (up to 75%). Such strains, 
while not being representative of most normal cereals, provide a good experimental 
model for investigating the role of starch composition in determining the metabolic 
responses to carbohydrate.
A study using starches from such mutant maizes demonstrated marked 
reductions in acute plasma glucose, IRI and IR-GIP responses in healthy subjects 
compared with starch from a variety of maize low in amylose (unpublished data). For 
the purposes of the chronic study described here, Hylon V (a starch from a mutant 
strain of maize which contains 45 to 50% amylose) was compared with com starch (25 
% amylose).
The second aspect under investigation was the role of processing in influencing 
the metabolic response to starches. This follows on from the acute study on human 
subjects using wheat starches (described in section 5.3). One batch of the Hylon V 
was autoclaved to promote the formation of RS. Since RS is formed predominantly if 
not exclusively from amylose, high RS contents can be achieved in this manner using 
starch preparations such as Hylon V. One batch of com starch was extruded to render
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it as readily digestible as possible. Raw Hylon V and com starch were also 
investigated.
The chronic effects of diets containing these 4 starch preparations on body 
weight, gut tissue weight and plasma glucose, IRI, IR-GIP and IR-GLP-1 in rats were 
compared.
7.2.1 STUDY DESIGN
This study was carried out in collaboration with the FMBRA, Chorleywood, 
where all the animal work and blood glucose and plasma insulin determinations were 
carried out.
Seventy two, male, 3 week old Sprague-Dawley rats were given an acclimation 
diet containing sucrose (caster sugar) as the sole source of carbohydrate. The 
composition of this diet is given in table 7.1.
After a period of 2 weeks on this diet, the animals were divided into 4 equal 
groups of 18 animals. Each group was then fed a diet identical in composition to the 
acclimation diet except that the majority of the sucrose was replaced with 1 of the 4 
different starch preparations (table 7.1). The precise composition of each diet is shown 
in table 7.2.
The animals were kept in groups of 3 to a cage. All the animals in one cage 
were given the same diet. Food intake for the 3 animals in each cage and individual 
body weights were assessed weekly throughout the trial.
The RS contents of the 4 starch preparations were determined by the method of 
Berry (Berry, 1986). Raw and autoclaved Hylon V were found to contain 8.3% and 
11.2% RS respectively. Raw and extruded com starch were found to contain 0.2% 
and 0.3% RS respectively.
2 M
At 3, 7 and 11 weeks after commencing the different starch diets, 6 animals 
from each group were fasted for 24 hours. Following the fast, they were presented 
with the same diets again and allowed to feed ad libitum. After 90 minutes of feeding, 
a tail vein blood sample was taken.
For the blood glucose analysis, whole blood was collected into tubes containing 
urinyl acetate to precipitate protein. Glucose concentrations were then determined by a 
glucose oxidase method. Plasma IRI concentrations were determined using an enzyme- 
linked immuno-sorbent assay (Kekow et al, 1988). Plasma IR-GLP-1 and IR-GIP 
concentrations were determined in the normal manner (section 2.2.7.2 and 2.3.4).
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TABLE 7.1 COMPOSITION OF ACCLIMATION AND 
STARCH DIETS
Acclimation Starch
Diet Diets
Ingredients (% by weight) (% by weight)
Caster Sugar 62.5 10.9
Starch — 51.6
Casein 15.0 15.0
Dried Egg 4.0 4.0
Solkafloc 9.0 9.0
Com Oil 4.0 4.0
Vitamin Mix 1.0 1.0
Mineral Mix 4.5 4.5
At 4, 8 and 12 weeks the same groups of 6 animals on each diet were fasted 
overnight. The following morning the animals were killed by exsanguination following 
phenobarbitone anaesthesia. Immediately after sacrifice the intestines were excised and 
any digesta present gently squeezed out by hand. The small intestinal, caecal and 
colonic tissue weights were determined.
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TABLE 7.2 COMPOSITION OF STARCH DIETS FOR 
MAIZE AND CORN STARCH STUDY
NSP = Non-Starch Polysaccharide
% BY WEIGHT
Raw Autoclaved Raw Extruded
Hylon V Hylon V Corn Starch Corn Starch
Carbohydrate 58.0 59.0 58.4 58.6
Fat 6.5 6.1 5.9 5.7
Protein 14.2 13.7 14.4 14.4
NSP 8.9 8.9 9.1 9.7
Ash 3.7 5.0 4.2 4.1
Moisture 8.7 7.3 8.0 7.5
7.2.2 RESULTS
7.2.2.1 BODY WEIGHT GAINS AND FOOD INTAKE
The body weights of the animals fed the different diets throughout the trial are 
shown in table 7.3. After 1 week, the animals fed the raw Hylon V exhibited 
significantly greater weight gains than the animals fed the other starches (p<0.05). In 
contrast, the weight gains for animals fed the raw com starch were greater than for 
animals fed raw Hylon V after 6,7 and 8 weeks on the diets (p<0.05). Animals fed the 
raw com starch also exhibited greater weight gains after 8 weeks than animals fed 
autoclaved Hylon V and after 7 and 8 weeks compared with animals fed extruded com 
starch.
The food efficiency ratios (body weight gain divided by food intake expressed 
as a percentage) are shown in table 7.4. Apart from the first week of the study, the 
animals fed the com starch diets, in particular the raw com starch, tended to have 
higher food efficiency ratios than the animals fed the Hylon V diets.
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TABLE 7.3 CHRONIC EFFECTS OF DIFFERENT 
DIETARY STARCHES ON RAT BODY 
WEIGHTS
Values indicate mean±S.E. (n=18 or 12 or 6 as shown) 
t  Denotes values significantly different from those for animals 
fed raw Hylon V (p<0.05)
* Denotes values significantly different from those for animals 
fed raw com starch (p<0.05)
WEIGHT (g)
Weeks n Raw Autoclaved Raw Extruded
on Diet Hylon V Hylon V Corn Starch Corn Starch
0 18 136±2 136±2 135±2 135±2
1 18 204±5 191±3t 190±3 t 189±3 t
2 18 247±7 252±3 257±4 249±5
3 18 308±8 310±4 321±5 309±6
4 12 352±10 355±6 372±9 357±7
5 12 392+12 390±8 416±13 390±9
6 12 414±12 * 419±9 449±15 417±9
7 12 440+12 * 453±9 480+15 443±9*
8 6 445±14 * 452±12 * 492±17 452+T2 *
9 6 453±18 455±15 506+35 450+T4
10 6 466±20 465±20 524±39 483±30
11 6 473±21 474±18 533+40 493+26
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TABLE 7.4 CHRONIC EFFECTS OF DIFFERENT 
DIETARY STARCHES ON FOOD 
EFFICIENCY RATIOS FOR RATS
Values indicate mean±S.E. (n=6 or 4 or 2 as shown)
RATIO (%)
Weeks n Raw Autoclaved Raw Extruded
on Diet Hylon V Hylon V Corn Starch Corn Starch
1 6 46.6±0.9 1 36.610.9 37.110.7 35.810.7
2 6 24.4±1.5 1 33.210.6 2 37.910.4 36.910.5
3 6 27.0±1.1 28.910.7 32.610.6 3 29.811.0
4 4 23.1±0.4 21.811.3 25.810.6 24.412.2
5 4 17.2±0.7 16.912.2 21.410.3 4 19.910.4
6 4 11.5±0.8 1 14.010.1 16.310.1 5 14.110.6
7 4 10.9±0.1 13.811.4 15.310.8 14.010.3
8 2 5.411.7 5.811.3 10.411.1 6.910.5
9 2 9.010.8 7.310.7 8.510.5 8.311.0
10 2 6.511.1 4.811.7 8.810.4 8.510.1
1 Denotes values significantly different from those for animals fed autoclaved Hylon V, 
raw com starch and extruded com starch (p<0.01)
2 Denotes values significantly different from those for animals fed raw com starch 
(p<0.05) and extmded com starch (p<0.01)
3 Denotes values significantly different from those for animals fed raw Hylon V 
(p<0.01) and autoclaved Hylon V (p<0.05)
4 Denotes values significantly different from those for animals fed autoclaved Hylon V 
(p<0.05)
5 Denotes values significantly different from those for animals fed autoclaved Hylon V 
and extruded com starch (p<0.05)
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1.2 .2.2  GUT TISSUE WEIGHTS
The gut tissue weights determined for rats after 4, 8 and 12 weeks on the 4 
different diets are given in table 7.5. There were no differences in small intestinal 
weights between the animals on the different diets. However, the caecal and colonic 
tissue weights were consistently lower for both animals fed the com starch diets than 
for animals fed the Hylon V diets.
7.2.2.3 BLOOD GLUCOSE CONCENTRATIONS
The 90 minute post-prandial blood glucose concentrations for the 4 groups of 
animals after 3, 7 and 11 weeks on the different diets are depicted in figure 7.1 and the 
values given in table 7.6. A slight decrease in post-prandial blood glucose 
concentrations was observed over the 11 week test period for 2 of the 4 diets. For the 
raw Hylon V diet, blood glucose levels were significantly lower after 11 weeks than 
they were after 3 and 7 weeks (p<0.05). Similarly, for the extmded com starch diet, 
blood glucose concentrations in the 11 week samples were significantly lower than in 
the 3 week samples. However, there was no significant decrease over the dietary 
period for either the autoclaved Hylon V or the raw com starch diet.
Comparison between the 4 diets revealed significantly higher blood glucose 
levels after 3 weeks for animals fed the extmded com starch diet compared with 
animals fed both the raw and autoclaved Hylon V diets (p<0.05). However, this 
difference was not found in the 7 or 11 week samples.
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TABLE 7.5 CHRONIC EFFECTS OF DIFFERENT 
DIETARY STARCHES ON RAT 
INTESTINAL WEIGHTS
Values indicate mean ± S.E. (n=6)
SMALL INTESTINAL WEIGHT (g)
Autoclaved Raw Extruded
Hylon V Corn Starch Corn Starch
Weeks 
on Diet
Raw 
Hylon V
4 2.6±0.1 2.910.1 2.510.1 2.510.1
8 2.8±0.2 2.910.3 2.610.1 2.310.1
12 2.7±0.1 2.710.1 2.610.2 2.510.1
CAECAL WEIGHT (g)
Weeks Raw Autoclaved Raw Extruded
on Diet Hylon V Hylon V Corn Starch Corn Starch
4 1.1±0.12 1 1.110.04 1 0.510.02 0.510.04
8 1.3±0.11 1 1.110.08 1 0.610.05 0.610.05
12 1.7±0.17 2 1.110.04 0.710.06 0.710.04
COLONIC WEIGHT (g)
Weeks Raw Autoclaved Raw Extruded
on Diet Hylon V Hylon V Corn Starch Corn Starch
4 1.4±0.12 1 1.310.03 1 0.910.04 0.910.04
8 1.6±0.11 3 1.310.04 4 1.210.09 1.010.04
12 1.6±0.09 3 1.210.02 1.210.06 1.010.06
1 Denotes values significantly different from those for animals fed raw and extruded 
com starch (p<0.01)
2 Denotes values significantly different from those for animals fed extmded com starch
(p<0.01)
3 Denotes values significantly different from those for animals fed autoclaved Hylon V, 
raw com starch and extmded com starch ((p<0.01)
4 Denotes values significantly different from those for animals fed extmded com starch 
(p<0.05)
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7.2.2.4 PLASMA IRI CONCENTRATIONS
The 90 minute post-prandial plasma IRI concentrations in the 4 groups of 
animals after 3, 7 and 11 weeks on the different diets are depicted in figure 7.2 and the 
mean values given in table 7.6. In contrast to the blood glucose concentrations, which 
showed an apparent tendency to decrease slightly throughout the duration of the study, 
plasma IRI concentrations tended to increase. This increase reached statistical 
significance at 11 weeks compared with 7 weeks for both the raw Hylon V and raw 
com starch diets (p<0.05).
After 11 weeks on the respective diets, post-prandial plasma IRI concentrations 
were significantly elevated in the animals fed raw com starch compared with animals 
fed the raw and autoclaved Hylon V diets. There were no other statistically significant 
differences, with respect to plasma IRI concentrations, between the animals on different 
diets.
7.2.2.5 PLASMA IR-GIP CONCENTRATIONS
The 90 minute post-prandial plasma IR-GIP concentrations in the 4 groups of 
animals after 3, 7 and 11 weeks on the different diets are depicted in figure 7.3 and the 
mean values given in table 7.7. The post-prandial plasma IR-GIP levels did not appear 
to be greatly influenced by the 11 week duration of the different dietary regimens. The 
only statistically significant difference occurred for animals fed the autoclaved Hylon V 
diet, for which plasma IR-GIP concentrations were higher in the 3 week samples than 
in the 7 week samples (p<0.05).
More marked differences were observed between the diets. Post-prandial 
plasma IR-GIP levels for animals fed extmded com starch were lower than for animals 
fed raw com starch (p<0.01 after 3 weeks ; p<0.05 after 7 weeks) and for animals fed 
on autoclaved Hylon V (p<0.05 after 3 weeks).
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FIGURE 7.1 CHRONIC EFFECTS OF DIFFERENT 
DIETARY STARCHES ON POST PRANDIAL 
BLOOD GLUCOSE CONCENTRATIONS IN 
RATS
Bars and error bars indicate mean+S.E. (n=6)
* Denotes values significantly different to values for raw and 
autoclaved Hylon V diets (p<0.05)
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FIGURE 7.2 CHRONIC EFFECTS OF DIFFERENT 
DIETARY STARCHES ON POST PRANDIAL 
PLASMA IRI CONCENTRATIONS IN 
RATS
Bars and error bars indicate mean+S.E. (n=6)
* Denotes values significantly different to values for raw and 
autoclaved Hylon V diets (p<0.05)
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TABLE 7.6 CHRONIC EFFECTS OF DIFFERENT 
DIETARY STARCHES ON POST PRANDIAL 
BLOOD GLUCOSE AND PLASMA IRI 
CONCENTRATIONS IN RATS
Values indicate mean ± S.E. (n=6)
BLOOD GLUCOSE (mM)
Time on Diet (Weeks)
Dietary Starch 3 7 11
Hylon V 5.41±0.291 5.64±0.22 4.40±0.27
Autoclaved Hylon V 5.24±0.241 4.52±0.22 4.46±0.33
Com Starch 5.78±0.20 4.71±0.54 5.13±0.42
Extmded Com Starch 6.31±0.15i 5.54±0.41 4.88±0.24
t Denotes values for extmded com starch significantly different from values for raw 
and autoclaved Hylon V (p<0.05)
PLASMA IRI (pg/1)
Time on Diet (Weeks)
Dietary Starch 3 7 11
Hylon V 1.28±0.15 1.29±0.24 2.03±0.232
Autoclaved Hylon V 1.54±0.35 1.17±0.29 2.15±0.49 2
Com Starch 2.19±0.71 1.97±0.68 4.95±1.05 2
Extmded Com Starch 1.76±0.39 1.96±0.67 3.70±0.54
2 Denotes values for com starch significantly different from values for raw and 
autoclaved Hylon V (p<0.05)
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7.2.2.6 PLASMA IR-GLP-1 CONCENTRATIONS
The 90 minute post-prandial plasma IR-GLP-1 concentrations in the 4 groups 
of animals after 3, 7 and 11 weeks on the different diets are depicted in figure 7.4 and 
the mean values given in table 7.7. There was no statistically significant alteration in 
the plasma IR-GLP-1 concentrations for each individual diet throughout the trial period.
The only significant difference caused by the different diets occurred after 3 
weeks when plasma IR-GLP-1 concentrations were significantly higher in animals fed 
raw Hylon V than in animals fed extruded com starch.
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FIGURE 7.3 CHRONIC EFFECTS OF DIFFERENT 
DIETARY STARCHES ON POST PRANDIAL 
PLASMA IR-GIP CONCENTRATIONS IN 
RATS
Bars and error bars indicate mean+S.E. (n=6)
* Denotes values significantly different to values for 
extruded com starch (p<0.05)
** Denotes values significantly different to values for 
extruded com starch (p<0.01)
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FIGURE 7.4 CHRONIC EFFECTS OF DIFFERENT 
DIETARY STARCHES ON POST PRANDIAL 
PLASMA IR-GLP-1 CONCENTRATIONS IN 
RATS
Bars and error bars indicate mean+S.E. (n=6)
* Denotes values significantly different to values for 
extmded com starch (p<0.05)
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TABLE 7.7 CHRONIC EFFECTS OF DIFFERENT 
DIETARY STARCHES ON POST PRANDIAL 
PLASMA IR-GIP AND IR-GLP-1 
CONCENTRATIONS IN RATS
Values indicate mean ± S.E. (n=6)
PLASMA IR-GIP (pM)
Time on Diet (Weeks)
Dietary Starch 3 7 11
Hylon V 286116 260118 232116
Autoclaved Hylon V 28219 1 226115 252118
Com Starch 3331341 253117 290143 2
Extmded Com Starch 202125 1 208118 165128 2
t Denotes values for extruded com starch significantly different from values for 
autoclaved Hylon V (p<0.05) and com starch (p<0.01)
2 Denotes values for extruded com starch significantly different from values for raw 
com starch (p<0.05)
PLASMA IR-GLP-1 (pM)
Dietary Starch 
Hylon V
Autoclaved Hylon V 
Com Starch 
Extruded Com Starch
Time on Diet (Weeks) 
3 7
19.2±3.23 11.4±1.4
12.4±3.2 15.9±2.8
13.0±4.0 6.2±1.6
3.811.8 3 5.213.5
11
21.115.2
17.516.1
14.314.3
12.814.2
3 denotes values for raw Hylon V significantly different from values for extmded com 
starch (p<0.05)
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7.2 .3  DISCUSSION
The increased caecal tissue weight found in the animals fed the Hylon diets 
compared with those fed the com starch diets suggested that the extent of small 
intestinal starch digestion varied significantly. With the high amylose, high RS content 
of both the Hylon V starch preparations it would not be surprising if significant 
quantities of the starch were malabsorbed. The high caecal tissue weight in animals fed 
these starches was likely to have been caused by increased bacterial fermentation of 
undigested starch which reached the caecum.
The slightly lower food efficiency ratios measured for the Hylon V diets 
compared with the com starch diets are consistent with the hypothesis that slightly more 
of the Hylon V starches were malabsorbed than were the com starches.
There were some differences in post-prandial blood glucose and plasma IRI, IR- 
GIP and IR-GLP-1 concentrations between the animals fed the different diets. After 3 
weeks, animals fed the extruded com starch diet had higher post-prandial glucose levels 
than the 2 Hylon V diets. This may have been due to rapid digestion of the extruded 
com starch compared with that for the high amylose, high RS Hylon V starches. 
However, after 7 and 11 weeks on the various diets, this difference had been reduced 
and was no longer statistically significant.
Conversely, the post-prandial IR-GIP and, in particular, the IR-GLP-1 levels 
were lower after 3 weeks for animals fed the extruded com starch diet than for animals 
on the other diets. Throughout the rest of the course of the trial the post-prandial IR- 
GLP- 1 levels for animals fed the extruded com starch increased, reaching similar 
concentrations to those observed in other groups, while IR-GIP levels remained 
slightly depressed.
The initial, depressed IR-GLP-1 concentrations might be explained by the fact 
that the readily digestible extmded com starch was predominantly absorbed in the 
proximal small intestine whereas the other more slowly digested starches led to more
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distal glucose absorption and consequently acted as a greater stimulus to tGLP-1 
secretion. However, in this case, the IR-GIP levels might be predicted to be elevated in 
the animals fed the extruded com starch diet since proximal intestinal glucose 
absorption stimulates GIP secretion. It may be that, due to rapid digestion of the 
extruded com starch, by 90 minutes post-prandially plasma IR-GIP levels had already 
peaked and were declining, whereas for the other diets there may have been a more 
sustained increase in IR-GIP concentrations.
Overall, the differences between the diets in plasma hormone and blood glucose 
levels were small. This suggests that there were no marked differences in the in vivo 
rates of digestion of the 4 starch preparations. Even though Hylon V was used, the 
range of RS contents for the different starches was not dramatically greater than that for 
the different wheat starches used in the acute trial described earlier (section 5.3). In that 
acute trial, the varying RS contents of different starches apparently had little effect on 
the starch digestibility in vivom man. In the chronic study described here, the raw and 
processed starches will have varied, not only in RS contents, but also in degree of 
gelatinization. However, this too seems to have had little effect on the initial rate of 
starch digestion.
All the animals exhibited slightly improved glucose tolerance with increasing 
duration of the diets. This was probably caused by the increase in plasma IRI levels 
observed for all the diets during the trial. The results suggest that, even though the 
Hylon V starches may have contained a slightly larger proportion of malabsorbed RS 
than the com starches, in all 4 diets most of the starch was in a readily digestible form. 
As with sucrose fed rats (Kergoat et al, 1987), this lead to elevated insulin levels, 
possibly as a result of hyper-reactivity of the pancreatic B cells to glucose.
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7.3 CHRONIC EFFECTS OF DIFFERENT 
CEREAL FLOURS ON PLASMA AND  
INTESTINAL TISSUE LEVELS OF GI 
HORMONES IN RATS
Following on from the acute study with humans subjects in which the metabolic 
responses to different whole cereals were investigated (section 5.5), the study 
described here was carried out to compare the chronic effects of differently processed 
flours from 2 cereal sources varying in non-starch polysaccharide content on plasma 
and gut tissue levels of hormones in rats.
7.3.1 STUDY DESIGN
The design of this study was essentially the same as that of the previous study 
described in section 7.2.1. Again 72, male, 3 week old Sprague-Dawley rats were 
placed on an acclimation diet for 2 weeks. In this case, the acclimation diet was fibre- 
free and was based on com starch. The composition of this diet is given in table 7.9.
The animals were then split into 4 groups of 18. The different groups were 
placed on diets based on white wheat, wholemeal wheat, pearl barley or stoneground 
barley flours as the soul source of carbohydrate. These different cereal flours were 
baked into biscuits (table 7.8) which were then crumbed and incorporated into the diets 
(composition in table 7.9). The nutrient composition of the different diets is given in 
table 7.10. As in the previous study, 3 animals, consuming the same diet were kept in 
each cage. Food intake for each group of 3 animals and individual body weights were 
measured weekly.
At 3, 7 and 11 weeks after commencing these different diets, 6 animals from 
each group were fasted for 24 hours. Following the fast they were allowed access to 
food for 90 minutes before having a tail vein blood sample (approximately 2ml) taken
230
for analysis of blood glucose and plasma IRI, IR-GIP and IR-GLP-1.
At 4, 8 and 12 weeks after commencing the diets, 6 animals from each group 
were fasted overnight. They were then killed by exsanguination following 
phenobarbitone anaesthesia. The intestines were immediately excised. The small 
intestine was divided into 3 sections of equal length (numbered 1 to 3 from proximal to 
distal intestine). The caecum and colon were taken together (section 4). Each section 
was cleared of any remaining digesta and then weighed and extracted as described in 
section 2.9. The tissue extracts were assayed for IR-GIP and IR-GLP-1.
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TABLE 7.8 COMPOSITION OF BISCUITS
Ingredients % W eight
Flour 63.2
Fat(Silkit) 12.6
Skimmed Milk Powder 1.3
Malt Extract 2.5
Ammonium Bicarbonate 1.7
Water 18.7
TABLE 7.9 COMPOSITION OF DIETS
% BY WEIGHT
Acclimation Test
Ingredients Diet Diets
Com Flour 72.8 — — —
Biscuit 80
Casein 15.7 8.5
Dried Egg 4.0 4.0
Com Oil 2.0 2.0
Vitamin Mix 1.0 1.0
Mineral Mix 4.5 4.5
2 3 2
TABLE 7.10 COMPOSITION OF CEREAL FLOUR DIETS
NSP = Non-Starch Polysaccharide 
% BY WEIGHT
White
Wheat
Wholemeal
Wheat
Pearl
Barley
Stoneground
Barley
Carbohydrate 56.4 46.6 51.0 45.9
Fat 14.0 16.0 17.2 16.4
Protein 15.5 15.0 14.6 16.0
NSP 6.8 14.9 9.8 14.2
Ash 4.6 5.4 5.2 5.4
Moisture 2.7 2.1 2.2 2.1
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7.3 .2  RESULTS
7.3.2.1 BODY WEIGHT GAINS AND FOOD INTAKE
The body weights of the animals in the different experimental groups 
throughout the trial period are given in table 7.11. There was no significant difference 
between the 4 dietary groups in weight gain during the trial. The food efficiency ratios 
(body weight gain divided by food intake expressed as a percentage) also did not differ 
significantly from group to group (table 7.12).
7 .3 .2 .2  GUT TISSUE WEIGHTS
The small and large intestinal tissue weights are given in table 7.13. Intestinal 
weight increased throughout the trial but there were no significant differences between 
the groups of animals on the different diets.
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TABLE 7.11 CHRONIC EFFECTS OF DIFFERENT 
DIETARY CEREAL FLOURS ON RAT 
BODY WEIGHTS
Values indicate mean±S.E. (n=18 or 12 or 6 as shown)
WEIGHT (g)
Weeks n White Wholemeal Pearl Stoneground
on Diet Wheat Wheat Barley Barley
0 18 153±3 151±3 150±2 149±3
1 18 218+6 214±3 218±5 216±4
2 18 286+8 273±4 284±5 277±4
3 18 338±13 317±7 333±9 325±9
4 12 401±16 372±8 387±7 376±11
5 12 443±18 411±9 427±7 413±12
6 12 476+20 444±10 463+9 445+13
7 12 501±19 467±13 480±8 468±15
8 6 523±23 511±7 508±11 517±23
9 6 548±23 536±17 528±11 540±31
10 6 566±25 557±21 548±14 564±31
11 6 573±21 549±12 560±32 558±19
TABLE 7.12 CHRONIC EFFECTS OF DIFFERENT 
DIETARY CEREAL FLOURS ON FOOD 
EFFICIENCY RATIOS FOR RATS
Values indicate mean±S.E. (n=18 or 12 or 6 as shown)
RATIO (%)
Weeks n White Wholemeal Pearl Stoneground
on Diet Wheat Wheat Barley Barley
1 18 50.3±1.0 50.6±1.0 52.110.9 54.111.4
2 18 53.4±5.2 43.5±0.5 46.510.5 45.510.7
3 18 37.7±1.2 32.711.4 31.910.7 35.611.2
4 12 34.8±1.5 32.911.0 29.910.6 27.810.6
5 12 28.8±1.1 25.911.0 25.912.0 27.610.6
6 12 21.7±1.2 22.810.8 23.410.5 23.010.6
7 12 20.9±0.2 23.210.3 18.311.9 20.511.0
8 6 17.6±0.5 16.211.1 14.711.5 18.710.7
9 6 15.6±1.3 17.910.3 14.010.2 14.411.4
10 6 11.3±0.9 11.912.5 12.710.6 14.510.1
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TABLE 7.13 CHRONIC EFFECTS OF DIFFERENT 
DIETARY CEREAL FLOURS ON RAT 
SMALL AND LARGE INTESTINAL 
WEIGHTS
Values indicate mean ± S.E. (n-6)
Small intestine includes gut sections 1 to 3
Large intestine includes caecum and colon (section 4)
SMALL INTESTINAL WEIGHT (g)
Weeks White Wholemeal Pearl Stoneground
on Diet Wheat Wheat Barley Barley
4 3.210.3 3.510.3 3.010.3 4.210.4
8 4.910.8 5.810.6 5.210.3 5.110.8
12 5.310.6 6.910.5 6.610.6 6.810.4
LARGE INTESTINAL WEIGHT (g)
Weeks White Wholemeal Pearl Stoneground
on Diet Wheat Wheat Barley Barley
4 1.510.1 1.910.1 1.710.1 2.010.1
8 2.210.2 2.410.1 2.710.2 2.610.2
12 2.510.2 2.510.2 2.610.2 2.410.2
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7.3.2.3 BLOOD GLUCOSE CONCENTRATIONS
The 90 minute post-prandial blood glucose concentrations are shown in figure 
7.5 and the values given in table 7.14. There was a trend towards lower glucose 
concentrations with increasing duration of all 4 dietary treatments. For the white wheat 
fed animals, the glucose levels at 3 weeks were significantly greater than at 7 and 11 
weeks (p<0.01). Similarly, the blood glucose levels in animals fed both barley diets 
were significantly greater after 3 weeks than after 7 weeks (p<0.05) and 11 weeks 
(p<0.01). For the wholemeal wheat fed animals, blood glucose levels were higher 
after 3 weeks than after 11 weeks (p<0.05). However, there were no significant 
differences in glucose levels between the diets after 3, 7 or 11 weeks.
7.3.2.4 PLASMA IRI CONCENTRATIONS
The 90 minute post-prandial plasma IRI concentrations are shown in figure 7.6 
and the values given in table 7.14. For rats the fed both the white wheat and 
wholemeal wheat diets, post-prandial plasma IRI concentrations were significantly 
higher after 7 weeks than after 3 weeks (p<0.05) and 11 weeks (p<0.01). Plasma IRI 
concentrations were also higher in the 7 week samples than in the 3 or 11 week samples 
for rats fed the 2 barley flour diets. However, this difference was not statistically 
significant for either diet.
After 3 weeks, the animals fed on the stoneground barley exhibited higher 
plasma IRI concentrations than animals fed the wholemeal wheat (p<0.05). At 11 
weeks plasma IRI levels were significantly higher for animals fed the stoneground 
barley diet compared with animals fed the white wheat diet (p<0.05). There were no 
other significant differences between the 4 dietary treatments.
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FIGURE 7.5 CHRONIC EFFECTS OF DIFFERENT 
DIETARY CEREAL FLOURS ON 
POST PRANDIAL BLOOD GLUCOSE 
CONCENTRATIONS IN RATS
Bars and error bars indicate mean+S.E. (n=6)
BLOOD GLUCOSE ( m M )
3 WEEKS 7 WEEKS 11 WEEKS
TIME ON DIET
WHITE WHEAT CZD WHOLEMEAL WHEAT
PEARL BARLEY STONEGROUND BARLEY
FIGURE 7.6 CHRONIC EFFECTS OF DIFFERENT 
DIETARY CEREAL FLOURS ON 
POST PRANDIAL PLASMA IRI 
CONCENTRATIONS IN RATS
Bars and error bars indicate mean+S.E. (n=6)
* Denotes values significantly different to those for animals fed 
stoneground barley (p<0.05)
PLASMA IRI ( u g / L )
WHITE WHEAT 
PEARL BARLEY
7 WEEKS
TIME ON DIET
[ _  J WHOLEMEAL WHEAT
STONEGROUND BARLEY
2 3 8
TABLE 7.14 CHRONIC EFFECTS OF DIFFERENT 
DIETARY CEREAL FLOURS ON 
POST PRANDIAL BLOOD GLUCOSE AND 
PLASMA IRI CONCENTRATIONS IN RATS
Values indicate mean ± S.E. (n=6)
BLOOD GLUCOSE (mM)
Dietary Cereal 3
Time on Diet (Weeks) 
7 11
White Wheat 8.11±0.67 5.56±0.34 5.69±0.23
Wholemeal Wheat 6.53+0.37 5.87+0.20 5.11±0.33
Pearl Barley 6.77+0.25 5.55+0.33 5.19±0.26
Stoneground Barley 7.60±0.46 6.22+0.33 5.15±0.27
PLASMA IRI (jig/l)
Dietary Cereal 
White Wheat 
Wholemeal Wheat 
Pearl Barley 
Stoneground Barley
Time on Diet (Weeks)
3 7 11
8.11+1.39 11.00±2.09 2.33+0.502
4.90±1.08i 9.40±0.88 3.54+0.66
5.40±0.62 8.25+2.28 5.34±1.00
7.86±0.92i 13.00+3.09 7.17+1.75%
1 Denotes value for animals fed stoneground barley significantly different from value 
for animals fed wholemeal wheat (p<0.05)
2 Denotes value for animals fed stoneground barley significantly different from value 
for animals fed white wheat (p<0.05)
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7.3.2.5 PLASMA IR-GIP CONCENTRATIONS
The 90 minute post-prandial plasma IR-GIP concentrations for the different 
dietary groups are shown in figure 7.7 and the values given in table 7.15. The 
concentrations remained fairly constant throughout the trial within each dietary 
treatment. The only statistically significant difference was that for animals fed the pearl 
barley flour diet the IR-GIP concentrations were higher after 7 weeks than after 3 
weeks (p<0.05).
There was also very little difference between IR-GIP concentrations for the 
groups of animals on the 4 diets. The only significant difference was that the levels for 
the pearl barley group after 3 weeks were lower than those for the wholemeal wheat 
and stoneground barley groups (p<0.05).
7.3.2.6 PLASMA IR-GLP-1 CONCENTRATIONS
The observed plasma IR-GLP-1 concentrations are shown in figure 7.8 and the 
values given in table 7.15. The concentrations decreased dramatically during the trial 
for animals fed the white wheat diet. The concentrations after 7 weeks were 
significantly lower than after 3 weeks (p<0.05) and the concentrations after 11 weeks 
were significantly lower than after both 3 weeks (p<0.01) and 7 weeks (p<0.05). 
There was no significant change in plasma IR-GLP-1 during the trial for animals given 
the other 3 diets.
The observed drop in plasma IR-GLP-1 concentrations for animals fed the 
white wheat diet is reflected in the statistical comparison between diets. At 3 weeks, 
the white wheat-fed animals exhibited the highest plasma IR-GLP-1 concentrations. 
These were significantly higher than those observed for animals fed the pearl barley 
diet. After 11 weeks, the plasma IR-GLP-1 concentrations in the white wheat fed 
animals were found to be significantly lower than those for the animals fed on 
wholemeal wheat (p<0.05).
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FIGURE 7.7
500 -1
400 -
CHRONIC EFFECTS OF DIFFERENT 
DIETARY CEREAL FLOURS ON 
POST PRANDIAL PLASMA IR-GIP 
CONCENTRATIONS IN RATS
Bars and error bars indicate mean+S.E. (n=6)
* Denotes values significantly different to those for animals fed 
pearl barley (p<0.05)
PLASMA I R - G I P  ( pM)
0
3 WEEKS 7 WEEKS 11 WEEKS
T I ME ON D I E T
WHITE WHEAT [ m  wholemeal wheat
PEARL BARLEY STONEGROUND BARLEY
FIGURE 7.8 CHRONIC EFFECTS OF DIFFERENT 
DIETARY CEREAL FLOURS ON 
POST PRANDIAL PLASMA IR-GLP-1 
CONCENTRATIONS IN RATS
Bars and error bars indicate mean+S.E. (n=6)
* Denotes values significantly different to those for animals fed 
white wheat (p<0.05)
PLASMA I R - G L P - 1  ( pM)
3 WEEKS 7 WEEKS 11 WEEKS
T I M E  ON DI E T
WHITE WHEAT 
PEARL BARLEY
□  WHOLEMEAL WHEAT 
^  STONEGROUND BARLEY
2 4
TABLE 7.14 CHRONIC EFFECTS OF DIFFERENT 
DIETARY CEREAL FLOURS ON 
POST PRANDIAL PLASMA IR-GIP AND 
IR-GLP-1 CONCENTRATIONS IN RATS
Values indicate mean ± S.E. (n=6)
PLASMA IR-GIP (pM)
Dietary Cereal
White Wheat 
Wholemeal Wheat 
Pearl Barley 
Stoneground Barley
Time on Diet (Weeks)
3 7 11
299±50 334±51 257±20
355±25i 350±55 306±21
212±24i 341±33 259±34
346±401 378±32 252±32
1 Denotes values for animals fed pearl barley significantly different from values for 
animals fed wholemeal wheat and stoneground barley (p<0.05)
PLASMA IR-GLP-1 (pM)
Dietary Starch
White Wheat 
Wholemeal Wheat 
Pearl Barley 
Stoneground Barley
Time on Diet (Weeks) 
3 7
22.8±6.12 11.0±2.5
14.3+2.2 20.3±6.6
8.413.1 2 11.014.7
17.612.8 11.714.9
11
0.310.2 3
16.916.9 3
8.311.9 
6.714.5
2 Denotes values for animals fed white wheat significantly different from values for 
animals fed pearl barley (p<0.05)
3 Denotes values for animals fed wholemeal wheat significantly different from values 
for animals fed white wheat (p<0.05)
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The wholemeal wheat diet appeared to produce the highest plasma IR-GLP-1 
concentrations and the pearl barley produced the lowest concentrations of the other 3 
dietary treatments. However, these differences did not reach statistical significance.
7.3.2.7 TISSUE EXTRACT IR-GIP CONCENTRATIONS
The IR-GIP concentrations in extracts of the 4 intestinal sections are depicted in 
figure 7.9 and the values given in table 7.16. The highest concentrations were found in 
the proximal small intestine (sections 1 and 2) and the lowest in the large intestine 
(section 4).
There was very little change in the concentrations observed in each section for 
each dietary treatment with time during the trial. The only statistically significant 
difference arose in the pearl barley fed animals, for which the concentrations in the 
terminal small intestine (section 3) were found to have decreased from week 4 to week 
12 (p<0.05).
The tissue IR-GIP concentrations were also very similar between the different 
dietary treatments. The only significant difference was that the levels observed in the 
large intestine (section 4) of the animals fed stoneground barley were greater after 12 
weeks than in animals fed white wheat (p<0.05).
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TABLE 7.16 CHRONIC EFFECTS OF DIFFERENT 
DIETARY CEREAL FLOURS ON GUT 
TISSUE IR-GIP CONCENTRATIONS IN 
RATS
Values indicate mean ± S.E. (n=6)
Gut Weeks 
Section on Diet
IR-GIP (pmoles/g wet weight tissue)
White Wholemeal Pearl Stoneground
Wheat Wheat Barley Barley
1 4 680±71 572±90 481171 6411118
1 8 529+68 615+118 469199 544198
1 12 578+121 579±94 650197 7141153
2 4 733+161 7921204 8861248 7921175
2 8 716±89 608147 8691225 500182
2 12 683+53 761183 716197 514160
3 4 361±108 4401205 220140 203125
3 8 241±32 172129 162115 166116
3 12 207±40 176122 124114 128114
4 4 61±16 49133 6018 6719
4 8 122±47 5116 4515 4214
4 12 43±4 1 49133 6018 6719 1
1 Denotes values for animals fed stoneground barley significantly different from values 
for animals fed white wheat (p<0.05)
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7.3.2.8 TISSUE EXTRACT IR-GLP-1 CONCENTRATIONS
The IR-GLP-1 concentrations in extracts of the 4 intestinal sections are depicted 
in figure 7.10 and the values given in table 7.17. In contrast to the observed 
distribution of IR-GIP, the highest concentrations of IR-GLP-1 were consistently 
observed in the distal small intestine (sections 2 and 3). The lowest levels were found 
in the proximal small intestine (section 1) but these were not always markedly less than 
those found in the large intestines.
For all 4 dietary treatments the IR-GLP-1 concentrations in sections 2,3 and 4 
appeared to be higher after 4 weeks than after 8 or 12 weeks. However, these 
differences were small and were only statistically significant for section 3 of the animals 
fed the white wheat diet (IR-GLP-1 levels at week 4 > at week 12 [p<0.05]) and for 
section 2 of the animals fed the stoneground barley (IR-GLP-1 levels at week 4 > at 
week 8 [p<0.05]).
The different dietary treatments appeared to have similar effects on the tissue 
levels of IR-GLP-1. Statistical comparison between the 4 treatments revealed that the 
only significant difference occurred after 4 weeks when the levels of IR-GLP-1 in gut 
section 3 for animals fed the white wheat diet were greater than in animals fed the pearl 
barley diet (p<0.05).
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TABLE 7.17 CHRONIC EFFECTS OF DIFFERENT 
DIETARY CEREAL FLOURS ON GUT 
TISSUE IR-GLP-1 CONCENTRATIONS 
IN RATS
Values indicate mean ± S.E. (n=6)
IR-GLP-1 (pmoles/g wet weight tissue)
Gut Weeks White Wholemeal Pearl Stoneground
Section on Diet Wheat Wheat Barley Barley
1 4 50±11 78±15 5918 75116
1 8 78±13 68±12 69115 88113
1 12 72±16 83±20 77117 7018
2 4 251±33 281±13 3241127 278144
2 8 211+18 230±18 209131 134144
2 12 230±36 250±37 237143 209133
3 4 403±33 1 302144 247132 1 297145
3 8 325±34 265147 256138 269150
3 12 250±35 215146 199126 168147
4 4 125±14 175145 99111 104116
4 8 104±17 88113 88111 71114
4 12 85±15 66110 81123 4314
1 Denotes values for animals fed white wheat significantly different from those for 
animals fed pearl barley (p<0.05)
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7.3.3 DISCUSSION
All 4 diets lead to very similar post-prandial blood glucose concentrations. As 
for the previous chronic study, blood glucose concentrations fell throughout the 
duration of all the dietary regimens. However, unlike the previous, study this 
improvement in glucose tolerance was not matched by an elevation of plasma IRI 
concentrations, which appeared to increase after 7 weeks of all 4 dietary treatments but 
then declined again after 11 weeks.
All 4 diets appeared to induce a slight fall in IR-GLP-1 concentrations in the 
middle to distal small intestine and in the large intestine. This might be an effect of 
ageing. This was most marked in the distal small intestine (gut section 3) of the rats fed 
the white wheat diet. These same animals exhibited a marked drop in plasma IR-GLP- 
1 concentrations from week 3, when their IR-GLP-1 levels were the highest of all 4 
groups, to week 12, when they had the lowest IR-GLP-1 levels of all 4 dietary groups.
White wheat was the most refined flour used in this study and had the lowest 
non-starch polysaccharide content. Consequently, of all of the flours investigated, 
white wheat flour would be predicted to be the source of the most rapidly digestible 
starch. The marked decrease in plasma IR-GLP-1 concentrations and the smaller 
decrease in gut tissue concentrations of IR-GLP-1, particularly in the distal small 
intestine, might reflect a chronic effect of rapidly absorbable forms of carbohydrate 
leading to attenuated tGLP-1 secretion. However, the results of the other chronic study 
described earlier showed initially depressed plasma IR-GLP-1 levels in rats fed the 
most rapidly digestible starch preparation, which then increased marginally, rather than 
decreased, throughout the rest of the trial. Therefore, these 2 sets of results appear to 
be contradictory and further investigation is required to clarify the matter.
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7.4 CONCLUSIONS
In the study described in section 5.3, there were only small differences in the 
acute metabolic responses in man to differently processed wheat starches compared 
with glucose. Much more marked differences had been previously observed for 
starches purified from mutant species of maize which varied dramatically in amylose 
and RS contents. The first study described in this chapter showed that there was little 
difference in the chronic effects of starches prepared from different cereal sources.
Purified starch is not a representative form of most dietary carbohydrate. Starch 
is normally consumed as an integral components of raw or processed cereals, fruits and 
legumes. In such forms, the starch may interact with other dietary component which 
can influence the rate of digestion and absorption.
In an acute study described in chapter 5, marked differences were observed in 
the metabolic response to glucose, rice and barley meals in man. In contrast, no 
differences were evident in the metabolic responses to wholemeal breads produced 
using different cereals (Elliott etal, 1991) and it was concluded that the milling of the 
cereals to produce flour and the subsequent cooking of the breads rendered the starches 
approximately equally digestible, regardless of cereal source.
The results obtained in the chronic study in which rats were fed diets based on 
flours of different cereal sources appear to confirm that following extensive processing, 
such as milling and baking, differences in starch composition and non-starch 
polysaccharide content of the grains have negligible effects on in vivo rates of starch 
digestion.
It seems that for significant differences in starch digestibilities to remain, the 
processing undergone by the source of starch must be mild enough for the starch 
granules to remain intact or for the cellular or granular structure of the cereal, fruit or 
legume to maintain sufficient structural integrity to impede enzymic degradation of the 
starch.
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CHAPTER 8
ACUTE GUT HORMONE 
RESPONSES TO A MIXED MEAL 
IN NORMAL, SHORT BOWEL 
AND CONSTIPATED SUBJECTS
251
8.1 INTRODUCTION
The diffuse nature of the endocrine system of the GI tract complicates its 
investigation compared with discrete endocrine glands such as the thyroid and pituitary. 
For compact endocrine glands, surgical removal can be employed to study the 
endocrine deficiency state. Removal of the entire GI tract is obviously not a tenable 
approach. The best that can be achieved is surgical removal of sections of the gut. 
However, even this approach has drawbacks. The overlapping distribution of the 
endocrine cells producing different GI hormones makes it impossible to specifically 
remove only those cells secreting one type of hormone. Furthermore, the removal of 
large sections of gut will produce mechanical changes in the function of the remaining 
sections that will, in turn, affect the levels of different hormones. Nevertheless, the 
monitoring of hormone levels in subjects with diseases affecting the GI tract or who 
have undergone surgical procedures used in the treatment of such diseases can provide 
interesting information concerning the possible functions of GI hormones. The 
mechanical changes in the function of the gut that were mentioned above can often be 
invoked to explain the gross changes observed in such cases.
Dumping syndrome is often observed in man following partial or total 
gastrectomy. The symptoms include post-prandial distension, sweating, tachycardia, 
hypotension and reactive hypoglycaemia. It has been mentioned (section 1.6.4) that 
patients with this syndrome exhibit dramatically increased IR-GLP-1 responses to food 
(Kreymann etal, 1987 ; 0rskov e tal, 1991). Bloom and co-workers have reported 
similarly raised post-prandial enteroglucagon levels (Bloom et al, 1972). It should be 
appreciated that the precise nature of the enteroglucagon measured by this group is not 
clear. Their assay depends on subtraction of pancreatic glucagon, measured with an 
assay specific for that form, from total glucagon-like immunoreactivity in plasma, 
measured with a second assay believed to crossreact with all peptides that contain the 
glucagon sequence (Alford etal, 1977). The majority of the enteroglucagon measured
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in this way is likely to be glicentin secreted from the distal small bowel. However, 
crossreactivity with other peptides cannot be ruled out.
Since both tGLP-1 and enteroglucagon are believed to be produced and secreted 
by the same endocrine cells in the gut it is not surprising that elevations of both 
hormones are seen to occur in parallel. The enhanced IR-GLP-1 and enteroglucagon 
responses to food are probably caused by the rapid exit of food from the stomach and 
consequent increase of nutrients being absorbed in the more distal small intestine. It 
has been proposed that the increased IR-GLP-1 levels observed may be responsible, at 
least in part, for the reactive hypoglycaemia associated with this syndrome by 
excessively stimulating secretion of insulin (0rskov etal, 1991).
Post-prandial measurements of gut hormone levels have been investigated in 
human subjects who have undergone jejuno-ileal or bilio-pancreatic bypass surgery as 
treatment for morbid obesity (Sarson et al, 1981). In both groups motilin and GIP 
responses to a test breakfast were found to be impaired whilst both basal and stimulated 
neurotensin and enteroglucagon levels were enhanced.
The reductions in GIP and motilin probably reflect the fact that the endocrine 
cells that produce both these hormones are found largely in upper small intestine. 
Jejuno-ileal bypass removes most of the capacity to secrete GIP and motilin and 
bilio-pancreatic bypass, while not physically removing the upper small intestine, 
nevertheless, causes nutrients not to bypass this section of the gut. Therefore, this is 
likely to be the cause of the impaired post-prandial responses for both these GI 
hormones.
Kajiwara and co-workers found that subjects that had undergone massive small 
bowel resection exhibited essentially normal plasma glucose levels but reduced insulin 
levels after an oral glucose load (Kajiwara etal, 1979). Plasma GIP levels were not 
measured in this study. However, it is tempting to speculate, in the context of the 
study outlined above, that the apparently impaired entero-insular axis observed in these 
subjects was due to a reduction in their GIP response to the oral glucose load.
2 5 3
Another study has been reported in which post-prandial glucose, GIP and 
insulin responses to oral glucose were compared in control subjects and subjects that 
had undergone small bowel resection (Lauritsen etal, 1980). Furthermore, the subjects 
were also given an IV infusion of glucose so as to match the post-prandial venous 
concentrations observed following the oral load. This allowed the workers to assess 
the incretin effects (defined as [integrated incremental area under the curve for insulin 
following oral glucose minus integrated incremental area under the curve following IV 
glucose infusion] divided by integrated incremental area under the curve following IV 
glucose infusion) for the different groups.
The short bowel subjects who participated in this study formed a heterogeneous 
population. They were subdivided into 3 groups. The first group was defined as those 
subjects with more than 150cm of residual jejunum but no ileum or colon. The second 
group had between 0 and 250cm of residual jejunum plus a preserved or partially 
preserved ileum. The third group had less than 150cm of residual jejunum.
Subjects with more than 150cm of residual jejunum were found to have a 
greater GIP response compared with healthy controls but their incretin effect was 
normal. In contrast, those subjects with a preserved ileum had normal GIP levels but 
an enhanced incretin effect. For subjects from the third group, with less than 150cm of 
residual jejunum, post-prandial GIP levels were not significantly different from the 
control group but their incretin effect was significantly reduced. For all the groups, the 
incretin effect correlated well with total residual small intestinal length rather than 
residual jejunal length. The workers concluded that their results pointed to the presence 
of one or more important incretins, other than GIP, to be found in the lower small 
intestine.
In contrast with GIP and motilin, enteroglucagon and neurotensin are produced 
predominantly in the distal small intestine. The increased levels of both of these 
hormones reported by Sarson and co-workers (Sarson et al, 1981) may be due, as 
suggested for dumping syndrome, to an increased quantity of nutrients reaching the
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distal small intestine before being absorbed. Enteroglucagon has been implicated as a 
trophic agent for the small intestine and may decrease intestinal motility (Bloom, 1972 ; 
Besterman etal, 1979). Neurotensin is believed to reduce gastric motility (Andersson 
et al, 1977). The increase in both these hormones, therefore, may represent a 
mechanism to compensate for the missing section of gut.
In another study gut hormone levels were measured after a test breakfast in 
subjects who had had partial ileal or colonic resections (Bloom et al, 1979). The 
subjects with partial ileal resections exhibited raised basal and post-prandial pancreatic 
polypeptide, motilin, gastrin and enteroglucagon levels. The subjects with colonic 
resections had similar pancreatic polypeptide levels to those seen in the subjects with 
ileal resections, but their motilin and gastrin levels were normal and their 
enteroglucagon levels were slightly, but not significantly, reduced compared with 
normal subjects.
Animal studies have also been carried out to investigate the effects of intestinal 
resection. In one such study rats that had undergone resection of their proximal small 
intestine were reported to exhibit raised plasma and ileal tissue levels of enteroglucagon 
compared with control animals (Jacobs et al, 1981). In the same study a small increase 
in plasma enteroglucagon was also observed in animals that had undergone resection of 
their distal small intestine, but this increase was not statistically significant.
In contrast, basal and stimulated total glucagon-like immunoreactivity was 
found to be depressed in dogs that had undergone resection of 75% of their distal small 
bowel (Barros D’Sa and Buchanan, 1977). Whilst this is apparently in contradiction to 
the studies in humans and rats, the difference may have been due to the greater extent of 
resection in this study and the consequent removal of the majority of enteroglucagon 
secreting cells.
IR-GLP-1 levels in subjects with gut resections have not been reported. In 
cases where enteroglucagon levels are raised, IR-GLP-1 concentrations would also be 
expected to be increased. However, as mentioned above, extensive gut resection can
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also lead to reductions in enteroglucagon. In the study described here we have 
compared fasting and fed plasma concentrations of IR-GLP-1, IR-GIP and IRI in 
groups of subjects with either end-jejunostomies or jejuno-colic anastomoses with the 
concentrations observed for normal healthy subjects.
A fourth group was also investigated. The subjects in this group suffered from 
constipation. Surprisingly for such a common complaint, gut hormone levels have not 
been extensively investigated in this syndrome. A small increase in enteroglucagon and 
a large increase in motilin have been reported in subjects with acute infective diarrhoea 
whereas no abnormalities have been found in the GI hormone levels of subjects 
suffering from irritable bowel syndrome (Bloom and Polak, 1981). Constipation can 
be variously associated with delayed gastric emptying, prolonged small intestinal transit 
time or prolonged colonic transit time (Read et al, 1986 ; Stivland et al, 1991 ; 
Reynolds etal, 1987). These factors are likely to influence GI hormone levels.
8.2 STUDY DESIGN
The study described here was carried out together with Dr J. Nightingale from 
St Mark’s hospital, London who recruited the volunteers and carried out the test meals. 
Two groups each of 6 subjects who had previously had surgery of the small bowel 
were investigated. The sex, age and the jejunal lengths of these short bowel subjects 
are summarized in table 8.1. All the subjects from both these groups had last 
undergone surgery between 3 months and 15 years prior to this trial.
The subjects in one group (2 females and 4 males, ages ranging from 32 to 70 
years [mean ± S.E. = 53±6 years]) had undergone end-jejunostomy (EJ) operations. 
Two of these subjects were on long-term parenteral nutrition (subjects 1 and 2). The 
other 4 required oral nutrition or electrolyte supplements to maintain nutritional status 
and fluid balance.
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TABLE 8.1 SEXES, AGES AND JEJUNAL LENGTHS OF 
SHORT BOWEL SUBJECTS
HPN = Home parenteral nutrition
END-JEJUNOSTOMY GROUP
Subject Sex Age Jejunal Time Since Nutritional
Number Length Last Surgery Or Fluid
(Years) (cm) (Months) Supplements
1 Male 32 50 68 HPN
2 Female 36 60 48 HPN
3 Female 62 90 3 Oral
4 Male 61 120 181 Oral
5 Male 70 130 127 Oral
6 Male 55 160 146 Oral
JEJUNO-COLIC ANASTOMOSIS GROUP
Subject Sex Age Jejunal Time Since Nutritional
Number Length Last Surgery Or Fluid
(Years) (cm) (Months) Supplements
7 Male 19 25 28 HPN
8 Male 25 25 36 HPN
9 Female 41 70 72 Oral
10 Male 51 75 23 None
11 Female 58 75 32 Oral
12 Male 60 75 147 None
The other group (3 female and 3 male, ages ranging form 19 to 60 years [mean 
± S.E. = 42±6]) had been given jejuno-colic anastomoses (JCA). Subjects 10 and 11 
had had their jejunum anastomosed to a short length of terminal ileum (15cm and 5cm 
respectively). For another 2 subjects (7 and 9), the jejunum had been anastomosed to 
their caecum. In the case of the final pair (subjects 8 and 12), the jejunum had been 
anastomosed to the proximal transverse colon. Two of the group (those with only 
25cm of jejunum remaining) were receiving long-term parenteral nutrition. Another 2
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took oral nutritional supplements. The last pair required no fluid or nutritional 
supplements. A third group consisting of constipated subjects was also investigated. 
There were 12 subjects in this group all of whom were female and their ages ranged 24 
to 55 (mean ± S.E. = 36±8). Finally, 12 normal healthy subjects, 7 females and 5 
males aged from 24 to 53 (mean±S.E. = 34±10) were included as a control group.
Several of the short bowel subjects were on the anti-secretory drugs omeprazole 
(subject 2), octreotide (subject 1) and ranitidine (subjects 3 and 4). They stopped 
taking these 3 respective drugs 5,3 and 1 days before the trial. A large number of the 
subjects were also using anti-diarrhoeal drugs (codeine and/or loperamide). They all 
stopped using these the evening before the trial.
All the volunteers were asked to consume, after an overnight fast, a test 
breakfast consisting of a large pancake served with orange juice. The components of 
the meal and their nutritional content are summarized in table 8.2.
To make the pancake, the flour, milk and egg were blended together in a jug for 
1 minute. Indium (20MBq of m in incorporated into microspheres) was added to the 
mixture which was then blended for another 5 seconds. This mixture was then rapidly 
poured into a hot browning dish to which the soya oil had previously been added. The 
pancake was cooked for 4 minutes before turning and cooking the other side for a 
further 3 minutes. It was then transferred to a plate where the sugar was sprinkled over 
the surface together with 2 level teaspoons of lemon juice. The subjects were asked to 
consume the pancake over 10 minutes with the orange juice, containing 40MBq of 
technetium (99Tc-EDTA), taken towards the end.
Venous blood samples were taken before the meal and at intervals for 3 hours 
post-prandially. The blood samples were treated as described in section 2.8 and 
assayed for IR-GLP-1, IR-GIP and IRI.
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TABLE 8.2 COMPOSITION OF TEST MEAL
WEIGHT ENERGY CHO PROTEIN FAT FIBRE
(g) (kcal) (g) (g) (g) (g)
1 Egg 70 80 0.2 6.8 6.1 ———
Flour 57 200 45.8 5.4 0.9 1.4
Milk 142 99 6.7 4.6 5.7
Soya Oil 14 126 --- --- 14.0 ---
Sugar 14 52 14.0 -------- -------- --------
Orange Juice 195 69 16.9 1.3 -------- ---
Total 492 626 83.6 18.1 26.7 1.4
Measurement of plasma glucose concentrations and assessment of liquid and 
solid gastric emptying rate were made at St Mark’s hospital. Solid gastric emptying 
was determined by following distribution of the radioactive indium microspheres along 
the GI tract of the volunteers using a gamma camera. Liquid gastric emptying was 
assessed in a similar fashion by following the distribution of the other radioactive 
isotope, technetium, which had been added to the orange juice.
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8.3 RESULTS
All the control subjects managed to consume the entire test meal within 10 
minutes. One of the subjects in the EJ group (subject 1) could not consume the entire 
pancake, even after 20 minutes, and left 80g. In the JCA group, subjects 7 and 8 ate 
the meal in 12 and 20 minutes respectively and subject 9 consumed as much as possible 
over 25 minutes leaving 63g uneaten. All the subjects in all the groups managed to 
drink the orange juice.
8.3.1 GASTRIC EMPTYING RATES
The results obtained for gastric emptying for the EJ, JCA and control subjects 
have been reported elsewhere (Nightingale etal, 1991). The initial rate of liquid gastric 
emptying, but not solid gastric emptying, for the EJ group was found to be 
significantly faster than for controls. Liquid and solid gastric emptying rates were 
normal for the JCA group. The gastric emptying rate data for constipated subjects were 
not available.
8.3.2 PLASMA GLUCOSE RESPONSES
Plasma glucose responses to the test breakfast observed for the 4 experimental 
groups are shown in figures 8.lA and 8. IB and the values given in table 8.3. Fasting 
plasma concentrations were similar in all groups. In the control group plasma glucose 
concentrations rose rapidly after the meal, reaching a peak 45 minutes post-prandially. 
After that the concentrations declined steadily, almost returning to fasting levels by the 
end of the 3 hour sampling period.
Figure 8.1A reveals that plasma glucose rose more slowly in the EJ group than
2 6 0
FIGURE 8.1 PLASMA GLUCOSE RESPONSES TO A 
TEST BREAKFAST IN HEALTHY, SHORT 
BOWEL AND CONSTIPATED SUBJECTS
Error bars indicate mean±S.E.
n=12 for control and constipated subjects
n=6 for short bowel subjects
EJ = End-jejunostomy subjects
JCA = Jejuno-colic anastomosis subjects
* Denotes values significantly different from controls (p<0.05)
** Denotes values significantly different from controls (p<0.01)
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TABLE 8.3 PLASMA GLUCOSE RESPONSES TO A
TEST BREAKFAST IN HEALTHY, SHORT 
BOWEL AND CONSTIPATED SUBJECTS
Values indicate mean±S.E.
n=12 for control and constipated subjects
n=6 for short bowel subjects
EJ = End-jejunostomy subjects
JCA = Jejuno-colic anastomosis subjects
* Denotes values significantly different from controls (p<0.05)
** denotes values significantly different from controls (p<0.01)
PLASMA GLUCOSE (mM)
TIME
(minutes)
CONTROL EJ JCA CONSTIPATED
-30 3.8±0.1 3.610.3 3.810.2 3.710.1
0 3.710.2 3.610.3 3.810.1 3.710.1
15 4.210.2 3.610.2 3.710.1 4.010.2
30 5.410.3 4.610.3 4.510.2 5.610.3
45 5.810.3 5.710.4 5.010.5 6.310.3
60 5.210.3 5.710.3 5.110.5 5.910.5
90 4.510.4 5.510.3 5.010.3 4.310.4
120 4.110.4 5.610.4 * 4.310.2 3.710.3
180 3.910.2 5.210.2 ** 4.210.1 3.910.1
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in the controls. Indeed, no increase was evident until the 30 minute time point for the 
EJ group compared with a clear increase at 15 minutes post-prandially in the controls. 
However, concentrations still peaked at 45 minutes in the EJ group with levels similar 
to those of the control group. The concentrations then remained elevated for the rest of 
the sampling period, being significantly higher than controls at 120 minutes (p<0.05) 
and 180 minutes (p<0.01) and also higher than JCA subjects at 180 minutes (p<0.05) 
post-prandially. The integrated incremental area under the curve over the 3 hour post­
prandial sampling period was significantly greater for the EJ group than for either the 
control or JCA groups (p<0.05).
The glucose response to the test breakfast in the JCA group was, like the EJ 
group, slightly delayed compared with controls. Peak values arose 60 minutes post- 
prandially. Overall, the response appeared flattened compared with that observed for 
the control group with plasma concentrations lower than controls from 15 to 60 minutes 
post-prandially and higher from 90 to 180 minutes. However, these differences did not 
reach statistical significance at any time point and there was also no significant 
difference between the control and JCA groups in the integrated incremental areas under 
the curve over the 3 hour post-prandial sampling period.
It should be noted that 2 subjects (subjects 7 and 8) from the JCA group 
produced totally flat plasma glucose profiles after the test meal. Both of these had had 
all but 25cm of their jejunum surgically removed. Consequently, the fiat glucose 
profiles probably reflected their inability to absorb glucose with the very limited section 
of small bowel still in continuity. Both subjects were on regular parenteral nutrition. 
These 2 subjects were responsible for the apparent slight reduction in mean peak post­
prandial glucose levels observed for the JCA group as a whole compared with controls.
The 2 subjects in the EJ group with the shortest remaining jejunal lengths 
(subjects 1 and 2) were also on regular IV nutrition. However, examination of their 
glucose responses to the meal revealed small increases during the 3 hour sample period. 
Presumably, their ability to absorb glucose was impaired but not totally abolished as in
263
the case of subjects 19 and 20. This may have been due to the slightly longer 
remaining length of jejunum in these 2 EJ subjects.
Both peak glucose concentrations and integrated incremental areas under the 
curve for the members of the JCA group were found to correlate with residual jejunal 
length (r=0.81, p<0.05 and r=0.93, p<0.01 respectively). There was no significant 
correlation between peak glucose concentrations or integrated incremental areas under 
the curve for the EJ group.
The post-prandial glucose response for the constipated group was very similar 
to that for the control group. There were no statistically significant differences between 
these 2 groups at any individual time points or in integrated incremental areas under the 
curve.
8.3.3 PLASMA IRI RESPONSES
The plasma IRI responses for the 4 experimental groups are shown in figures 
8.2A and 8.2B and the values given in table 8.4. IRI concentrations rose steadily post- 
prandially for the control group, reaching a peak at 45 minutes. The graph suggests 
that a second peak occurred at 120 minutes post-prandially. However, inspection of 
individual values revealed that an increase in plasma IRI, albeit a large increase, was 
only evident in 2 of the 12 members of the group at this time point. This was sufficient 
to raise the mean to produce the apparent second peak. The large variation from subject 
to subject at this time is evident from the magnitude of the S.E. .(figures 8.2A and B).
Fasting plasma IRI concentrations for the 2 short bowel groups were similar to 
those of the control group. However, the post-prandial increases in plasma IRI were 
generally lower for both these groups compared with controls. Plasma IRI 
concentrations were not significantly lower for the EJ at any individual time point but 
the integrated incremental area under the curve for this group was significantly less than
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FIGURE 8.2 PLASMA IRI RESPONSES TO A TEST 
BREAKFAST IN HEALTHY, SHORT 
BOWEL AND CONSTIPATED SUBJECTS
Error bars indicate mean±S.E.
n=12 for control and constipated subjects
n=6 for short bowel subjects
EJ = End-jejunostomy subjects
JCA = Jejuno-colic anastomosis subjects
* Denotes values significantly different from controls (p<0.05)
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TABLE 8.4 P L A S M A  IRI R E S P O N S E S  TO  A  T E ST  
B R E A K F A S T  FO R H E A L T H Y , SH O RT  
BO W EL A N D  C O N ST IP A T E D  SU B JE C T S
Values indicate mean±S.E.
n=12 for control and constipated subjects
n=6 for short bowel subjects
EJ = End-jejunostomy subjects
JCA = Jejuno-colic anastomosis subjects
* Denotes values significantly different from controls (p<0.05)
P L A S M A  IRI (m U /1)
CONTROL EJ JCA CONSTIPATEDTIME
(minutes)
-30 9.612.4 15.816.2 11.312.1 6.011.0
0 10.312.7 13.115.2 . 5.410.7 5.510.5
15 22.613.2 13.114.8 11.514.0 18.014.1
30 39.116.3 25.714.4 20.214.9 44.118.5
45 48.916.3 31.715.5 22.015.4 * 57.519.3
60 44.317.0 34.115.2 27.217.8 51.515.5
90 53.818.0 31.813.5 33.8110.6 42.616.6
120 59.2120.1 27.714.7 19.915.1 30.913.4
180 30.315.9 23.915.1 14.213.2 18.912.1
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for the control group (p<0.05). Plasma IRI levels were significantly lower in the JCA 
group at 45 minutes post-prandially (p<0.05) and the integrated incremental area under 
the curve over the 3 hour sampling period was lower (p<0.05) than for the control 
group.
Subjects 7 and 8, from the JCA group, who had both produced flat glucose 
responses to the meal also exhibited no post-prandial increase in plasma IRI 
concentrations. From the EJ group, subjects 1 and 2 had produced impaired glucose 
responses to the test breakfast. Subject 1 had slightly elevated fasting IRI levels but the 
concentration did not change appreciably after the meal. Subject 2, on the other hand, 
had normal fasting plasma IRI concentrations and a small post-prandial increase in 
plasma IRI concentrations, consistent with impaired but not abolished glucose 
absorption.
Peak IRI concentrations and integrated incremental areas under the curve for the 
EJ group correlated with residual jejunal length (r=0.86 and 0.88 respectively, p<0.01 
in both cases). For the JCA group there was only a positive correlation between 
integrated incremental areas under the curve for IRI and residual jejunal length (r=0.83, 
p<0.05).
The fasting and post-prandial plasma IRI levels for the constipated group 
appeared normal (figure 8.2B) and did not significantly differ from those of the control 
group.
8 .3 .4  P L A SM A  IR -G IP  R E S P O N S E S
The plasma IR-GIP responses to the test breakfast are depicted in figures 8.3A 
and 8.3B and the values given in table 8.5. In all 4 groups plasma IR-GIP rose 
steadily for 2 hours post-prandially before levelling off for the third hour. Fasting 
concentrations appeared to be elevated in both short bowel groups compared with the
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FIGURE 8.3 P L A SM A  IR -G IP  R E S P O N S E S  TO  A  T E ST  
B R E A K F A ST  IN  H E A L T H Y , SH O R T  
BO W EL A N D  C O N S T IP A T E D  SU B JE C T S
Error bars indicate mean±S.E.
n=12 for control and constipated subjects
n=6 for short bowel subjects
EJ = End-jejunostomy subjects
JCA = Jejuno-colic anastomosis subjects
* Denotes values significantly different from controls (p<0.05)
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TABLE 8.5 P L A SM A  IR -G IP  C O N C E N T R A T IO N S  
FO L L O W IN G  A  T E ST  B R E A K F A S T  FO R  
H E A L T H Y , SH O R T BO W EL A N D  
C O N ST IP A T E D  SU B JE C T S
Values indicate mean±S.E.
n=12 for control and constipated subjects
n=6 for short bowel subjects
EJ = End-jejunostomy subjects
JCA = Jejuno-colic anastomosis subjects
* Denote values significantly different from controls (p<0.05)
P L A S M A  IR -G IP  (p M )
TIME
(minutes)
CONTROL EJ JCA CONSTIPATED
-30 35±13 119±26 110179 39116
0 23±11 105±23 * 69146 32113
15 55±20 148±25 * 61116 87126
30 134±31 261±53 177162 140126
45 214±45 370±88 227184 237140
60 272±56 475+109 2961119 280141
90 317±58 579±137 * 3141109 376145
120 388±38 4881136 3041104 435128
180 358±38 5681141 3461113 419124
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control group, but the only statistically significant difference was at 0 minutes between 
the EJ and control subjects (p<0.05). There were no significant differences between 
the post-prandial levels at any time point or in incremental areas under the curve 
observed for the control, constipated and JCA groups. However, the integrated 
incremental areas under the curve for IR-GIP for the JCA group were found to correlate 
with residual jejunal length (r=0.83, p<0.05)
The concentrations of IR-GIP in the EJ group were consistently higher 
throughout the sampling period than for the other 3 groups. These differences between 
the post-prandial IR-GIP concentrations for the EJ and control group reached statistical 
significance at 15 and 90 minutes and for the total area under the curve for the 3 hour 
sampling period (p<0.05 in all cases).
As might be predicted from the glucose results, subjects 7 and 8, from the JCA 
group, exhibited fiat IR-GIP responses indicative of their inability to absorb nutrients. 
The post-prandial increase in plasma IR-GIP concentrations observed for subject 1 (EJ 
group) was also low, while that for subject 2 was close to normal. The fact that subject 
1 was included in the calculations emphasizes the markedly increased IR-GIP response 
in the EJ group.
8.3.5 IR-GLP-1 RESPONSES
The IR-GLP-1 results obtained for the 4 experimental groups in this study are 
depicted in figures 8.4A and 8.4B and numerical values given in table 8.6. The mean 
fasting IR-GLP-1 concentration in the control group was 16.1±1.3pM (mean±S.E.). 
This is in good agreement with the studies described in chapter 5. The concentrations 
rose post-prandially to apeak of 29. l±4.1pM at 30 minutes and remained significantly 
elevated for 2 hours (p<0.05 at 45 minutes; p<0.01 at 30, 90 and 120 minutes; 
p<0.001 at 60 minutes).
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FIGURE 8.4 PLASMA IR-GLP-1 RESPONSES TO A 
TEST BREAKFAST IN HEALTHY, SHORT 
BOWEL AND CONSTIPATED SUBJECTS
Error bars indicate mean±S.E.
n=12 for control and constipated subjects
n=6 for short bowel subjects
EJ = End-jejunostomy subjects
JCA = Jejuno-colic anastomosis subjects
* Denotes values significantly different from controls (p<0.05)
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TABLE 8.6 PLASMA IR-GLP-1 RESPONSES TO A
TEST BREAKFAST FOR HEALTHY, SHORT 
BOWEL AND CONSTIPATED SUBJECTS
Values indicate mean±S.E.
n= 12 for control and constipated subjects
n=6 for short bowel subjects
EJ = End-jejunostomy subjects
JCA = Jejuno-colic anastomosis subjects
* Denotes values significantly different from controls (p<0.05)
PLASMA IR-GLP-1 (pM)
TIME CONTROL EJ JCA CONSTIPATED
ED
(minutes)
-30 17.4±2.2 13.115.1 2.211.1 : 15.313.8
0 14.8±1.2 14.016.0 6.813.0 21.914.1
15 19.7±3.0 15.914.6 17.614.3 25.914.9
30 29.1±4.1 17.815.3 11.714.1 * 24.914.9
45 24.0±3.9 14.915.2 12.014.5 26.014.8
60 27.5±2.2 21.916.7 16.813.7 26.014.8
90 24.7±3.2 17.715.1 15.014.1 22.113.7
120 25.1±2.2 22.016.5 15.614.1 32.514.9
180 20.8±2.6 15.415.5 12.114.3 31.714.8 *
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For the EJ group fasting concentrations were slightly but not significantly lower 
than for controls (mean±S.E. = 13.6±3.6pM). The post-prandial levels were also 
lower than controls but not significantly so. The plasma concentrations in this group 
did appear to rise somewhat post-prandially but the concentrations were only 
significantly greater than fasting values at the 30 and 120 minute time points (p<0.05 in 
both cases).
The IR-GLP-1 concentrations in all the plasma samples of subject 1, who had a 
reduced glucose, IRI and IR-GIP response to the meal, were lower than the detection 
limit of the assay. This subject had the least residual jejunal length of all the subjects in 
the group. The apparent absence of IR-GLP-1 from the plasma of this subject is likely 
to have been due to a massive reduction in the number of GLP-1 secreting endocrine 
cells as a result of the extensive surgery carried out on the GI tract.
The plasma concentrations of IR-GLP-1 did appear to increase at some stage for 
all the other subjects in this group including subject 2 who had only 10cm more 
residual jejunum than subject 1. However, the rises were small and occurred at widely 
differing times.
The mean fasting IR-GLP-1 concentration of the JCA group was the lowest of 
all 4 groups studied (mean±S.E.= 5.3±2.0pM) and significantly lower than controls at 
the -30 minute time point and than constipated subjects at 0 minutes (p<0.05). The 
post-prandial concentrations were consistently greater than the fasting concentrations 
(p<0.05 at 15, 90 and 120 minutes ; p<0.01 at 60 minutes) but still lower than the 
concentrations measured in the other 3 groups. The differences reached statistical 
significance at 30 minutes when compared with controls (p<0.05) and at 120 and 180 
minutes compared with constipated subjects (p<0.05 and p<0.01 respectively).
The fasting concentrations in the plasma of subjects 7 and 8 were below the 
detection limit of the assay. However, small post-prandial increases were observed for 
both subjects, with IR-GLP-1 concentrations rising sufficiently to be measured at 15, 
60 and 120 minutes for subject 7 and at 30 and 120 minutes for subject 8. The fasting
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concentrations in subject 9 were also too low to be measured accurately, but this subject 
exhibited a reasonable post-prandial rise in plasma IR-GLP-1 concentrations with a 
peak of 20.7pM at the 90 minute time point. The remaining 3 members of the group 
produced IR-GLP-1 responses reasonably similar to those found in the control group. 
The presence of IR-GLP-1 in the plasma of subjects 7 and 8, with only 25cm of 
residual jejunum, contrasts with its apparent absence from the plasma of subject 1, 
from the EJ group who had 50cm of residual jejunum. This difference is likely to be 
due to the presence of IR-GLP-1 secreting cells in the colon which remains in 
continuity in the JCA group.
There was no significant correlation between residual jejunal length and basal or 
peak IR-GLP-1 concentrations or integrated incremental areas under the curve for IR- 
GLP- 1 for either the EJ or JCA groups.
The fasting IR-GLP-1 concentrations in the constipated group were similar to 
those in the control group (18.9±2.8pM [mean±S.E.] for constipated subjects 
compared with 16.1±1.3pM for controls). Plasma concentrations were significantly 
elevated post-prandially (p<0.05 at 15 and 16 minutes; p<0.01 at 45 minutes; p<0.001 
at 120 and 180 minutes). Over the first 90 minutes after the meal the concentrations 
observed for the constipated group were similar to those for the control group. For the 
last hour of sampling, when IR-GLP-1 concentrations were decreasing in the control 
group, the concentrations in the constipated group continued to increase. This 
difference reached statistical significance at 180 minutes post-prandially (p<0.05). The 
integrated incremental areas under the curve for the IR-GLP-1 responses for the 2 
groups did not differ significantly.
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8.4 DISCUSSION
The results of analysis of gastric emptying rates revealed more rapid initial 
emptying of liquids for the EJ group compared with control subjects (Nightingale eta], 
1991). The residual jejunal length inversely correlated with liquid gastric emptying. In 
contrast, the JCA group had normal gastric emptying. Both EJ and JCA patients suffer 
from poor nutrient absorption due to loss of absorptive intestinal surface as a result of 
surgery. In addition, EJ patients have high stomal loss of water and electrolytes 
(Nightingale etal, 1990). This may well be caused by the rapid liquid gastric emptying 
observed in these subjects.
Increased gastric emptying was not observed for the JCA group probably as a 
result of the action of some factor produced by the presence of the colon in continuity. 
This putative factor was termed a ’’colonic brake”. Obvious candidates for the ’’colonic 
brake” include GI hormones such as neurotensin found largely in the ileum and PYY, 
enteroglucagon and tGLP-1 found in the ileum and colon.
Low levels of IR-GLP-1 were found in fasting and post-prandial plasma 
samples from both short bowel groups compared with control and constipated subjects. 
It is known that tGLP-1 can prolong gastric emptying (Wettergren etal, 1990). 
Consequently, the low levels observed in the EJ group could contribute to the increased 
gastric emptying of liquids. On the other hand, the results suggest that tGLP-1 is not 
the ’’colonic brake” for the JCA group.
In addition to the measurement of insulin, GIP and tGLP-1 described here, 
other research groups have measured the post-prandial levels of gastrin (Department of 
Clinical Biochemistry and Clinical Nutrition, St Luke’s Hospital, Guildford), 
pancreatic polypeptide, somatostatin, motilin, neurotensin, enteroglucagon and PYY 
(Royal Postgraduate Medical School, Hammersmith Hospital, London) in the same 
samples. In this way it was hoped to be possible to produce a comprehensive GI and 
pancreatic hormonal profile for these short bowel patients and more clearly define
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potential candidates for the putative ’’colonic brake”.
The results obtained from the measurement of these other hormones do not 
form an integral part of this thesis as the experimental work was not carried out here. 
However, I will briefly outline some of the results obtained that are pertinent to the 
discussion of the effects of short bowel syndrome on gastric emptying and the entero- 
insular axis.
Motilin, which is released from the upper small intestine (Polak and Buchan, 
1979), can stimulate gastric emptying (Christofides etal, 1981). For JCA subjects, the 
levels were normal. The fasting and post-prandial plasma motilin levels in the EJ 
subjects were found to be significantly elevated compared with controls. However, 
motilin concentrations in EJ subjects were found to correlate with jejunal length, as 
might be expected since patients with the shortest residual jejunal length will have had 
the greatest proportion of motilin secreting cells removed. Furthermore, gastric 
emptying rates were also fastest in EJ subjects with the shortest residual jejunal length. 
Inspection of the motilin concentrations in the EJ subjects with the least residual 
jejunum revealed near normal gastric emptying rates. Consequently, it seems unlikely 
that elevated motilin concentrations were the major cause of the rapid gastric emptying 
rates observed for this group of patients.
Enteroglucagon, from the ileum and colon, has been shown to slow intestinal 
transit. However, levels of enteroglucagon did not significantly differ at any time for 
either short bowel group from the values for control subjects.
Neurotensin is found predominantly in the ileum (Polak et al, 1977) and can 
delay gastric emptying in man (Blackburn etal, 1980). Both EJ and JCA subjects had 
significantly lower fasting and post-prandial plasma neurotensin concentrations 
compared with controls. The low levels of this hormone seen in both short bowel 
groups were likely to have been as a direct result of the removal of the neurotensin 
secreting cells during the surgical procedures undergone by these subjects. The low 
plasma neurotensin concentrations might be expected to increase gastric emptying rates
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in both these groups.
PYY, which is found in the same endocrine cells as enteroglucagon (Ali- 
Rachedi eta/,1984 ; Bottcher etal, 1984) can slow gastric emptying (Allen etal, 1984 ; 
Savage etal, 1987). EJ subjects had lower lasting plasma PYY concentrations than 
controls and the concentrations remained significantly lower for the EJ subjects 
compared with controls throughout the 3 hour post-prandial sampling period. In 
contrast, the lasting PYY concentrations in JCA subjects were elevated compared with 
controls. Furthermore, post-prandial plasma PYY concentrations rose considerably for 
the JCA group to give markedly greater concentrations than those observed for the 
control subjects (p<0.005 for all time points from 30 to 180 minutes, inclusive).
Consequently, it is reasonable to hypothesize that the low concentrations of 
tGLP-1, neurotensin and PYY observed in the EJ subjects were responsible, to varying 
extents, for the rapid gastric emptying in that group of subjects and that, whilst tGLP-1 
and neurotensin were also low in the JCA group, markedly elevated PYY levels served 
to antagonize the effect and normalize gastric emptying.
The apparent delay in plasma glucose absorption in both short bowel groups 
compared with controls is difficult to explain, particularly in the context of the rapid 
gastric emptying of liquids demonstrated for the EJ group. Analysis of total integrated 
post-prandial glucose responses to the test breakfast suggested that glucose absorption 
was normal or near normal in all short bowel subjects except those who had undergone 
the most extensive resections. Subjects 7 and 8, from the JCA group, had only 25cm 
of residual jejunum. The lack of post-prandial responses in any of the parameters 
measured in these 2 subjects was indicative of their inability to absorb significant 
amounts of nutrients.
Subjects 1 and 2 (EJ group), with 50 and 60cm of residual jejunum 
respectively, were the 2 patients who had undergone the next most extensive resection 
of the small bowel following subjects 7 and 8. Subject 1 exhibited impaired glucose 
and IR-GIP responses to the meal and no detectable IRI or IR-GLP-1 responses.
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Subject 2 had appreciable responses in all 4 parameters even though she had only 10cm 
more residual jejunum than subject 1. The abolished or impaired plasma glucose and 
hormonal concentrations for these 4 subjects explain the necessity for them to undergo 
regular home parenteral nutrition.
Fasting plasma IRI concentrations in both short bowel groups were not 
significantly different from the controls. However, the post-prandial responses were 
lower for the short bowel groups. Since the glucose response to the meals was normal 
for the short bowel subjects, this implies that these subjects had an impaired ’’incretin 
effect”. This is in agreement with the studies carried out by Kajiwara and co-workers 
(Kajiwara etal, 1979) and Lauritsen and co-workers (Lauritsen etal, 1980) described 
in the introduction to this chapter.
GIP was unlikely to have been responsible for this reduced ’’incretin effect” as 
plasma concentrations for the JCA group were very similar to those in the control 
groups, while both the fasting and post-prandial concentrations were slightly elevated 
in the EJ group. In contrast, IR-GLP-1 concentrations in the plasma of the subjects 
from both short bowel groups were lower than those in control subjects. These results 
add weight to the concept that tGLP-1 from the lower small intestine and large intestine 
may well act as a physiological incretin and that resection of the lower small bowel 
impairs secretion of this hormone producing a concomitant reduction in ’’incretin 
effect”.
Enteroglucagon, PYY and tGLP-1 are all secreted from the same endocrine cells 
in the GI tract (Vamdell etal, 1985 ; Vaillant and Lund, 1986 ; Ali-Rachedi etal, 1984 ; 
Bottcher etal, 1984). Therefore, it is surprising that plasma IR-GLP-1 concentrations 
were found to be low and enteroglucagon concentrations normal in both short bowel 
groups whilst PYY was low in EJ subjects and markedly elevated in JCA subjects.
Since the highest concentrations of enteroglucagon and tGLP-1 are found in the 
ileum and colon (discussed in chapter 4) EJ subjects might be predicted to have low 
levels of all 3 of these hormones. In JCA subjects the presence of the colon in
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continuity in the GI tract means that more of the L cells that produce these hormones 
remain than in the EJ patients. Furthermore, although the number of L cells in the GI 
tract of JCA patients will be considerably less than in normal control subjects, the short 
small intestinal length in the former means that a greater proportion of the ingested 
nutrients will reach the large bowel and this could potentially enhance the stimulation of 
secretion of these hormones. However, only increased plasma concentrations of PYY 
were observed in the JCA subjects.
The most likely explanation for the differential release of these 3 hormones from 
colonic L cells in JCA patients is that adaptation takes place following the surgery. 
This adaptation leads to greatly enhanced PYY gene expression in the colon of JCA 
subjects. Enteroglucagon and tGLP-1, on the other hand, are co-encoded by the same 
gene. Up-regulation of the proglucagon gene sequence cannot explain the normal 
enteroglucagon and low IR-GLP-1 concentrations observed in both short bowel groups. 
The differences are likely to be due either to a change in the stability of one of these 2 
proglucagon fragments or to their differential extraction rates from circulation.
The gastric emptying data for the constipated subjects were, unfortunately, 
unavailable. However, normal plasma glucose, GIP and insulin responses to the test 
breakfast were observed for the constipated subjects. This suggests that gastric 
emptying and small bowel transit were unaffected by this condition. It is likely that the 
difference with these patients lay in prolonged large intestinal transit time. This may 
explain the prolonged elevation of IR-GLP-1 levels that was observed in these subjects.
It is worth noting that there was a significant post-prandial elevation in plasma 
IR-GLP-1 concentrations in the control subjects. The peak IR-GLP-1 concentration 
arose 30 minutes post-prandially and levels remained elevated above fasting throughout 
the sampling period. The fasting and fed plasma concentrations observed for this 
group were consistent with those reported for normal human subjects in chapter 5. In 
most of those studies peak plasma IR-GLP-1 concentrations were also observed 30 
minutes post-prandially. The fact that elevation of the post-prandial IR-GLP-1 was
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more sustained in the study described here compared with those in chapter 5 was 
probably due to the fact that this study involved a large mixed meal as opposed to the 
smaller single nutrient meals described earlier.
280
CHAPTER 9
FINAL DISCUSSION AND 
FUTURE WORK
28
9.1 FINAL DISCUSSION
A sensitive RIA specific for amidated forms of GLP-1 was developed and 
validated. This was subsequently used to investigate the effects of individual 
macronutrients and various whole foods on IR-GLP-1 secretion in man and several 
animal species. In addition, the tissue specific processing of the region of the 
proglucagon gene product encompassing the sequence of GLP-1 was investigated in 
rodents and pigs.
In man, comparison of post-prandial concentrations following ingestion of 
carbohydrate, fat and protein meals, suggested that all 3 macronutrients could act as 
stimuli to IR-GLP-1 secretion. Further acute studies in which various carbohydrate 
loads were given to healthy subjects provided conclusive evidence that carbohydrate 
can elicit increases in circulating IR-GLP-1 concentrations.
A surprising aspect of the results was the timing of the post-prandial increases 
in plasma IR-GLP-1 concentrations. In all the acute studies involving carbohydrate 
loads, peak concentrations arose 30 to 45 minutes post-prandially. In one such study, 
there was a marked increase following ingestion of glucose, but no detectable increase 
following ingestion of rice or barley. Plasma glucose and IR-GIP measurements 
demonstrated that the carbohydrate from the rice and barley was absorbed much more 
slowly than for the glucose. This evidence strongly suggests that tGLP-1 is secreted 
from the small intestine in response to glucose absorption. However, the timing of the 
observed increases implied that the glucose stimulated tGLP-1 release from the 
proximal small intestine. This is unexpected, since enteroglucagon-secreting cells, 
which are also the cells that are supposed to secrete tGLP-1, are found predominantly 
in the distal small intestine and the colon.
Measurement of IR-GLP-1 concentrations along the GI tracts of mice and rats 
confirmed that the highest concentrations of IR-GLP-1 are found in the distal small 
intestine. However, detectable levels of IR-GLP-1 were found even in the duodenum.
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It may be that there are sufficient tGLP-1 secreting cells in the proximal small intestine 
in man to account for the small increases in plasma IR-GLP-1 observed shortly after 
ingestion of carbohydrate.
The increases in plasma IR-GLP-1 following ingestion of the single component 
meals were small and transient. Slightly larger and much more sustained increases 
were observed following ingestion of the mixed meals in the 24 hour study (chapter 6) 
and particularly following ingestion of the large, mixed meal test breakfast by the 
control and constipated subjects participating in the short bowel study (chapter 8). 
Therefore, it seem that the combined effect of different nutrients provides a greater 
stimulus to tGLP-1 secretion than do the individual nutrients.
The fasting plasma concentrations measured in man with the novel assay for IR- 
GLP- 1 were similar to those reported by Kreymann and co-workers (Kreymann et al, 
1987). Pooling the measurements of fasting IR-GLP-1 from all the meal studies 
involving healthy human subjects (84 fasting measurements taken on different 
occasions from 40 different subjects), concentrations were found to be 13.2±0.7pM 
(mean ± S.E., n=84). Peak post-prandial concentrations were normally in the order of 
30pM. This was slightly lower than the concentrations observed by Kreymann and 
co-workers (Kreymann etal, 1987). Nevertheless, they found that an IV infusion of 
synthetic tGLP-1, which produced a plateau concentration of approximately 50pM IR- 
GLP- 1 in plasma, combined with an IV infusion of glucose produced greatly elevated 
insulin levels compared with the glucose infusion alone. The peak plasma 
concentrations measured with the assay developed in this project would, therefore, 
probably be sufficient to significantly stimulate insulin secretion from the pancreas. 
The rapid post-prandial increases in IR-GLP-1 observed for all meals meant that plasma 
concentrations of this hormone peaked at approximately the same time as plasma 
glucose concentrations. This is the ideal situation if tGLP-1 does, indeed, play an 
important role as an incretin in man.
In short bowel subjects, the ’’incretin effect” appeared to be impaired as post-
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prandial glucose concentrations were normal in most patients but plasma IRI 
concentrations were somewhat reduced. This added considerable weight to the idea 
that tGLP-1 acts as a physiological incretin in man, since plasma IR-GIP concentrations 
were normal or even slightly elevated but plasma IR-GLP-1 concentrations were lower 
than in healthy control subjects.
Slight increases in post-prandial IR-GLP-1 concentrations were evident in all 
the subjects except those with the most extensive resections. Therefore, it seems that 
tGLP-1 can be secreted, albeit in small amounts, from the proximal jejunum in man.
Circulating IR-GLP-1 concentrations were measured for the first time in species 
other than man. Pigs exhibited substantially greater post-prandial IR-GLP-1 
responses, as measured with the novel assay, than were observed in man. Preliminary 
evidence suggested that for pigs, dietary fat could be a greater stimulus to IR-GLP-1 
secretion than carbohydrate. This contrasts with the case for GIP secretion in pigs for 
which carbohydrate provides a greater stimulus than fat (Ponter etal, 1991).
Since the antiserum raised against synthetic tGLP-1 was specific for amidated 
forms of the peptide, it proved possible to use this antiserum, in conjunction with a 
second, ’’side-viewing” antiserum which crossreacted with any peptide containing the 
sequence of GLP-1(7-36), to investigate differences in the molecular forms of IR-GLP- 
1 produced in rat and porcine small intestine and pancreas. Tissue extracts of rat ileum 
appeared to contain a single form of IR-GLP-1 which was detected equally well by 
both antisera. It is most likely that this form corresponded to tGLP-1.
A single molecular form of IR-GLP-1 predominated in rat pancreas as well. 
This also crossreacted to a similar extent with both antisera. It could correspond to 
tGLP-1, GLP-1 ( 1 -36)amide or some other truncated amidated form of the peptide.
If the predominant form of IR-GLP-1 secreted by rat pancreas is GLP-1(1- 
36)amide or any other form in which the N-terminus extends beyond the histidine 
residue at position 7, it is unlikely to be biologically active. In this case, measurements 
of IR-GLP-1 in rat plasma using any current method, will suffer from the fact that, in
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addition to the biologically active hormone secreted from the gut, inactive forms, 
secreted from the pancreas, will also be detected.
On the other hand, if the predominant form of GLP-1 produced in rat pancreas 
is tGLP-1, it could stimulate insulin secretion in a paracrine fashion. The pancreas 
could then contain substantially higher concentrations of biologically active GLP-1 than 
measured in plasma.
The results obtained from gel filtration of porcine pancreatic extracts showed a 
dramatic difference in the molecular forms of IR-GLP-1 present compared with those in 
the rat. The ’’side-viewing” antiserum crossreacted with a major peak which eluted at a 
position corresponding to that of all the smaller forms of GLP-1 (GLP-1(1-37), GLP- 
l(l-36)amide, GLP-1(7-37) and tGLP-1). Several other forms with larger apparent 
molecular weights may also have been present. The antiserum specific for C-terminally 
amidated forms crossreacted only very marginally with the low molecular weight form 
and did not detect any of the larger forms at all. The minimal crossreactivity of this 
antiserum implies that the low molecular weight form had not undergone C-terminal 
amidation to any significant extent, probably as a result of low levels or even a 
complete absence of the relevant enzyme activity in porcine pancreas.
Consequently, for pigs, the assay for GLP-1 developed as part of this project is 
effectively specific for IR-GLP-1 secreted from the gut. In this regard, the specificity 
of our antiserum for C-terminally amidated forms of the peptide appeared ideal. 
However, gel filtration of porcine ileal extracts showed that there could, potentially, be 
a severe drawback associated with this specificity. Both antisera crossreacted with a 
single, low molecular weight immunoreactive form of GLP-1 in such extracts, but the 
levels detected with the ’’side-viewing” antisemm were somewhat higher than the levels 
detected with the other antiserum. The most likely explanation for this is that some non- 
ami dated forms of GLP-1 were present in the tissue extract. The presence of such 
forms in ileal extracts does not necessarily mean that non-amidated forms of GLP-1 are 
secreted from this tissue in vivo, but the possibility that they are secreted has to be
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considered. GLP-l(7-37) seems to have the full biological activity of tGLP-1 but it 
only crossreacts with our antiserum to a minimal extent. If  significant quantities of 
GLP-1(7-37) are secreted from porcine intestines, the GLP-1 assay developed for this 
project would underestimate the true concentrations of biologically active GLP-1 in pig 
plasma.
In summary, all the experimental evidence obtained in this project points 
towards tGLP-1 acting as an important physiological incretin in man and pigs. The 
molecular forms of IR-GLP-1 found in pancreas and intestines vary from species to 
species.
A second RIA for GIP was developed and validated. The hope was to obtain 
an antiserum with greater specificity for the 5000-IR-GIP form than the old antiserum 
raised against porcine GIP. With this in mind a synthetic fragment of human GIP, 
containing the 2 amino acid residues which differ from the sequence of porcine GIP, 
was used to raise the new antiserum. The apparent plasma GIP concentrations 
determined with both assays were compared for lean and obese subjects in the acute 
study described in chapter 3. Similar GIP concentrations were detected by both assays. 
These results appeared to mle out any major role for methodological differences in GIP 
measurement in determining whether or not abnormal plasma GIP concentrations are 
detected in obesity. Unfortunately, experiments designed to determine the relative 
crossreactivity of the 2 anti-GIP antisera with different immunoreactants in plasma were 
unsuccessful. If both anti sera exhibit similar crossreactivity with the Vq-IR-GIP and 
the 8000-IR-GIP forms, the question of their effect on apparent plasma GIP 
concentrations in lean and obese subjects remains unanswered. Nevertheless, the 
similarity of the plasma GIP concentrations measured with the 2 anti-GIP antisera, 
raised separately against different antigens, provides reassurance that the apparent GIP 
concentrations measured with both assays are, in fact, good indicators of the actual GIP 
concentrations in plasma.
The same study showed there were no consistent differences in the plasma IR-
286
GIP concentrations in obese subjects compared with lean subjects, although the former 
did exhibit the characteristic hyperinsulinaemia. Due to the large amount of conflicting 
experimental evidence concerning prevailing GIP concentrations in obesity, this study, 
on its own, cannot necessarily be taken as conclusive evidence that plasma GIP levels 
are in the normal range for all obese subjects.
It may be that large liquid meals can produce enhanced GIP responses in obese 
subjects due to a greater tolerance of such meals and more rapid liquid gastric emptying 
as a result of habitual ingestion of greater quantities of food than lean subjects. 
However, liquid test meals are not representative of most meals consumed as part of 
any normal diet. It was on this basis that a mixed meal of high energy content, 
containing both solid and liquid components, was selected for our study. For this 
meal, there appeared to be no difference between the lean and obese subjects in the 
gastric emptying rates crudely estimated using paracetamol.
It may be that plasma GIP concentrations are abnormal in morbidly obese 
subjects whereas in mildly obese subjects the difference is not as great. The subjects 
selected for our study were not morbidly obese (BMIs ranging from 29.2 to 36.1 
kg/m2). This could have contributed to the lack of difference in GIP concentrations 
between the lean and obese groups. However, the results of this study, at the very 
least, cast substantial doubts on the importance of GIP in the development of the 
hyperinsulinaemia commonly associated with obesity.
In summary, both the old and new GIP assays measure similar plasma GIP 
concentrations probably as a results of similar specificities of both antisera. Post­
prandial plasma GIP concentrations were normal in obese subjects. It therefore, seems 
unlikely that GIP plays an important role in the pathogenesis of obesity.
A series of experiments, funded by the Ministry of Agriculture Fisheries and 
Food were carried out in conjunction with the FMBRA, Chorleywood. In these, the 
role of various physico-chemical characteristics of dietary starches in determining the 
post-prandial metabolic responses was examined. This is of interest particularly in
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relation to diabetes for which sources of starch that give flattened glycaemic responses, 
compared with rapidly absorbable forms of carbohydrate, have been recommended to 
form the basis of high carbohydrate, high non-starch polysaccharide* diets (British 
I Diabetic Association, 1982).
In one acute study, the glycaemic responses to purified wheat starch 
preparations were found to be only marginally lower than for an equivalent load of 
glucose. The 2 starch preparations had been processed differently to give different RS 
contents. The RS contents of both preparations fell within the range expected for most 
processed, cereal-based whole foods. Since wheat is the major cereal source for the 
U.K., the results of this study suggested that RS is not an important factor to be taken 
into consideration with respect to our normal diet.
In a second study, the acute metabolic responses to brown rice were found to be 
unaffected by cooking time. One of the physical factors affected by cooking is the 
degree of gelatinization of the starch in the rice. Preliminary in vitro experiments 
revealed that boiling of brown rice induced rapid starch gelatinization. Consequently, it 
was found that once the rice had been cooked sufficiently to be edible, the starch was 
predominantly gelatinized. Other such experiments using white rice had showed that, 
although much shorter cooking times were necessary for the rice to be rendered edible, 
the rate at which the starch gelatinized was also considerably faster and the overall 
effect was similar. In foods where the starch source undergoes processing, it is likely 
to be even more susceptible to gelatinization during subsequent cooking. Therefore, 
the degree of gelatinization of starch is likely to only play a significant role in 
determining metabolic responses to raw foods, foods subjected to minimal cooking and 
foods for which gelatinization is limited during cooking by the presence of low 
quantities of water.
As mentioned earlier, a third acute meal study showed marked differences in the 
metabolic response to rice and barley compared with glucose. This contrasted with the 
results obtained for the pure wheat starch preparations. It was concluded that close
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interactions of starch with other components present in the whole cereal grains were 
responsible for reducing the rate of degradation of the starch and giving the flattened 
glycaemic responses. This effect was somewhat more marked for the barley than for 
the rice. It was suggested that the difference might have been due to the greater 
quantity of non-starch polysaccharide on the exterior of the barley grains acting as a 
physical barrier to the degradative enzymes.
Chronic studies in rats showed only small effects on plasma and tissue IR-GIP 
and IR-GLP-1 concentrations of different types of dietary starch and flour. In one 
study, 2 Hylon V (high amylose, high RS) preparations appeared to be somewhat less 
extensively digested than com starch as demonstrated by the lower weight gains and 
food efficiency ratios for animals fed Hylon V. This was also reflected in the fact that 
animals fed Hylon V exhibited greater large intestinal weights than the animals fed com 
starch, presumably as a result of more extensive large intestinal fermentation of 
malabsorbed starch in the Hylon V fed animals. However, the differences in plasma 
glucose, IRI, IR-GIP and IR-GLP-1 concentrations between the groups were small. 
This suggests that, although the Hylon V starches contained more RS, most of the 
starch in all 4 preparations was in a form that was readily digestible.
In a second, similar study only very small differences between plasma glucose 
and IRI and plasma and tissue IR-GIP and IR-GLP-1 were evident in animals fed diets 
based on 4 different cereal flours. Therefore, milling of cereals to produce flour would 
appear to eliminate any large differences in starch digestibility between different cereals.
In summary, it seems that close interactions with other food components and 
intact cellular structures may interfere with enzymic degradation of starches 
consequently producing flattened glycaemic responses. In contrast, for most cooked 
foods starch gelatinization and RS formation are unlikely to be important in determining 
the rate of starch digestion.
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9.2 FUTURE WORK
Whilst the role of GIP in the pathogenesis of hyperinsulinaemia lies in serious 
doubt, no attempts have yet been made to investigate the possible role of tGLP-1. The 
concentrations of plasma IR-GLP-1 were shown to be slightly elevated in genetically 
obese mice although the intestinal concentrations were normal. It would certainly be of 
interest to measure fasting and post-prandial IR-GLP-1 concentrations in obese 
subjects. With the availability of the sensitive RIA to GLP-1 developed for this project, 
such measurements would be possible.
A great deal still remains to be resolved concerning the different IR-GLP-1 
forms produced in tissues expressing the proglucagon gene in different animal species. 
If IR-GLP-1 is to be measured routinely in man with the novel assay, the molecular 
forms of IR-GLP-1 in human tissue and especially in human plasma need to be 
investigated.
For the precise structure of these various IR-GLP-1 forms to be determined, a 
system such as high performance liquid chromatography which is capable of greater 
resolution would be needed. Development of other antisera with specificities for the N- 
terminally truncated forms of GLP-1 (GLP-l(7-37) and tGLP-1) and the N-terminally 
extended forms (GLP-1(1 -36)amide, GLP-l(l-37) and MPGF) could be used as an 
alternative approach or, better still, together with high performance liquid 
chromatography precisely to detail the molecular processing of this fraction of the 
proglucagon gene product in different tissues in different species and clarify the 
molecular forms being measured in plasma.
Development of antisera against other portions of the sequence of GLP-1 could 
also potentially have other advantages. If an antiserum could be developed which 
bound at the extreme C-terminus of tGLP-1 and did not crossreact with N-terminally 
extended forms of the peptide, it might crossreact equally well with both biologically 
active forms of the peptide (GLP-1(7-37) and tGLP-1). Conversely, if the amounts of
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GLP-1(7-37) secreted from human and porcine intestines are negligible, such an N- 
terminal specific antiserum might be used in conjunction with the C-terminal amide 
specific antiserum to form the basis of an immunoradiometric assay. Hopefully, such 
an assay would have the advantages of greatly improved sensitivity and specificity. It 
should be appreciated that there were substantial variations in the quality of the different 
batches of radiolabeled tGLP-1 produced throughout this project. An 
immunoradiometric assay would also have the advantage of not being reliant on the 
production of high specific activity radiolabeled tGLP-1 which retains 
immunoreactivity.
The relative importance of GIP and tGLP-1 as physiological incretins is unclear. 
Infusion of both hormones into healthy subjects to produce the post-prandial 
concentrations observed in the studies described in this thesis together with IV glucose 
infusion might be used to estimate the relative contributions of the 2 hormones to the 
total ’’incretin effect”. An alternative approach to addressing this problem might be to 
attempt specific immunoneutralization of either GIP or tGLP-1 or both by injection of 
anti-GIP and anti-tGLP-1 antisera into animals.
The mechanism of tGLP-1 secretion from the gut is also of considerable interest. 
The distribution of tGLP-1 along the GI tract, being predominantly located in the distal 
small intestine, is not apparently suitable for a hormone which is to act as an incretin 
and which, therefore, needs to be secreted rapidly after ingestion of food. 
Nevertheless, I have suggested that tGLP-1 may be secreted from the proximal small 
intestine in response to nutrient absorption. This possibility could be investigated by 
perfusion of intestinal loops with glucose. Similarly, the mechanism of stimulation of 
tGLP-1 secretion might be investigated by gut perfusion experiments with a range of 
different sugars, fatty acids, amino acids and peptides.
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